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Summary 
Over the last seven decades, antibiotics have been essential components of 
modern medicines and this is one of the leading causes for our increased life expectancy. 
However, due to development of resistance to the existing antibiotics, there is an urgent 
need to look for new analogues or new bacterial targets which are essential for the 
survival of pathogens. Recently, aminoacyl-tRNA synthetases (aaRSs) have emerged as 
promising and clinically validated targets. Aminoacyl-tRNA synthetases are a family of 
enzymes which play a key role in the translation process and are responsible for charging 
tRNA with the correct amino acid. Although these enzymes are conserved during 
evolution, yet some structural divergence has occurred allowing selective inhibition of the 
bacterial aaRSs over their human orthologs. Because of their crucial role in protein 
synthesis and the possibility of selective inhibition, these enzymes have been considered 
as a prime antibiotic target. Numerous aaRS inhibitors have been reported in the 
literature, either from natural or synthetic origin. However, none of them (except 
mupirocin) has been developed yet into a clinically useful antibiotic. Last year, a new 
drug application (NDA) for Tavaborole (a benzoxaborole derivative) from Anacor 
Pharmaceuticals has been accepted by the US FDA for the treatment of onychomycosis.  
More recently, inhibitors based on the reaction intermediate (aa-AMP) have been 
designed and evaluated for antibacterial activity. Among them, aminoacyl-sulfamoyl 
adenosine (aaSA) analogues proved to be the strongest inhibitors of the corresponding 
aaRSs in vitro. However, these analogues could not progress further due to their lack of 
selectivity and poor cell penetration. In 1998, Cubist Pharmaceuticals reported a series of 
aryl-tetrazole containing sulfamates as selective aaRS inhibitors. Despite of excellent 
activity and high selectivity, these analogues could not be pursued further due to their 
poor cell penetration and high serum albumin binding. 
Elaborating on these findings, we attempted to improve the in vivo efficacy of the 
aryl-tetrazole containing sulfamates by coupling them with a siderophore (trihydroxamate 
or biscatecholate). Although no antibacterial activity was observed in whole-cell assay 
screening, trihydroxamate-based siderophore-drug conjugates (SDCs) did show nice in 
vitro activity in cell extracts (except ∆ABN extracts which lack peptidase activity). 
Therefore, we concluded that the SDCs are efficiently metabolized by broad-specificity 
 ii 
 
peptidases to release the active moiety. Thus, failure of uptake is the main reason for the 
inactivity of these trihydroxamate-based SDCs. Most probably, the iron-transport system 
may be selective for adenylates or very closely resembling derivatives. In addition, the 
biscatecholate-based SDC was not metabolized by broad-specificity peptidases as the 
SDC was protected at its N-terminal. Thus failure to release the active moiety is the likely 
reason for the absence of whole-cell activity of this latter SDC. 
Visual inspection of the compounds reported by Cubist Pharmaceuticals, and of 
albomycin and mupirocin reveals that these compounds vary from aaSA analogues in 
having either a heterocyclic base or a modified pyrimidine base or no base at all, the latter 
as found in mupirocin. However, these analogues displayed excellent activity and good 
selectivity against their respective aaRSs. These observations prompted us to investigate 
the pharmacophoric importance of the adenine base in aaSA analogues. In chapter 3, 
different natural and unnatural base containing isoleucyl-sulfamoyl nucleosides were 
designed, synthesized and evaluated for their antibacterial activity. To our surprise, the 
order of the in vitro inhibitory activity found was uracil (U)> adenine (A) = cytosine (C)> 
4-aminobenzimidazole (4-ABI)> 4-nitrobenzimidazole (4-NBI)> guanine (G). Moreover, 
hexapeptidyl conjugates of these analogues were prepared in an attempt to promote the 
uptake of these analogues. Unfortunately, only transient antibacterial activity was noticed 
for purine derivatives (A, I, 4-ABI), while no activity was observed for the in vitro 
strongly active uracil derivative. This observation again supports our hypothesis that the 
YejABEF transporter is selective for peptidyl-adenylate analogues and closely resembling 
derivatives. 
Part of our synthetic efforts focused on improvement of the in vivo efficacy of 
aaSA analogues by combining them with a peptide carrier (either a siderophore or a McC 
hexapeptide). During these studies, we consistently observed the formation of a 
cycloadenosine derivative as a side product. In an effort to reduce this side reaction, we 
proposed the synthesis of aminoacyl-sulfonamides (aaSoAs) as a potentially more stable 
alternative for aaSA analogues. Towards this end, we designed and synthesized several 
aaSoAs. We further compared the activity of these aaSoAs along with the intermediate 
sulfamate (SA) and sulfonamide (SoA) cores with their corresponding aaSA analogues. It 
was shown however that these analogues are not able to inhibit the corresponding aaRSs. 
Only the AspSoA analogue to our surprise showed some selective antibacterial activity 
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against E. coli wt. Although, sulfamate (SA) is not active against the tested aaRSs, it did 
display a broad-spectrum of activity in whole-cell assays. However, the mode of action of 
this sulfamate core structure remains to be determined. 
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Samenvatting 
Tijdens de afgelopen zeven decennia maakten antibiotica een essentieel onderdeel 
uit van ons geneesmiddelenarsenaal en deze vormen één van de belangrijkste redenen 
voor onze toegenomen levensverwachting. Ten gevolge van de ontwikkeling van 
resistentie tegen de bestaande antibiotica is er echter een dringende behoefte om op zoek 
te gaan naar nieuwe analogen of naar nieuwe bacteriële doelwitten die essentieel zijn voor 
het overleven van pathogene organismen. De laatste jaren werd hiervoor door meerdere 
onderzoeksgroepen opnieuw sterk gefocust op aminoacyl-tRNA synthetasen (aaRSs) als 
veelbelovende en klinisch gevalideerde doelwitten. De aminoacyl-tRNA synthetasen zijn 
een familie van enzymen die een sleutelrol spelen in het vertaalproces en die 
verantwoordelijk zijn voor het laden van het tRNA met de corresponderende aminozuren. 
Hoewel deze enzymen over de tijden heen weinig geëvolueerd zijn, is er toch voldoende 
structurele divergentie opgetreden waardoor selectieve remming van de bacteriële aaRSs 
mogelijk wordt zonder noemens-waardige inhibitie van hun menselijke analogen. 
Vanwege hun cruciale rol in eiwitsynthese en de mogelijkheid van selectieve inhibitie, 
worden deze enzymen dan ook beschouwd als een belangrijk bacterieel doelwit. Talrijke 
aaRS remmers van natuurlijke of synthetische oorsprong werden reeds gerapporteerd in 
de literatuur, doch buiten het mupirocine werd echter geen van hen reeds ontwikkeld tot 
een klinisch bruikbaar antibioticum. Vorig jaar werd wel een nieuwe geneesmiddelen 
applicatie (New Drug Application, NDA) voor Tavaborole (een benzoxaborool derivaat) 
van Anacor Pharmaceuticals goedgekeurd door de Amerikaanse FDA voor de 
behandeling van onychomycose. 
De laatste jaren werden meerdere remmers op basis van het reactie tussenproduct 
van de synthetasen (het aa-AMP) ontworpen en geëvalueerd voor antibacteriële activiteit. 
Hierbij bleken bij in vitro studies de sulfamaat (aaSA) analogen steeds als sterkste 
remmers van de overeenkomstige aaRSs naar voor te treden. Toch werd geen vooruitgang 
meer geboekt met deze analogen, wat te wijten is aan hun gebrek aan selectiviteit en 
slechte celopname. In 1998 rapporteerde Cubist Pharmaceuticals een reeks van aryl-
tetrazool bevattende sulfamaten als selectieve aaRS remmers. Ondanks hun uitstekende 
activiteit en hoge selectiviteit werden deze analogen niet verder ontwikkeld vanwege hun 
slechte celpenetratie en hoge serum albumine binding. 
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Voortbordurend op deze bevindingen hebben we gepoogd om de in vivo 
werkzaamheid van deze aryl-tetrazool bevattende sulfamaten te verbeteren door hen te 
koppelen aan een siderofoor op basis van een trihydroxamaat of biscatecholaat structuur. 
Hoewel er geen antibacteriële activiteit werd waargenomen in cellulaire testen, 
vertoonden de trihydroxamaat gebaseerde siderofoor conjugaten (SDC's) wel een 
behoorlijke in vitro activiteit gebuik makend van cel extracten (behalve voor ∆ABN 
extracten waarbij de peptidase activiteit ontbreekt). We concluderen bijgevolg dat de 
SDC's efficiënt worden gemetaboliseerd door brede specificiteit peptidasen waarbij het 
actieve deel vrijgezet wordt. Gebrekkige opname is bijgevolg de belangrijkste reden voor 
de inactiviteit van deze trihydroxamaat gebaseerde SDC's. Waarschijnlijk is het 
ijzertransportsysteem hierbij selectief voor adenylaat structuren of sterk gelijkende 
derivaten. Bovendien werd het biscatecholaat gebaseerde SDC niet gemetaboliseerd door 
brede specificiteit peptidasen wanneer dit conjugaat beschermd was aan het N-terminaal 
uiteinde. Het niet vrijkomen van het actieve deel is bijgevolg de meest plausibele reden 
voor de afwezigheid van activiteit in celculturen. 
Uit visuele inspectie van zowel de Cubist Pharmaceuticals verbindingen als van 
albomycin en mupirocine, blijkt dat deze verbindingen verschillen van de aaSA analogen 
wat betreft het base gedeelte, met ofwel een ongewone heterocyclische verbinding, een 
gemodificeerde pyrimidine ring of afwezigheid van een base zoals bij het mupirocine. 
Nochtans vertonen deze analogen een uitstekende activiteit en een goede selectiviteit 
tegen hun respectieve aaRS doelwit. Deze waarnemingen vormden voor ons de aanleiding 
om het belang van de adenine base in aaSA analogen te onderzoeken. In hoofdstuk 3 
werden verschillende isoleucyl-sulfamoyl nucleosiden met een natuurlijke of 
onnatuurlijke base geconcipieerd, gesynthetiseerd en geëvalueerd op hun antibacteriële 
werking. Tot onze verbazing bleek hierbij de volgorde van de in vitro remmende activiteit 
als volgt: uracil (U)> adenine (A) = cytosine (C) > 4-aminobenzimidazole (4-ABI) > 4-
nitrobenzimidazole (4-NBI) > guanine (G). Tevens werden hexapeptidyl conjugaten van 
deze analogen bereid in een poging om hun opname te promoten. Helaas werd slechts een 
voorbijgaande antibacteriële activiteit bemerkt voor de purinederivaten (A, I, 4-ABI), 
terwijl geen activiteit werd waargenomen voor het in vitro sterk actieve uracil derivaat. 
Deze waarneming ondersteunt opnieuw onze hypothese dat de YejABEF transporter 
selectief peptidyl-adenylaat analogen of sterk gelijkende derivaten herkent. 
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Een deel van onze synthetische inspanningen was gericht op verbetering van de in 
vivo werkzaamheid van aaSA analogen door verbeterde opname, wat kon beoogd worden 
door ze te conjugeren met een peptide (zij het een siderofoor of een McC signaalpeptide). 
Tijdens onze studies hebben we hierbij steeds de vorming van een cycloadenosine 
derivaat waargenomen als bijproduct. In een poging deze nevenreactie te beperken 
beoogden we vervolgens de synthese van aminoacyl-sulfonamiden (aaSoAs) als een 
potentieel stabieler alternatief voor aaSA analogen. Hiertoe werden verschillende aaSoAs 
ontworpen en gesynthetiseerd. We vergeleken hierbij de biologische activiteit van deze 
aaSoAs alsook deze van de intermediaire sulfamaat (SA) en sulfonamide (SoA) kernen 
met deze voor de overeenkomstige aaSA analogen. Hierbij werd jammer genoeg 
aangetoond dat deze sulfonamide analogen niet in staat zijn de overeenkomstige aaRSs te 
remmen. Alleen het AspSoA analoog bleek enige selectieve antibacteriële activiteit te 
vertonen tegen wild type E. coli. Hoewel het sulfamaat (SA) in vitro niet actief bleek 
tegen de geteste synthetasen, vertoont dit product wel een breed spectrum van activiteit in 
cellulaire assays. Het werkingsmechanisme hiervan dient echter nog te worden bepaald. 
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FDA   food and drug administration 
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G   guanine 
GluAdT  Glu-tRNAGln amidotransferase 
HOBt   N-hydroxybenzotriazole 
HBTU   O-Benzotriazole-N,N,N',N'-tetramethyl-uronium-hexafluoro-
phosphate 
HPLC   high performance liquid chromatography 
HRMS   High resolution mass spectrometry 
HTS   High throughput screening 
IC50   half maximal inhibitory concentration 
LB   Lysogeny Broth 
LPS   lipopolysaccharides 
McC/MccC  Microcin C 
MHA   Muller-Hinton agar 
MIC   minimum inhibitory concentration 
mM   millimolar 
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MS   mass spectrometry 
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PTSA   p-toluenesulfonic acid 
rt   room temperature 
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SDC   siderophore-drug conjugate 
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tBu   tert-butyl 
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TEA   Triethylamine 
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1 General Introduction 
 
1.1  Introduction 
Alarming resistance to the existing antibiotics provides continuous stimulus to 
search for new antimicrobial agents or new cellular targets which are essential for the 
survival of the pathogen. In recent years, aminoacyl-tRNA synthetases (aaRSs) have 
emerged as an essential and clinically validated target for the development of 
antimicrobial agents. Given their indispensible role in protein synthesis and significant 
divergence between prokaryotic and eukaryotic aaRSs, these enzymes are considered as a 
promising target for the development of antimicrobial agents. This chapter covers an 
overview on the role of aaRSs in protein synthesis, and their classification, and discusses 
the existing aaRS inhibitors from natural and synthetic origin and recent developments in 
the field. This is followed by a brief discussion on the poor in vivo efficacy problem 
associated with the in vitro strongly inhibitory aminoacyl-sulfamoyl adenosines (aaSAs) 
and a Trojan-horse strategy to overcome it.  Being aaRS inhibitors and Trojan-horse 
antibiotics, microcin C and albomycin will be discussed in detail as they form basis for 
this thesis. 
Human evolution can be viewed from a medical point of view as a continuous 
fight between human and its pathogens.[1] Until the first half of the twentieth century, 
infectious diseases were the leading cause of mortality and morbidity. Therefore it is not 
surprising that earlier research was focused on infectious diseases with the main concern 
on prevention or therapy of infectious diseases. There are several landmark discoveries 
during the course of the last century such as the discovery of penicillin by Alexander 
Fleming in 1929 and the first introduction of the sulpha drugs by Domagk in 1932. There 
also was a tremendous increase in new antimicrobials during 1940-1960. Till early 1970s, 
mankind was confident that infectious diseases can be prevented and controlled with the 
existing antimicrobial agents. In 1969, Surgeon General William H. Stewart told the 
United State congress that it was time to ‘close the book on infectious diseases’.[2] With 
victory declared, efforts for research on infectious diseases were reduced or almost 
eliminated. However, infectious diseases are still the second leading cause of mortality 
worldwide, causing over 13.3 billion deaths per year.[3] This is the result of the emergence 
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of new diseases, the re-emergence of diseases once controlled and more specifically the 
development of antimicrobial resistance. 
Antibiotic resistance can be divided in two types, the natural or intrinsic and the 
acquired resistance. Acquired resistance is the major mechanism.[4] Herein, bacteria 
acquired resistance through three major mechanisms: (1) prevention of accumulation of 
the antimicrobial agent either by decreasing influx or increasing efflux (2) mutation(s) 
leading to alteration in the drug target which therefore prevent drug binding or effective 
action (3) Antibiotic inactivation either by hydrolysis or modification.[5] In contrast, 
intrinsic resistance is the result of general adaptive processes and is not necessarily linked 
to any specific class of antimicrobials. An example includes the absence of an uptake 
transport system for antimicrobials or poor permeability of the outer membrane of Gram-
negative bacteria. The cell envelop permeability barrier is particularly strong in Gram-
negative pathogens like Pseudomonas aeruginosa and other Gram-negative bacteria. P. 
aeruginosa is well known for its intrinsic resistance due to its rigid, less diffusible cell 
membrane and its ability to develop multidrug resistance following therapy.[5a] Many 
antimicrobial agents are inactive against certain strains of bacteria because they simply 
can not enter the cell.[6]  
The bacterial resistance to every antimicrobial agent is unavoidable and provides 
continuous stimulus to search for new bacterial targets which are essential for the survival 
of microbes or for new antimicrobial agents which preferably act by novel mode(s) of 
action. Strategies to overcome resistance involve further development of the existing 
classes of antibiotics and the use of combinations of existing antibiotics, as well as 
searching for new classes of antibiotics. The former strategy is likely the most promising 
as it is cost effective and yields new antibiotics in a relatively short period. However, 
there is always a greater risk of rapid reoccurrence of resistance. Therefore efforts should 
be directed to the development of new classes of antibiotics with preferably different 
mode(s) of action to prevent development of cross-resistance. In theory, a new class of 
antibiotics must fulfil three criteria in which the new target must be essential for the 
bacterial cell function (i.e. the target should be validated), the new antibiotic must be very 
selective for the bacterial target and bacteria should not be able to develop resistance to 
these class of antibiotics.[7] Alternatively, efforts should be invested to look for 
unexploited and essential cellular targets. One such target is aminoacyl-tRNA synthetase. 
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1.2  Aminoacyl-tRNA synthetases (aaRSs) 
In last couple of decades, aminoacyl-tRNA synthetases (aaRSs) have emerged as a 
promising and clinically validated target for the development of new antimicrobial agents 
as exemplified by the clinical use of mupirocin (Bactroban® by GSK).[8] Aminoacyl-
tRNA synthetases (aaRSs) are at the heart of protein synthesis and play an indispensible 
role in translating the genetic code. They are present in all living organisms and are 
responsible for ligation of the correct amino acid to their cognate tRNAs which are 
subsequently used in protein synthesis.[9] The fidelity and accuracy of the translation is 
largely dependent on the ability of each of tRNA synthetases to ligate the correct amino 
acid to their correct tRNA because the nature of interaction between tRNA and mRNA is 
independent of the nature of the amino acid attached to tRNA.[9b] As a general rule, there 
is one tRNA synthetase for each of the 20 amino acids, but there are some exceptions to 
this rule, of which the most notable is glutaminyl-tRNA synthetase being absent in Gram-
positive bacteria. Instead, these bacteria have an amidotransferase which converts 
mischarged Glu-tRNAGln to Gln-tRNAGln.[10] 
1.2.1 Role of aminoacyl-tRNA synthetase in protein synthesis 
The aminoacylation of tRNA occurs in a two steps process (Figure 1-1).[11] In the first 
step, nucleophilic attack of the α-carboxyl of the amino acid takes place on the α-
phosphate of the adenine triphosphate (ATP) to form an enzyme bound mixed anhydride 
(i.e. aminoacyl adenylate, aa-AMP) with the displacement of pyrophosphate (PPi). In the 
second step, the activated amino acid is transferred to the 3’-terminal adenosine of the 
corresponding tRNA to form aminoacyl-tRNA (aa-tRNA) and adenosine monophosphate 
(AMP). This esterification step involves a nucleophilic attack by either the 2’- or 3’- 
ribose hydroxyl group of the terminal adenosine of the tRNA generating the activated aa-
tRNA. These correct aa-tRNAs interact with elongation factor (EF-1a in eukaryotes and 
Archea, EF-Tu in prokaryotes) to translate mRNA within the A site of the ribosome.[12] 
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a) Formation of enzyme bound aa-AMP complex. 
 
b) Transfer of amino acid to the tRNA 
Figure 1-1: Aminoacylation of tRNA catalyzed by aaRS. The aminoacylation reaction 
depicted here is catalyzed by a class II aaRS (aminoacylation of the 3’-hydroxyl of 
terminal adenosine). In case of class I aaRS, the 2’-hydroxyl of the terminal adenosine is 
acylated. 
1.2.2 Aminoacyl-tRNA synthetase: an attractive target 
The aaRSs represent an ideal and validated target for the discovery of new 
antimicrobials for a number of reasons. Firstly, these enzymes play a crucial role in 
translating the genetic code and thus are of vital importance for the survival of the 
pathogen.[13] Secondly, although the function of these enzymes is conserved throughout 
evolution, yet significant structural differences have occurred between prokaryotes and 
eukaryotes. Therefore selective inhibition of the bacterial aaRS over its human orthologs 
can be achieved.[14] Thirdly, significant homology exists among prokaryotes implying that 
aaRS inhibitors may yield broad-spectrum antibiotics. Furthermore, these enzymes are 
stable, soluble, easy to purify and can be assayed by high throughput screening (HTS).[15] 
Development of the assay method is always the main bottle-neck for the discovery of new 
antibacterials. Because of their conserved functionality, the assay developed for one aaRS 
can be easily adapted for other aaRS.[16] Crystal structures of many aaRSs are now 
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available which further helps in rational drug design and thus accelerates the process of 
antibiotic development.[17] 
1.2.3 Classification of aminoacyl-tRNA synthetases 
 Despite of the conserved mechanism of catalysis of all 21 aaRS, they are 
classified into two unrelated classes: 11 in class I and 10 in class II (with LysRS found in 
both classes). This classification is mainly based on their structural differences. The 
active site of class I synthetases consists of two dinucleotide-binding Rossmann folds 
with HIGH and KMSKS motif which stabilizes the transition state.[18] On the contrary, 
the active site of class II synthetase contains a barrel like structure of anti-parallel β-
sheets surrounded by loops and α- helices that provides a rigid template for the 
recognition and binding of the amino acid and ATP.[15-19] In addition, a class I synthetase 
binds ATP in the extended conformation whereas a class II synthetase binds the 
nucleotide in the bent conformation.  
Table 1-1: Summary of structural differences and classification of tRNA synthetases 
(Copied from ref.[19a]) 
Feature Class I tRNA synthetase Class II tRNA synthetase 
Active site 
architecture 
Two dinucleotide-binding 
Rossmann folds 
Barrel like anti-parallel β-sheets 
surrounded by α-helices 
Site of esterification 2’-hydroxyl 3’-hydroxyl 
Enzyme approaches 
tRNA 
From minor groove From major groove 
Sub-classification Ia Ib Ic IIa IIb IIc 
LeuRS   HisRS   
IleRS GlnRS TyrRS ProRS AsnRS  
ValRS GluRS TrpRS SerRS AspRS PheRS 
CysRS LysRS-I  ThrRS LysRS-II  
MetRS   GlyRS   
ArgRS   AlaRS   
 
 Furthermore, there is a difference in the position of esterification at the ribose of 
the 3’-adenosine of the tRNA with amino acid. Class I synthetases esterify at the 2’-
hydroxyl whereas class II synthetases esterify at the 3’-hydroxyl of the terminal ribose.[20] 
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This can be explained by the binding of the tRNA to its synthetase. Class I enzymes 
approach the acceptor stem of the tRNA from the minor groove side with the variable 
loop facing the solvent, whereas class II synthetases approach the major groove side of 
the acceptor stem and the variable loop faces the synthetase. However this generalization 
of modes of tRNA binding being specific for each class of aaRS remains somewhat 
unclear due to the fact that very few crystal structures of aaRSs contain tRNA. Moreover, 
extensive biochemical studies revealed that AlaRS recognizes the minor groove of the 
tRNAAla although it belongs to class II of the synthetases.[21] However, the recognition of 
the cognate tRNA by each aaRS involves the discriminator base N73, the acceptor stem 
and the anti-codon present in the tRNA. To maintain accuracy of aminoacylation with an 
error rate of ~1 in 10,000 all aaRS contain a distinct structural domain for anti-codon 
recognition. Some aaRS contain a zinc-binding domain for the acceptor stem recognition. 
A series of intricate contacts with the substrate amino acid and the cognate tRNA with 
stabilization of the transition state provide the first level of specificity.[19b] However 
certain amino acids (e.g. Val and Ile) are structurally so similar that misactivation of the 
amino acid may occur. Therefore two different proof reading mechanisms exist to 
decrease the error rate. These mechanisms have been discussed in the next section. Based 
on their sequence homology and domain architecture, tRNA synthetases are further 
classified into subgroups has been summarized in Table 1-1. 
1.2.4 Editing mechanism of aaRS 
As mentioned earlier, the accuracy of protein synthesis not only depends on the 
recognition of the cognate tRNA and the correct amino acid by aaRS but also on 
subsequent editing of errors.[22] Since the tRNAs are relatively large molecules with 
adequate structural differences, their selection is not a big problem.[23] Moreover the 
accuracy is further enhanced by stabilization of the transition state for aminoacylation in 
cognate tRNA bound aaRS complexes.[24] In contrast, amino acids are small molecules 
and differ from each other only by their side chain.  The structural differences between 
the amino acids are very marginal so that aaRS fail to distinguish between them with 
adequate selectivity leading to misactivation of an amino acid. For example, the IleRS 
may misactivate valine with an error rate of 1 in 150 whereas the error rate in 
misinterpretation of the isoleucine codon as valine is only 1 in 3000. As shown in Figure 
1-2, the aaRS is able to minimize errors in this selection at two points in the 
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aminoacylation reaction. At a first point as an aaRS bound aa-AMP (pre-transfer editing) 
and at the second point as an enzyme bound aminoacyl-tRNA (post-transfer editing). In 
pre-transfer editing, the misactivated amino acid (xx-AMP, Figure 1-2) is hydrolysed 
back into the amino acid and AMP, whereas in the post-transfer editing, the incorrectly 
aminoacylated tRNA (xx-tRNA, Figure 1-2) is hydrolysed into the amino acid and the 
tRNA. 
 Figure 1-2: Editing pathways of aminoacyl-tRNA synthetases 
 
The catalytic site of aaRS is specific enough to activate and transfer only the 
correct amino acid. This accuracy can be achieved by the recognition of specific 
properties of the cognate amino acid and steric exclusion of the amino acids with bulkier 
side chains. In addition, the difference in the sugar puckering and the orientation of the C-
4’-C-5’ of the ribose play an important role to discriminate between the cognate and non-
cognate aa-AMP.[25] Therefore, the first sieve serves to exclude the amino acids bulkier 
than the cognate amino acids. However, the amino acids with smaller size which can form 
sufficient interaction with the aaRS may pass through the first sieve and may be 
incorrectly activated. Therefore, those aaRS where amino acid discrimination is 
threatened have evolved with an editing site to meet the fidelity requirement of the cell. 
The editing site serves as a second sieve and acts by hydrolysing the non-cognate aa-
AMP. The editing site is too small to fit the cognate amino acid, therefore capable of 
hydrolysing non-cognate amino acid (with smaller size).  This is called the double sieve 
model as proposed by Fersht A. R. et al.[26] The existence of pre-transfer editing was first 
proposed by Berg and co-workers. However, because of the transient nature of the 
intermediate aa-AMP, it has been long controversial to explain the accuracy and fidelity 
of aminoacylation.[22, 27]  It was then inferred from the early pre-steady state kinetic 
experiments on IleRS by Fersht et al. where accumulation of the non-cognate Val-
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tRNAIle was much lower than expected. This study suggested pre-transfer editing of the 
misactivated valine (Val-AMP) by hydrolysis of Val-AMP.[26] This mechanism of editing 
by aaRS (pre- or post-transfer editing) has been review by Martinis and Boniecki.[28] 
1.2.5 Indirect biosynthesis: relaxed specificity in AspRS and GluRS 
Although the notion that all living organisms have one aaRS for each amino acid 
is widespread, there are a few exceptions like archea and some of the bacteria. For 
example GlnRS is absent in some Bacilli where as GlnRS and AsnRS are absent in 
archaebacteria.[10a, 29] They have indirect pathway for synthesis of Gln-tRNAGln and Asn-
tRNAAsn, both proceeding via mis-aminoacylated intermediates Glu-tRNAGln and Asp-
tRNAAsn respectively. However, these mischarged tRNA can not participate in protein 
synthesis as they are not recognized by the elongation factors and therefore the accuracy 
and fidelity of the translation is maintained.[9c, 30] The basis for this relaxed specificity of 
GluRS and AspRS is found to be the lack of recognition of the third position of the 
anticodon in tRNA. For example, AspRS can recognize both tRNAAsp (GUC anticodon) 
and tRNAAsn (GUU anticodon).[30c] The same is also true for GluRS.[30b] The mischarged 
tRNAs are then converted to their correctly charged tRNA by a tRNA dependent 
amidotransferase (AdT). Two types of amidotransferase have been found in bacteria and 
archea. The GatCAB is a heterotrimeric AdT and is found in most of the bacteria and 
some archea and can use Glu-tRNAGln and Asp-tRNAAsn as substrates,[31] whereas GatDE 
is a dimeric AdT and is found only in archea and uses only Glu-tRNAGln as a substrate.[32] 
The transamidation reaction requires an acceptable amide donor (such as glutamine, 
asparagine or ammonia), the mischarged tRNA, ATP and Mg2+. The transamidation 
reaction may proceed via an aminoacyl phosphate intermediate (e.g. 1.6, Figure 1-4) as it 
has been observed that ATP is cleaved to ADP when incubated with Glu-tRNAGln. The 
role of the different subunits of GatCAB and GatDE is not yet clear. The transamidation 
of Asp-tRNAAsn and Glu-tRNAGln has been reviewed elsewhere.[10a, 16] Direct and indirect 
synthesis of Gln-tRNAGln is depicted in Figure 1-3 as an example. A similar pathway is 
also followed for synthesis of Asn-tRNAAsn.  
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Figure 1-3: Dual pathways for synthesis of Gln-tRNAGln. The upper half depicts the 
direct pathway catalyzed by GlnRS whereas the lower half depicts the indirect pathway 
and is catalyzed by non-discriminating GluRS followed by transamidation by GluAdT. 
(Figure adapted from the ref.[31a]) 
 
As the transamidation pathway is not present in eukaryotic cells, 
amidotransferases (AdTs) are interesting targets for the development of antibacterial 
agents. Inhibition of amidotransferases (AdTs) should give the same effect as aaRS 
inhibition. Hereto, some analogues resembling either the 3’- end of the aminoacyl-tRNA 
(1.1 and 1.2, Figure 1-4) or transamidation reaction intermediates (1.6) have been 
synthesized and evaluated for their antibacterial activity.[31b] However, it has been found 
that aspartycin (1.3, Figure 1-4) is not a substrate for AdT, whereas glutamycin (1.4, 
Figure 1-4) strongly inhibits AdT (GatCAB) with Ki of 0.105 mM. The Asp-KP (1.7) 
failed to inhibit AdT probably due to lack of the adenosyl moiety. Moreover, a series of 
chloramphenicol analogues was synthesized and evaluated as inhibitors of H. pylori 
GatCAB transamidase. The compound 1.7 proved to be the most active analogue of this 
series with respect to Asp-tRNAAsn with a Km of 2 µM and Ki value of 27 µM.[33] 
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Figure 1-4: Structures of the aminoacyl-tRNA substrates (1.1 and 1.2) and respective 
inhibitors (1.3, 1.4 and 1.5) along with the intermediate in the amidotransferase reaction 
(1.6) and its inhibitor (1.7) respectively. 
1.3  Existing tRNA synthetase inhibitors 
To date, numerous aaRS inhibitors have been reported in the literature either from 
natural or synthetic origin. Most of them are competitive inhibitors and act by occupying 
the active site of the corresponding aaRS. Recently, aaRS inhibitors which selectively 
target the editing site have been reported. Some of the most important aaRS inhibitors 
from natural and synthetic origin will be discussed in the next section. 
1.3.1 Natural products as tRNA synthetase inhibitons  
Natural products illustrate a diverse set of chemical structures as aaRS inhibitors 
of which most important natural products are depicted in Figure 1-5. Although the natural 
products demonstrate the possibility of selective inhibition, yet none of these analogues 
(except mupirocin) reached the clinic.[16] Most important natural products as aaRS 
inhibitors have been described in following section. 
Mupirocin: only aaRS inhibitor on the market 
Mupirocin (pseudomonic acid, 1.8, Figure 1-5) is a natural antibiotic produced by 
Pseudomona fluorescens and has a unique chemical structure. It consists of a short fatty 
acid (9-hydroxy nonanoic acid) linked to monic acid through an ester linkage with the tail 
portion closely resembling the isoleucyl moiety.[20a, 34] It acts as a competitive IleRS 
inhibitor and binds to IleRS in a very similar way as Ile-AMP. The tetrahydropyran ring 
General introduction 
11 
 
takes the place of the ribose, with the epoxide ring occupying the same domain as the 
phosphate group, the tail portion mimicking the isoleucine and the fatty acid chain 
binding at the adenine binding pocket. Mupirocin is mainly active against most of the 
Gram-positive bacteria, including S. aureus (MIC = 0.06-0.5 µg/mL) and S. pyogens 
(MIC = 0.12-0.5 µg/mL). It is barely active against Gram-negative bacteria (MIC 128 
µg/mL for E. coli).[34a, 35] It is the only aaRS inhibitor used clinically and marketed as 
Bactroban® by GSK. Because of the poor bioavailability, and instability owing to its ester 
function, mupirocin is used as a topical ointment.[36] Although mupirocin is less active 
against Gram-negative bacteria, high local concentration can be achieved by topical use. 
Unfortunately, the clinical use of mupirocin is further restricted due to the 
emergence of high levels of resistance encoded by the plasmid mediated mupA gene.[37] 
The mupA gene codes for the structurally different IleRS which is not inhibited by 
mupirocin.[38] Because of limited systemic stability of mupirocin, there is a long standing 
interest in developing mupirocin-based analogues with improved pharmacological 
properties such as hydrolytic stability, improved potency and selectivity.[39] These 
analogues have been discussed under the mupirocin-based synthetic aaRS inhibitors 
section. 
Indolmycin 
Indolmycin (1.9, Figure 1-5) is a secondary metabolite produced by Streptomyces 
griseus ATCC 12648 (formerly known as S. albus BA3972A) and related strains.[40] It is 
a structural analogue of L-tryptophan and is a potent competitive inhibitor of the bacterial 
TrpRS as shown for E. coli.[41] It was patented by Pfizer in 1965, however further 
development was halted because indolmycin is relatively inactive against commonly 
occurring pathogens. Moreover it has been found that indolmycin inhibits catabolism of 
tryptophan in rat liver.[20a] The narrow spectrum of activity may be partly attributed to its 
hydrophobic nature which restricts its uptake by pathogens.[42] However, efforts have 
been invested to enhance the hydrophilicity of indolmycin but without success.[43] 
Recently, indolmycin has been described by Takeda Pharmaceuticals (Japan) as TAK-083 
and was claimed to have potent activity against H. pylori (MIC 0.008-0.031 µg/mL).[44] In 
addition, Takeda Pharmaceuticals have patented TAK-083 containing formulation for the 
prevention and treatment of disease associated with H. pylori infections.[20a] However, 
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certain strains of S. aureus are found to develop high level resistance to indolmycin by a 
point mutation (H43N) in TrpRS, whereas naturally occurring Streptomycetes coelicolor 
A3(2) are resistant to indolmycin due to the presence of auxiliary TrpRS1.[41b] 
Borrelidin 
Borrelidin (1.10, Figure 1-5) was first isolated from Streptomyces rochei in 
1949.[45] It has a unique structure and consists of a 18 membered polyketide macrocycle 
and has a broad-spectrum of antibacterial activity.[46] It is a potent but non-selective 
inhibitor of ThrRS which limits its clinical use as an anti-infective agent.[47] Moreover, 
resistance to borrelidin has been developed by over-production of ThrRS or by a single 
point mutation in the ThrRS gene.[48] 
Cispentacin and icofungipen 
Initially, cispentacin (1.11, Figure 1-5) was isolated from Bacillus cereus in 1989 
and subsequently from Streptomyces setonii.[49] It is a cyclic β-amino acid derivative and 
is a weak inhibitor of ProRS.[50] It is actively transported by the amino acid permease 
leading to high intracellular levels in several fungi. It is an orally active antifungal agent. 
As it is a weak inhibitor of ProRS, efforts have been invested by Bayer AG in search of a 
new cispentacin analogue with improved oral activity and safety. During their efforts 
BAY 10-8888 (1.12, Figure 1-5) was identified as the most active compound of the 
series.[51] Although still based on cispentacin, BAY 10-8888 has a different mode of 
action. It acts as a potent inhibitor of fungal IleRS. The compound was then licensed to 
GlaxoSmithKline (formerly known as PLIVA) and renamed as PLD-118. Icofungipen is 
its generic name.[52] Analogous to cispentacin, icofungipen is also actively transported by 
the amino acid permease and accumulates in several fungi up to 200-fold of the 
extracellular concentration. Although low mycologic eradication rates were observed in 
HIV-positive patients as compared to fluconazole, icofungipen showed good efficacy and 
high tolerability in phase I and II of clinical trials after oral administration.[19b]  
Cladosporin 
Cladosporin (1.13, Figure 1-5) is a secondary metabolite isolated from various 
fungal genera such as Cladosporium, Aspergillus, Eurotium, and Chaetomium.[53] It 
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belongs to the isocoumarin class and is reported to have antifungal, antiparasitic, 
insecticidal, antibacterial and anti-inflammatory activity. In 2012, Winzeler et. al. 
reported that cladosporin is a potent and selective inhibitor of the cytosolic LysRS of 
Plasmodium falciparum (IC50 = 61 nM) whereas only weak inhibitory activity was 
detected against human LysRS at high micromolar range.[53] Despite of high selectivity 
and potent activity against liver-stage infections, cladosporin could not progress to 
clinical development due to poor oral bioavailability, which is a key requirement for 
antimalarial therapy. 
Agrocin 84  
Agrocin 84 (1.14, Figure 1-5) is a natural antibiotic produced by Agrobacterium 
radiobacter K84 used for biocontrol of the plant tumor.  It is an Leu-AMP analogue 
decorated with a D-glucofuranosyloxyphosphoryl group linked to the N6 of the adenine 
moiety via a phosphoramidate linkage enabling uptake of the compound by the pathogen. 
Once internalized, the compound gets cleaved to release the toxic moiety which can act as 
a competitive inhibitor of LeuRS. The toxic moiety likewise comprises a stable 
phosphoroamidate mimicking aa-AMP.[54] 
Ascamycin 
Ascamycin (1.15a, Figure 1-5) is another example of a natural nucleotide 
antibiotic produced by Streptomyces species. Although it closely resembles 5’-O-(N-L-
alanyl)-sulfamoyl adenosine (AlaSA), it has a different mode of action. It acts by 
inhibiting polyuridylate-directed polyphenylalanine synthesis. It shows selective 
antibacterial activity against Xanthomonas citri and X. oryzae due to the dealanylating 
activity of the Xc-aminopeptidase present on the cell surface of Xanthomonas, whereas its 
dealanyl analogue (1.15b, Figure 1-5) is a broad-spectrum antibacterial agent.[55] 
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Figure 1-5: Chemical structures of few well-known aaRS inhibitors from natural source. 
(Note: Microcin C (1.17) and albomycin (1.18) will be discussed in detail in the next 
section 1.4 and 1.5.4 respectively.) 
Chuangxinmycin 
Chuangxinmycin (1.16, Figure 1-5) is a natural product isolated from 
Actinoplanes tsinanensis. As a consequence of its structural similarity with L-tryptophan 
and indolmycin, it also inhibits TrpRS (IC50 = 30 nM for E. coli TrpRS).[56] 
Chuangxinmycin is reported to have antibacterial activity against a number of Gram-
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positive and Gram-negative bacteria under in vitro conditions. Moreover, early preclinical 
studies indicated that this compound exhibits efficacy against E. coli and Shigella 
dysenteriae in a mouse model.[56] Despite of early promising results, there is no further 
report on the clinical development of this compound.[20a] 
1.3.2 Synthetic or aminoacylation reaction mechanism-based inhibitors 
The early efforts in the search of antibiotics from natural source produced a 
number of aaRS inhibitors with a diverse set of chemical structures. However for various 
reasons, none of them (except mupirocin) reached the clinic. Therefore, during last 
decade, efforts have been dedicated to rational design of compounds based on either a 
substrate mimic or a non-hydrolysable mimic of aa-AMP (1.19, Figure 1-6). 
Non-hydrolysable aa-AMP analogues 
As described earlier, aminoacyl-AMP (1.19, Figure 1-6) is a key intermediate in 
the aminoacylation of tRNA. The aa-AMP has two to three orders of magnitude of higher 
affinity for the enzyme as compared to the substrate amino acid or ATP. Consequently, 
non-hydrolysable mimics of aa-AMP are expected to show excellent potency as 
compared to either substrate amino acid or ATP. The non-hydrolysable mimics of aa-
AMP form the largest class of aaRS inhibitors. To date, the labile phospho ester linkage 
has been replaced with hydrolytically stable linkages such as aminoalkyl-phosphate 
(1.20),[39c, 57] ester (1.21),[58] amide (1.22),[58a] N-alkoxy-hydroxamate (1.23), 
hydroxamate (1.24),[58] aminoacyl-sulfamate (1.25),[25, 39c, 57a, 59] sulfamides (1.26),[39c] N-
alkoxy-sulfamide (1.27) and N-hydroxy sulfamide (1.28).[60] The general structure for 
each class of compounds is depicted in Figure 1-6. Among them, only two classes of the 
compounds (aminoalkyl-adenylate and aminoacyl-sulfamates) closely mimic the negative 
charge density around the reactive acyl-phosphate of aa-AMP. Aminoalkyl-adenylate 
keeps the phosphate group but holds an aminoalkyl group instead of the aminoacyl 
whereas the aminoacyl sulfamate keeps the aminoacyl group but replaces the phosphate 
linkage with a sulfamate one. As a general trend, the aminoacyl-sulfamates have proved 
to be the most potent inhibitors with IC50 in the nanomolar range whereas aminoalkyl 
adenylate analogues are millimolar inhibitors of the corresponding aaRS in vitro. 
However, both of these analogues could not progress to clinical development due to their 
lack of selectivity (due to high structural similarity with the aa-AMP) and the poor in vivo 
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efficacy (due to poor cell penetration). As noted earlier in this section the aaSA analogues 
closely mimic the negative charge density as seen across the reactive acyl-phosphate, thus 
at physiological pH, all aaSA analogues exist as zwitterions with a negative charge on the 
sulfamate nitrogen and a positive charge at the α-amine of the amino acid. Because of 
their polar nature, these compounds can not diffuse easily through hydrophobic cell 
membrane. Therefore, most of the modifications of non-hydrolysable aa-AMP analogues 
are aimed to improve the selectivity and the in vivo efficacy. 
Aryl-tetrazole containing aminoacyl-sulfamates 
In 1998, Cubist Pharmaceuticals reported the synthesis and biological evaluation 
of a new class of aminoacyl-sulfamates where the adenine base was replaced with an aryl-
tetrazole moiety and is linked to the ribose via a two carbon linker. These analogues 
proved to be potent and selective inhibitors of the corresponding aaRS with selectivity up 
to 3000-fold. Of the numerous compounds of this class, two aryl-tetrazole containing 
sulfamates are given in Figure 1-6 as examples. Despite of excellent in vitro potency and 
good selectivity, these analogues could not progress to clinical development due to their 
poor in vivo efficacy and high serum albumin binding.[8, 61] However, these analogues 
demonstrated that selective inhibition of the pathogen aaRS can be achieved by replacing 
the adenine base of the aaSA analogues with heterocycles which deviate significantly 
from adenine. 
Mupirocin-based aaRS inhibitors 
Mupirocin is the only aaRS inhibitor approved by the FDA for clinical use. 
However, its use is limited to topical application due to poor stability at physiological 
conditions. Therefore, efforts have been invested to improve the pharmacological 
properties of mupirocin. Hereto, a series of β-diketone derivatives have been synthesized 
and evaluated. The two most important analogues of this series are depicted in Figure 1-6. 
The compounds 1.31 (MIC of 1 µg/mL against S. aureus) and 1.32 (MIC of 0.5 µg/mL 
against S. aureus) displayed excellent antibacterial activity and improved 
pharmacological properties such as reduced serum binding. Both compounds were 
effective in treating mice infected with S. aureus, both after oral and subcutaneous 
administration.[39b] The compound SB234764 (1.33, Figure 1-6) is a rationally designed  
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Figure 1-6: aa-AMP (1.19), its non-hydrolysable analogues and few representative 
synthetic analogues as aaRS inhibitors. 
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femtomolar inhibitor of IleRS with Kd <0.01 nM. The compound combines the structural 
features of mupirocin (1.8, Figure 1-5) and isoleucyl-sulfamoyl adenosine (1.25, general 
structure for aaSA, Figure 1-6).[39a, 39c] Besides these analogues, several other 
modifications of mupirocin have been attempted but none of them was developed into 
clinically useful antibiotics. 
MetRS inhibitors 
In 2009, a novel series of diaryldiamine derivatives have been reported as 
bacterial MetRS inhibitors. These compounds are originally developed by 
GlaxoSmithKline and Replidyne for treatment of S. aureus and Clostridium difficile 
infections. As outlined by Critchley et al.[62] one of the analogue of this series, REP3123 
(1.34, Figure 1-6) was active against 108 clinical isolates with MIC range of 0.5-1 
µg/mL. REP3123 proved to be a strong and selective inhibitor of C. difficile MetRS with 
a calculated inhibition constant (Ki) of 0.02 nM with a selectivity of > 1000-fold for 
bacterial MetRS over its human orthologs. Later, these leads were further optimized by 
Buckner and colleagues in their efforts to fight trypanosomiasis.[63] A new series of 
diaryldiamines was uncovered, selectively inhibiting the bloodstream form of 
Trypanosoma bruci at low nanomolar concentration (1.35, Figure 1-6). The 
aminoquinolone heterocycle was further replaced with substituted arylurea derivatives to 
improve the bioavailability of these analogues (1.36, Figure 1-6).[64] 
AN2690: an editing site inhibitor of LeuRS 
Recently, Anacor Pharmaceuticals reported a series of substituted benzoxaborole 
derivatives for treatment of fungal infections, especially onychomycosis (nail fungal 
infection) and other cutaneous infections caused by fungi, yeast, molds or dermatophytes. 
AN2690 (1.37, Figure 1-6) is the most active compound of the series. Unlike other aaRS 
inhibitors, AN2690 is a non-competitive editing site inhibitor of LeuRS and acts by 
trapping the tRNALeu through covalent bonding of boron with the 2’- and 3’-hydroxyl 
function of the 3’-terminal adenosine.[9a] The compound is claimed to penetrate through 
the nail bed by virtue of its physicochemical properties. It is a broad-spectrum antifungal 
agent with MIC 0.06-1 µg/mL. Unlike other antifungal agents, AN2690 has minimal 
affinity for keratin and the presence of 5% keratin does not affect its MIC value. Clinical 
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studies on human nails showed that the compound penetrates 250 times better than a 
conventional antifungal agent like ciclopirox.[65] AN2690 showed good efficacy and 
safety in phase I and II clinical trials and is now in phase III of clinical development for 
the treatment of onychomycosis. 
1.4  Microcins 
Microcins are ribosomally synthesized peptide antibiotics produced by the family 
of Enterobacteriaceae mainly E. coli strains of fecal origin.[66] Microcins are usually 
small molecules with molecular weight less than 10 kDa.[66b] Microcins were formerly 
called ‘colicins’ as they both are produced by the same family of bacteria, have the same 
mode of action and both are encoded by plasmid. However, microcins are differing from 
the colicins in many aspects like molecular weight and the mode of production and 
secretion out of the producing cells. Microcins are low molecular weight compounds 
usually less than 10 kDa whereas the colicins are much bigger (from 25-80 kDa). Colicin 
production is induced by the SOS system whereas microcins are produced when the 
bacteria approaches the stationary phase (the nutrients are depleted and cells become 
starved).[66b, 67] Until now, only 11 microcins have been identified and these microcins are 
MccB17, McC7, McE492, McJ25, McL, McV (also known as ColV), McD93, McH47, 
McI47, McM, Mc24.* However only the first six microcins have been structurally 
characterized.[68] In addition, based on the post-translational modifications, microcins are 
classified into two classes, modified and unmodified microcins. The unmodified 
microcins are usually polypeptides with a molecular weight ranging from 8 to 10 kDa and 
examples include McE492, McL and McV. In contrast, the modified microcins are 
usually smaller peptides with a molecular weight <5 kDa. These microcins are 
extensively modified post-translationally and examples include McB17, McC7, McJ25, 
McD93, McH47, McI47, McM and Mc24.[69] Being an aaRS inhibitor and relevant to this 
thesis, only microcin C has been discussed here.  
1.4.1 Microcin C (McC) 
 Microcin C (McC, 1.17a, Figure 1-5) is a nucleotide-peptide antibiotic produced 
by some E. coli strains during the stationary phase of growth. It is the smallest known 
microcin and consists of a modified AMP attached to the α-carboxyl group of aspartic 
acid through an N-acyl-phosphoramidate linkage. The later amino acid itself is at the C-
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terminal end of a formylated heptapeptide.[70] The phosphate group of AMP is further 
decorated with a aminopropyl group.[66a] Microcin C displayed a broad-spectrum of 
antibacterial activity, being  active against many Gram-negative and Gram-positive 
bacteria.[71] Previously, McC51 and McC7 are believed to be different microcins, 
however detailed NMR and mass spectrometry studies in combination with biochemical 
assays revealed that McC7 and McC51 are identical and thereafter both are referred to as 
McC.[70, 72] 
1.4.2 Biochemical synthesis of McC 
In E. coli, the plasmid carrying the mccABCDEF gene cluster determines the 
production, maturation, and extracellular export of McC and also provides self 
immunity.[73] Biosynthesis of McC begins with the translation of a 21 bp-long gene, mccA 
which is among one of the shortest protein-coding bacterial genes known. The 
heptapeptide product of mccA (formyl-MRTGNAN) undergoes extensive modifications 
as shown in Figure 1-7. The polypeptide product of mccB gene (MccB) catalyzes the 
attachment of heptapeptide to AMP in a two steps process, each requiring one molecule 
of ATP.  In the first step, the nucleophilic attack of the α-carboxylate of Asn7 on the α-
phosphate of ATP leads to formation of a heptapeptide-succinimide via heptapeptide-
AMP. Similarly, in the second step, the nucleophilic attack of the succinimide nitrogen on 
the α-phosphate of ATP gives a reactive intermediate which upon hydrolysis gives the 
heptapeptide attached to AMP through an N-acyl-phosphoramidate linkage. The reaction 
results in conversion of Asn7 to Asp7 with the nitrogen linked to AMP.[74] 
 
 
 
 
 
 
*Some authors prefer to use Mcc abbreviations for microcin. For e.g. Microcin C7 can be 
abbreviated as MccC7 or McC7 
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 Figure 1-7: Synthesis and maturation of microcin C by MccB, MccD and MccE. 
 
Following formation of the correct phosphoramidate linkage, the heptapetide 
adenylate is further modified by interplay between MccD and the N-terminal end of 
MccE which together responsible for the attachment of 3-aminopropyl to the phosphate 
moiety. MccD shows signature motifs as found in S-adenosylmethionine and MccE is 
similar to the 5’-phosphate-dependent decarboxylase. Therefore, it is hypothesized that 
the attachment of the 3-aminopropyl group may also follow a similar pathway, in which 
MccD may be responsible for transfer of a 3-amino-3-carboxyl group onto the 
heptapeptide-adenylate, followed by MccE catalyzing a decarboxylation yielding mature 
microcin C.[66a] It has been found anyhow that the 3-aminopropyl group increases the 
antibacterial activity by 10-fold (Figure 1-7).[75] 
1.4.3 McC: Trojan-horse inhibitor 
Mature microcin C is actively taken up by sensitive cells via YejABEF 
transporter. The McC peptide part is crucial for the recognition by the YejABEF 
transporter. Although the biological function of YejABEF and the natural substrate for 
the transporter is not known, it is believed that the YejABEF transporter may be involved 
in the transport of oligopeptides (containing N-terminal formyl-methionine) inside the 
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cells. In analogy, it has been observed that the same transporter contributes to the 
virulence of Salmonella and in addition ∆yej mutants became sensitive to antimicrobial 
peptides (AMPs).[76] Moreover, it has been shown that McC analogues with a shorter 
peptide length (less than six amino acids) are not recognized by the YejABEF transporter 
and formyl-methionine at the N-terminal increase the recognition by the transporter.[77] 
Once internalized, McC is processed by peptide deformylase followed by one of the 
broad-specificity aminopeptidases pepA, pepB or pepN to release the toxic moiety which 
is a non-hydrolyzable analogue of aspartyl-adenylate and inhibits AspRS. The mature 
McC does not inhibit the in vitro aminoacylation reaction and processed McC does not 
inhibit the growth of sensitive cells up to millimolar concentrations. Thus McC acts as a 
Trojan-horse antibiotic where the hexapeptide facilitates the transport of mature McC.[78]  
1.4.4 Mechanisms of McC resistance or self immunity against McC 
As AspRS of McC producing cells can be easily inhibited by processed McC, 
there must be mechanisms to ensure that McC production is not detrimental to the 
producing cells. One such mechanism involves MccC, a superfamily efflux pump 
encoded by the mccC gene and responsible for export of mature McC out of producing 
cells. It has been observed that deletion of mccC is dentrimental to the producing cells 
whereas over-expression of mccC alone provides resistance to McC sensitive cells. These 
observations indicate that MccC can provide resistance to internally produced or 
externally added McC.[70, 72, 75]  
A Trojan-horse mechanism of action of McC further suggests that the 
accumulation of processed McC inside the producing cells is unavoidable; however the 
producing cells remain viable. Hereto, the internally produced processed McC is 
detoxicated by two different mechanisms. The first mechanism involves the acetyl-CoA-
dependent acetyltransferease activity of the C-terminal of MccE protein (MccECTD). 
MccECTD specifically acetylates the α-amino group of aminoacyl-nucleotides and does 
not depend on the nature of the amino acid nor the bond between the amino acid and the 
nucleotide nor the nature of the nucleotide (purines or pyrimidines). However, intact McC 
lacking the formyl group is not a substrate for MccE.[79] Acetylation of the α-amino of 
aspartate of processed McC may prevent its interaction with AspRS which provides the 
molecular basis for self immunity provided by MccE. The MccE acetyltransferase shares 
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homology with the bacterial Nα-acetyltransferases of the Rim family which are 
responsible for acetylation of ribosomal protein. 
MccF is a serine protease which cleaves the carboxamide bond between the Asp7 
residue of intact or processed McC and the nucleotide which confers the second line of 
defence mechanism against internally accumulated processed McC. Unlike to MccE, 
MccF is rather specific for aspartate or glutamate containing aminoacyl-nucleotides. It 
has been observed that MccF could not hydrolyse the phosphoramidate bond found in 
agrocin 84 or the amide bond found in albomycin.[80] 
1.4.5 McC-based analogues as potential antibiotics 
Microcin C is an attractive and versatile platform to design biologically active 
peptide-adenylates. Indeed the McC peptide moiety has been coupled to various aaSA 
analogues (Figure 1-8) which are evaluated for antibacterial activity. It has been found 
that these analogues also act as Trojan-horse inhibitors and growth inhibitory activities 
were comparable to native McC. However, the activities of the compounds containing a 
non-polar amino acid (Ile, Leu, Val, Ala, etc) at the seventh position proved slightly 
lower.[81] In addition, compounds lacking a formyl group at the N-terminal showed less 
active as compared to native McC but more active than McC lacking formyl and the 
aminopropyl group.[82] Deviation from McC structure could be quite extensive and McC 
analogues with different peptide moieties can be obtained by site-specific mutagenesis of 
mccA gene, or by chemical or enzymatic synthesis. It has been observed that the 
compounds with a shorter peptide chain (less than six amino acids) were poorly 
recognized by the YejABEF transporter. Replacing the N-terminal methionine with 
another amino acid abolishes the activity. Exclusion of Arginine at position 2 results in a 
drastic decrease in potency of the compound.[77] The nucleotide part also plays a vital role 
in the recognition by the YejABEF transporter. The compounds with an aryl-tetrazole 
moiety substituting for the adenine base apparently were not recognized.[83] 
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Figure 1-8: General structure for McC-based synthetic analogues (fXaaSA) targeting 
different aaRS. (fXaaSA, where X = MRTGNA, aa = amino acid). 
1.5  Limited permeability of the outer membrane: a hurdle in 
antimicrobial therapy 
As mentioned earlier, due to the emergence of multi-drug resistant pathogens, 
there is an urgent need for new anti-infective agents.[84] There are several mechanisms of 
bacterial resistance such as increased production of enzymes that inactivate/metabolise 
drugs, mutations leading to target alteration, efflux of the drug out of the bacterial cell 
and most important the limited permeability of cells. In most of Gram-positive bacteria, 
the cell wall consists of multilayer of peptidoglycan which forms the rigid structure and 
provides mechanical strength to the cell. On the contrary, the cell wall of Gram-negative 
bacteria consists of one or few layers of peptidoglycan, the periplasmic space and the 
outer membrane. The outer membrane of Gram-negative cell consists of 
lipopolysaccharides (LPS), lipoproteins and phospholipids which provides main barrier to 
many antibiotics. The cell envelop permeability barrier is particularly strong in Gram-
negative pathogens like Pseudomonas aeruginosa, Burkholderia cepacia, and other 
Gram-negative bacteria.[1b] These species are mainly associated with pneumonia, 
bacteraemia, and lung infection in cystic fibrosis. P. aeruginosa is well known for its 
intrinsic resistance due to its rigid, less diffusible cell membrane and its ability to develop 
multidrug resistance following therapy.[5a] Many antimicrobials are not effective against 
Gram-negative bacteria simply because they couldn’t cross the cell membrane and reach 
the site of action. 
There are several ways to overcome resistance due to limited permeability of the 
outer membrane of Gram-negative pathogens. One of them is the combination of drugs 
with an element acting on the outer membrane of the bacterial cell wall and altering its 
permeability, leading to increased concentration of drugs in bacterial cells. Examples of 
compounds acting on the outer membrane include pore forming antimicrobial peptides. 
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Alternatively, one can make use of the bacterial essential nutrient uptake system by a 
Trojan-horse mechanism.[5a] Therefore, an iron transport system is the most suitable for 
this Trojan-horse strategy as it is essential for all living organisms and plays a central role 
in the diverse biological functions. 
1.5.1 Why iron? 
It has been well documented that iron is an essential micronutrient for all forms of 
life except lactic acid bacteria.[6, 85] It plays an ubiquitous role in the variety of metabolic 
and informational cellular pathways. Several enzymes acting in the primary and 
secondary metabolic processes possess an iron containing cofactor. Iron is also an 
important part of the biological redox system. The reversible Fe2+/Fe3+ redox pair makes 
iron an extremely versatile catalytic centre or enables its use as an efficient electron 
carrier.[86] Thus, iron is important for numerous biological processes such as 
photosynthesis, respiration, the citric acid cycle, oxygen transport, gene regulation, DNA 
biosynthesis etc.[6] Although iron is one of the most abundant elements in the earth crust, 
it does not occur in its biologically relevant ferrous form.[86a] Under aerobic condition 
ferrous ion is unstable. In aqueous environment, iron readily involves in the Fenton 
reaction to give ferric ion, and it further aggregates into an insoluble ferric hydroxide 
polymer. Therefore the availability of iron is limited to 10-18 M due to the low solubility 
of ferric hydroxide (Ksp = 10-38)[85] in aerobic conditions at physiological pH. In 
biological fluids, iron is tightly bound to high affinity proteins such as transferrin, 
lactoferrin or ferritin which further limit the growth of pathogens.[87] Bacteria require 10-6 
M internal iron concentration to achieve optimal growth.[88] Virulence and even survival 
of infectious microbes largely depends on a key micronutrient like iron.[89] To circumvent 
this discrepancy, many microbes, plants and even higher organisms (i.e. octopi) 
synthesize and utilize very specific low molecular weight iron chelators called 
siderophores (previously called siderochrome).[85, 90] 
1.5.2 Siderophores: a weapon in a battle for iron acquisition 
As mentioned in the previous section, siderophores are low molecular weight iron 
chelators secreted by all microorganisms as part of an iron acquisition system. Under 
physiological condition, iron mainly exists in the ferric state (Fe3+) which is relatively 
hard as compared to its reduced and biologically relevant ferrous (Fe2+) form. In general, 
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siderophores have strong affinity for the ferric form. Therefore siderophores usually 
contain hard ligands bearing oxygen to coordinate with Fe3+. However, upon 
internalization, Fe3+ is reduced to Fe2+, in which the affinity of the siderophore for iron 
(II) is drastically reduced and iron is released as Fe2+.  Till date, more than 500 
siderophores have been reported in the literature and based on their chemical structure 
(iron chelating moieties), they are classified into four main groups. These include α-
hydroxycarboxylates, hydroxamates, catecholates and mixed ligand siderophores. The 
mixed ligand siderophore is usually comprised of combinations of two or all three 
aforementioned iron chelating moieties. Some general structures for siderophores are 
depicted in Figure 1-9. However, a detailed chemistry and biology of siderophores falls 
beyond the scope of this thesis and hence will not discuss here. Chemical synthesis of 
siderophores, their mechanisms of iron acquisition and transport across the cell membrane 
have been reviewed elsewhere.[91] 
 
 
Figure 1-9: General structures of siderophores (shown with a single subunit of the iron 
chelating moieties). 
1.5.3 Siderophore-mediated drug delivery: a Trojan-horse strategy 
In summary, bacterial iron acquisition mechanisms are essential, efficient and 
vital for survival and virulence in the infected host. Therefore, the iron acquisition system 
is considered as an ideal target for anti-infective therapy. There are mainly three 
approaches which can be used to develop anti-infective agents which include (i) iron 
starvation via competitive chelation, (ii) siderophore biosynthesis inhibition[92] and (iii) 
Trojan-horse antibiotics using siderophore-mediated drug delivery. This dissertation deals 
with the third approach where the iron uptake system can be misused to circumvent the 
resistance associated with the low permeability barrier. Indeed, there are a few examples 
of natural siderophore-drug conjugates (SDCs) which include albomycin, ferrimycin, 
salmycin, etc. These antibiotics are actively taken up via the iron transport system 
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followed by metabolism to release the active moiety which elicits its toxic effect. Here, 
albomycin, salmycins and ferrimycins will be discussed as examples of sideromycins.  
1.5.4 Albomycin 
In 1951, albomycin was discovered by Gause and Brazhnikova.[93] However, the 
correct structure was not determined until 1982 by Benz et al.[94] Albomycin is a Trojan-
horse antibiotic produced by Streptomyces strain ATCC 700974 as a mixture of closely 
related substances (1.18a-c, Figure 1-5).[95] In 1955, albomycin was used in the Soviet 
Union to treat bacterial infections in children.[93] It is a potent SerRS inhibitor and 
consists of a thioxylofuranosyl pyrimidine moiety linked to a siderophore (an iron 
chelator part) thus called sideromycin antibiotic. The siderophore part is comprised of a 
L-ornithine tripeptide-based trihydroxamate and is connected to the active moiety via an 
amide linkage.[96] Albomycins were classified as δ1, δ2 and ε based on the substituent at 
the cytidine base (1.18a-c). The siderophore part is responsible for the uptake of 
albomycin by virtue of its ability to form a complex with iron and is recognized by the 
iron channel. It is highly active against most of the Gram-negative and some of Gram-
positive bacteria with MIC of 5 ng/mL against E. coli and 10 ng/mL against 
Streptococcus pneumoniae.  
The transport of albomycin across the bacterial cell membrane has been studied in 
detail in E. coli K-12 and it was found that it is transported across the cell membrane by 
the same transport system as that of ferrichrome (a natural siderophore consisting of a 
cyclic hexapeptide with three glycines and three modified ornithines). The albomycin 
transport system is encoded by four genes fhuABCD.  First albomycin is actively 
transported across the outer membrane of E. coli K-12 and delivered to the periplasmic 
space by the FhuA protein. In the periplasmic space it interacts with the FhuD protein and 
is shuttled to an ATP Binding Cassette (ABC) transport system embedded within the 
cytoplasmic membrane (FhuBC). Upon recognition of FhuD loaded with albomycin, 
FhuBC triggers the hydrolysis of ATP which in turn opens the channel through which 
albomycin is translocated to the cytoplasm.[97] Hereto, upon uptake, albomycin is 
metabolized by the serine peptidase (pepN) to release the toxic moiety which resembles 
seryl-adenylate and thus selectively inhibits bacterial SerRS. In case of Salmonella 
typhimurium, peptidase A is capable of releasing the toxic moiety.[98] 
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Resistance to albomycin has been observed through a point mutation in the FhuB 
gene which also results in loss of ability to recognize and transport ferrichrome and hence 
leads to decreased bacterial fitness.[95b, 99] Moreover, a single point mutation in the ATP 
binding domain of FhuC also confers resistance to albomycin.[100] Recently, albomycin 
proved to be effective in treating mice infected with Streptococcus pneumoniae or 
Yersinia enterolitica.[95b] However, the use of albomycin as a potential antibiotic is 
limited due to difficulties in obtaining sufficient amounts by isolation or chemical 
synthesis. Benz et al. synthesized an albomycin δ1 analogue replacing ribose for 
thioribose moiety. However, the newly synthesized analogue was to be inactive.[101] The 
synthesis of the ornithine tripeptide-based trihydroxamate was further improved by Miller 
by using indirect oxidation method.[102] 
1.5.5 Biochemical synthesis of albomycin 
 Figure 1-10: Proposed biosynthesis of albomycin in Streptomyces sp. ATCC 700974 
(adapted from ref.[103]) 
 
Recently, biosynthesis of albomycin has been proposed based on  detailed genetic 
and biochemical studies.[103] The gene cluster abmABQ is proposed to be responsible for 
General introduction 
29 
 
biosynthesis of the ferrichrome siderophore part of albomycin. AbmA is a flavin-
dependent monooxygenase and responsible for synthesis of Nδ-hydroxylation of L-
ornithine whereas AbmB is an N-acyltransferase and acetylates the Nδ-amino moiety 
using acetyl-CoA as a cofactor. Collectively AbmA and AbmB afford Nδ-acetyl-Nδ-
hydroxy-L-orninthine (AHO) as a building block which is used by AbmQ, a non-
ribosomal peptide synthetase (NRPS) for iterative condensation to yield the tripeptide 
siderophore. After off loading of siderophore tripeptide, AbmC and another ATP utilizing 
enzyme are proposed to be responsible for the formation of the remaining amide bonds 
including the amide bond between the unusual 4’-thioxylosyl amino acid and the serine. 
Biosynthesis of the unusual 4-thioxylofuranosyl-cytidine moiety is very complex 
process and involves reactions such as oxidation, isomerisation, sulfur insertion and ring 
closure. Next, a typical N-glycosidic bond is formed by displacement of phosphate group 
at the anomeric carbon of thiosugar and is catalyze by AbmG. Finally, after attachment of 
the ferrichrome siderophore, the cytidine base is further modified by N3 methylation and 
N-carbamoylation catalyzed by AbmI and AbmE respectively. The biosynthetic pathway 
of albomycin is depicted in Figure 1-10.[103] 
1.5.6 Salmycin 
Salmycins (1.42, Figure 1-11) were isolated from cultures of Streptomyces 
violaceus DSM8286 by Vertesy and co-workers as a mixture of four different 
compounds. Salmycins showed potent activity against Streptococci and Staphylococci 
strains.[104] Because of stability reasons, salmycins B and C were isolated under acidic 
conditions whereas salmycin A and D were isolated strictly under neutral conditions. 
Unlike albomycins, salmycins contain danoxamine (iron carrier) which is 
connected to the amino-disaccharide (active moiety) through an ester linkage. The exact 
mode of action of salmycin is unclear however; it is believed that they act as a protein 
synthesis inhibitor.[99] In 2000, Roosenberg and Miller postulated that upon reduction of 
iron, intramolecular cyclization confers the release of the active moiety in salmycins 
(Figure 1-11). In order to investigate the transport ability of danoxamine-drug conjugates 
and to elucidate the mechanism of drug release they coupled the danoxamine siderophore 
with commercially available antibiotics such as ciprofloxacin, triclosan and Lorabid® 
through either an ester or amide linkage.[105] They showed that the SDCs are actively 
taken up via the iron-channel. The order of antibacterial activity found was SDCs with an 
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ester linkage> parent drug> SDCs with amide linkage. The data clearly show that the 
release of the active moiety is the bottleneck in using siderophores as delivery agents. 
However, the proposed mechanism of drug release of salmycins remained to be 
confirmed.[105] 
 
Figure 1-11: Structures of salmycin A-D and drug-release mechanism of danoxamine-
drug conjugates. (adapted from ref.[105]) 
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It has been observed that mutants of Gram-positive bacteria such as S. 
pneumoniae and S. aureus showed cross resistance among salmycins and albomycins. 
Moreover, the toxic effect of salmycin and albomycin can be nullified by addition of 
ferrichrome and ferrioxamine to the medium. These facts suggest that salmycin and 
albomycin presumably utilize the same uptake mechanism (iron-transport).[99] Albomycin 
has a broad-spectrum of activity and it is effective against Gram-positive and Gram-
negative bacteria while salmycin is primarily active against Gram-positive bacteria. As 
compared to albomycin, salmycin proved to be more effective against multidrug resistant 
S. aureus (MRSA), especially with efflux mediated multidrug resistance (ERSA). 
However, comparative in vivo studies by Braun et al revealed that salmycin is less active, 
probably due to its labile ester linkage. Miller et al. reported synthesis of 
desferrisalmycin[104a], siderophore danoxamine[106] and several danoxamine-drug 
conjugates (manuscript in preparation according to ref.[105]). 
1.5.7 Ferrimycins 
Ferrimycin was isolated form Streptomyces griseoflavus (Strain ETH 9578) as a 
mixture of ferrimycin A and B.[107] Because of narrow-spectrum of activity, less attention 
has been given to ferrimycins. Ferrimycin A comprise of ferrioxamine B as an iron carrier 
connected to the active part via aminohydroxybenzoic acid bridge (1.43, Figure 1-12). 
 
 
Figure 1-12 Structure of ferrimycin A 
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1.5.8  Synthetic siderophore-drug conjugates (SDCs): an application of Trojan-
horse strategy 
Inspired by the natural sideromycins, siderophore-mediated drug delivery has 
been demonstrated previously.[89, 108] Numerous synthetic SDCs of β-lactam antibiotics 
with different natural and synthetic siderophores have been prepared and evaluated for 
antibacterial activity. A few examples of such synthetic SDCs have been depicted in 
Figure 1-13. A commercially available antibiotic Lorabid® was coupled to a natural 
trihydroxamate siderophore (SDC 1.44) and a mixed-ligand siderophore (SDC 1.45). 
Both these SDCs exhibit mild antibacterial activity against Gram-positive and Gram-
negative bacteria and showed delayed microbial growth as compared to the control. It has 
been found that mixed-ligand siderophore containing SDCs (1.45) appear to be able to 
use more than one iron-transport to deliver the active moiety to exert its toxic effect.[108b] 
Analoguosly, Marvin et al. designed and synthesized a tris-catecholate 
siderophore with tripodal backbone and its conjugates with ampicillin (1.46) and 
amoxicillin (1.47). In iron-deficient media, both SDCs displayed significantly increased 
antibacterial activity against Gram-negative bacteria (MIC 0.05 to 0.39 µM) compared to 
their parent drugs (>100 µM) especially against P. aeruginosa while inhibitory activities 
of SDCs were impaired in iron rich media. The SDCs utilize energy-dependent iron-
transport system for uptake which accounts for their enhanced antibacterial activity.[109] 
In the same line, Mollmann and co-workers synthesized different catechol type 
SDCs and tested them for antibacterial efficacy. They further optimized the lead SDC 
structure with respect to the number of catechol moieties and the length of the linker 
separating the siderophore and the active moiety. A special feature of these SDCs is that 
the catecholate groups were masked either with acetyl, acetoxyl, methoxycarbonyloxy or 
with a cyclic dioxobenzoxazinyl group. The masking groups were claimed to cap the 
catechol groups thus preventing negative side effects.[5a, 110] Representative structures of 
the two SDCs (1.48 and 1.49) have been given in Figure 1-13. 
Thus, overall the choice of siderophore, linker and drug all are very crucial for 
siderophore-mediated drug delivery. Iron channel mediated active transport may also 
reactivate drugs to which resistance has been developed by alteration in membrane 
permeability. Moreover, after penetration of SDCs across the outer membrane, the active 
moiety must be released to enable its inhibitory activity. Finally, siderophore alone or 
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SDCs may exert inhibitory activity simply by withholding iron which is essential for 
survival and virulence of pathogens. 
 Figure 1-13: Selected examples of synthetic siderophore-drug conjugates (SDCs). 
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1.6 Hypothesis and objectives of this dissertation 
Although, aaSA analogues proved to be excellent inhibitors of the corresponding 
aaRSs, further development was halted due to their poor in vivo efficacy and their lack of 
selectivity. Moreover, synthesis of aaSA analogues is cumbersome and low yielding due 
to a cyclic degradation product formed during their synthesis. Therefore, we set out 
specific objectives for our work as outlined below. 
1.6.1. Siderophore-drug conjugates (SDCs): a Trojan-Horse strategy to 
improve the in vivo efficacy of aminoacyl-sulfamate derivatives. 
Siderophore Linker Drug
Iron binding
Fe+3
Siderophore Linker Drug
Fe+3
Siderophore receptors/
iron channel
Cell membrane
Cytosol
Outside
Siderophore Linker Drug
Fe+3
Fe+2 Fe+3
Iron
reductase
Siderophore Linker Drug
Siderophore Linker Drug+
Figure 1-14: Siderophore-mediated drug delivery. 
 
In a first part as described in chapter 2, we attempted to improve the in vivo 
efficacy of aminoacyl-sulfamate derivatives by combining them with a siderophore (an 
iron chelator part). In 1998, Cubist Pharmaceuticals reported a series of aryl-tetrazole 
containing aminoacyl-sulfamates as potent and selective inhibitors of the corresponding 
aaRSs. However, further development was halted due to their lack of cell-penetration and 
high serum albumin binding. We were interested to determine, whether the compounds 
reported by Cubist Pharmaceuticals when coupled to a siderophore part of albomycin or 
biscatecholate could function as a Trojan-horse inhibitors. Moreover, high selectivity of 
these analogues is an added advantage. Therefore, we hypothesized that when a 
siderophore-drug conjugate (SDC) would be presented to bacteria, it will be internalized 
by active transport using specialized transport (e.g. iron channel). Once inside the cell, the 
iron(III) should be reduced to iron (II) and the conjugate should be metabolized by broad-
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specificity peptidases to release the active moiety and thus exert its antibacterial effect 
(Figure 1-14).  
To test our hypothesis, the aryl-tetrazole containing sulfamates were coupled to 
the siderophore (trihydroxamate or biscatecholate) to yield SDCs which were evaluated in 
vitro as well as in cellular system for their potential antibacterial activity. The growth 
inhibitory properties of newly synthesized SDCs were determined in MHA, M63 and LB 
medium. To facilitate antibacterial evaluation and mechanism of action studies, the LB 
medium was supplemented with or without iron chelator. However, for unclear reasons, 
our attempts to synthesize triscatecholate siderophore (linear enterobactin analogue) 
failed. Moreover, we failed to get the desired aaSA containing trihydroxamate-based SDC 
due to their instability. 
1.6.2. Determination of the pharmacophoric importance of the adenine base 
in aminoacyl-sulfamoyl adenosines (aaSAs). 
Visual inspection of the compounds reported by Cubist Pharmaceuticals (1.29 and 
1.30, Figure 1-6), and of albomycin (1.18, Figure 1-5) and mupirocin (1.8, Figure 1-5) 
revealed that these structures vary from aaSA analogues in having a heterocyclic base, a 
modified base or no base moiety at all as in mupirocin, respectively. This observation 
prompted us to investigate the pharmacophoric importance of the adenine base in 
aminoacyl-sulfamoyl-adenosines (aaSAa). Therefore, in second part as described in 
chapter 3, we synthesized and evaluated several isoleucyl-sulfamoyl nucleoside analogues 
with either uracil, cytosine, hypoxantine, guanine, 1,3-dideaza-adenine (benzimidazole) 
or 4-nitro-benzimidazole as the heterocyclic base (Figure 1-15). Based on the structure 
and antibacterial activity of microcin C, we also prepared their hexapeptidyl conjugates in 
an effort to improve their uptake potential. 
 
Figure 1-15: General structure of base substituted 5’-O-(N-isoleucyl)sulfamoyl 
nucleosides 
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1.6.3  5'-(N-aminoacyl)-sulfonamido-5'-deoxyadenosine: Attempts for a stable 
alternative to aminoacyl-sulfamoyl adenosines 
Finally, it has been reported in the literature that during their synthesis 
sulfamoylated adenosines are prone to form cycloadenosine derivatives resulting in low 
yields for the different reactions and difficult purifications (Figure 1-16). Therefore, in the 
final part of this thesis, we looked for a stable alternative to aaSA analogues. Hereto, we 
hypothesized that deletion of the 5’-oxygen would render the C-5’ less electrophilic and 
less prone to attack by N3 of the adenine moiety. 
 
 
Figure 1-16: Cyclic adenosine derivative formed during synthesis of different aaSA 
analogues. 
Thus a series of hitherto unknown aminoacyl sulfonamide (aaSoA) derivatives 
was prepared and evaluated in vitro as well as in a cellular system for their potential 
antibacterial inhibitory properties. Despite of numerous methods reported in the literature 
for synthesis of various sulfonamides. However, in our case, assembly of 5’-sulfonamido-
5’deoxyadenosine (SoA) intermediate proved cumbersome but was finally realized using 
1,3-dichloro-5,5-dimethyl hydantoin (DCDMH). These synthetic efforts will be described 
in chapter 4. 
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2 Siderophore-drug conjugates (SDCs): a Trojan-horse 
strategy to improve the in vivo efficacy of aminoacyl-
sulfamate derivatives 
 
 
 
Abstract 
In 1998, Cubist Pharmaceuticals patented a series of aminoacyl tRNA synthetase 
(aaRS) inhibitors based on aminoacyl sulfamoyladenosines (aaSAs) where the adenine 
base was substituted by an aryl-tetrazole moiety linking to the sugar via a two-carbon 
spacer. Although being strong and specific inhibitors of bacterial IleRS, these compounds 
could not be pursued further due to low cell penetration and strong binding to serum 
albumin. In this chapter, we attempted to improve the in vivo efficacy of these compounds 
by combining them with an iron transport module called siderophore (either 
trihydroxamate or biscatecholate). We found that trihydroxamate-based SDCs of aryl-
tetrazole variants still lacked antibacterial activity. However, these SDCs were readily 
processed by E. coli aminopeptidases with the release of toxic aaRS inhibitors. Hence, the 
lack of activity in the whole-cell assay was due to inability of the new compounds to be 
taken up by the cells. Possibly the absence of a nucleotide moiety in these analogues is 
responsible for facilitated transport for these compounds. Moreover, the biscatecholate-
based SDC was not processed by the aminopeptidases and therefore failed to release the 
toxic aaRS inhibitor. However, for unclear reason, our attempts to synthesize the tris-
catecholate siderophore (linear enterobactin) were not successful. 
 
Part of this chapter was published earlier in an adapted form as:  
“Microcin C and albomycin analogues with aryl-tetrazole substituents as nucleobase 
isoster are selective inhibitors of bacterial aminoacyl-tRNA synthetase but lack efficient 
uptake.” Vondenhoff, G. H., Gadakh, B., Severinov, K., and Van Aerschot A., 
ChemBioChem, 2012, 13 (13), p-1959-1969.[83]  
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2.1  Introduction 
As mentioned in the previous chapter, increasing resistance to antibiotics is a 
major problem worldwide and provides the stimulus to search for new antibacterials or 
new cellular targets which are essential for the survival of pathogen.[111] One such target 
is aminoacyl-tRNA synthetases (aaRSs). These enzymes play an indispensable role in 
protein synthesis. These enzymes are responsible for the attachment of the correct amino 
acid to its cognate tRNA. Aminoacylation occurs in a two step process. In a first step the 
amino acid is activated to form aminoacyl-adenylate (aa-AMP) and in a second step is 
esterified to the 2’- or 3’-hydroxy group of the 3’-end of the respective tRNA.[9b, 9c, 11] To 
date numerous aaRS inhibitors have been discovered either from natural or synthetic 
origin.[12, 39c, 112] The best known aaRS inhibitors to date are aminoacyl sulfamoyl 
adenosines that are non-hydrolyzable isosters of the aminoacyladenylate (aa-AMP), 
which is the reactive intermediate in the aminoacylation of tRNA. Unfortunately these 
compounds could not be pursued further due to their lack of selectivity and poor in vivo 
efficacy.[25, 59a]  
In 1998, Cubist Pharmaceuticals® reported synthesis and evaluation of a new 
series of aaRS inhibitors where the adenine base was replace with an aryl-tetrazole 
moiety and connected to the ribose through a two carbon linker. The tetrazole moiety is 
linked to either one or two five- or six-membered heterocycles. These analogues exhibit 
excellent in vitro activity with improved selectivity up to 3000 fold.[61] Some of the most 
important compounds, along with IleSA (2.1) are depicted in Figure 2-1 and their 
inhibitory properties are listed in Table 2-1. As can be seen, aryl-tetrazole-containing 
compounds 2.2 and 2.3 exhibit good activity against E. coli IleRS and poor activity 
against the human homologue (an especially profound difference is seen with CB168 
(2.3)). Of  the numerous compounds of this class synthesized and tested, only CB432 
(2.2) showed moderate activity against a broad range of bacteria including 
Staphylococcus aureus, S. epidermidis, S. saprophyticus, Streptococcus pneumonia, S. 
pyogenes, Enterococcus faecium, E. faecalis, Bacillus subtilis, Haemophilus influenzae, 
Klebsiella pneumoniae and Moraxella catarrhalis with MIC values ranging between 2 
and 100 µg/mL. In addition, CB432 (2.2) showed activity during treatment of mice 
infected with S. pyogenes. However, these compounds could not be pursued further as  
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Table 2-1 Comparison of IC50 values (in nM) for the selected Cubist Pharmaceuticals 
compounds along with Ile-SA against IleRS isolated from different microorganisms and 
human 
SN Compound S. aureus E. faecalis E. coli Human 
1. Ile-SA (2.1) 2.9 2 2 20 
2. CB 432 (2.2) 0.5 9 3.2 450 
3. CB 168 (2.3) 5 20 1.3 3000 
4. CB 286 (2.4) 4 10 1.3 524 
5. CB 360 (2.5) 4 4.4 12 190 
6. CB 447 (2.6) 0.5 8.6 1 570 
7. CB 628 (2.7) 3 6.3 27 455 
 
 Figure 2-1: Chemical structures of a few aryl-tetrazole containing sulfamate derivatives 
along with Ile-SA 
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potential antibiotics due to their poor in vivo efficacy and high affinity to serum 
albumin.[8] We were interested to determine, whether the compounds designed by Cubist 
Pharmaceuticals® when attached to the transport module of albomycin or to 
biscatecholate, could function as an aryl-tetrazole containing Trojan-horse inhibitor. To 
test our hypothesis, we concentrated on two different lead compounds, CB432 and CB 
168 (2.2 and 2.3, Figure 2-1). The compound CB 432 was opted in view of its broad-
spectrum of antibacterial activity, selectivity and moderate efficacy in an animal model, 
whereas CB168 was chosen for its great potential as a selective inhibitor of bacterial 
IleRS. Our hypothesis was that an aryl-tetrazole containing sulfamate coupled to a 
siderophore could be recognized by the iron channel. Once internalized, it could be 
metabolized by non-specific peptidases to release the active moiety and thus exert its 
antibacterial effect. Moreover, excellent selectivity of the parent analogues is an added 
advantage. 
2.2  Results 
2.2.1 Synthesis of L-ornithine-based trihydroxamate siderophore 
To test our hypothesis, we decided to couple the active moiety with the albomycin 
siderophore part as the latter is known to form a strong complex with iron and to be 
recognized by the iron-channel and to be metabolized by peptidases to release the active 
moiety.[96, 98] Therefore, we first focused our effort to the synthesis of L-ornithine 
tripeptide 2.14. The required L-ornithine tripeptide was synthesized starting from L-
ornithine.HCl 2.8 as outline in Scheme 2-1. Selective protection of the δ-amino group 
was achieved via Cu(II) complex of the L-ornithine followed by Boc protection of the δ-
amino group using Boc anhydride in the presence of 2N NaOH to afford the bis(Nδ-Boc-
L-ornithinato) Cu(II) complex 2.9 which upon copper removal gave compound 2.10.  
Similarly, Nα-Cbz-Nδ-Boc-L-ornithine 2.11 was obtained in a one-pot reaction using 8-
hydroxyquinoline as a copper sequestering agent and benzylchloroformate as a protecting 
agent in a mixture of acetone and water. This protocol omits a separate copper removal 
step.[113] As shown in Scheme 2-1, the required tripeptide was synthesized by employing 
an active ester mediated coupling between 2.10 and 2.11 as per literature procedure.[102] 
The active ester was prepared by reacting 2.11 with NHS and DCC in THF as a solvent. 
The resulting urea derivative was filtered off and the filtrate was used as such in the next 
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step. The active ester of 2.11 was reacted with 2.10 in a mixture of THF: water to provide 
dipeptide 2.12 in almost quantitative yield. Under the same coupling conditions, the 
dipeptide 2.12 was converted to tripeptide 2.13. The Νδ-Boc groups were cleaved by 
using TFA:water to yield appropriately protected tripeptide 2.14.[102] The desired 
siderophore (2.19) was synthesized starting from tripeptide 2.14 via its imine 2.15 which 
upon m-CPBA catalyzed oxidation afforded oxaziridine 2.16. Acid catalyzed ring 
opening of the oxaziridine afforded hydroxylamine hydrochloride 2.17 which was then 
acetylated using acetic anhydride and potassium acetate buffer (pH 4) to provide 
compound 2.18. Finally, the O-acetyl groups were removed by treatment with Hunig’s 
base in methanol to yield the desired siderophore as a DIPEA salt 2.19 (Scheme 2-2).[102]  
 
 
Scheme 2-1: Synthesis of L-ornithine tripeptide 
Reagents and conditions: (i) Cu(CH3COO)2•H2O,  2N NaOH, Boc2O, acetone: H2O, rt, 
44 h; (ii) 8-hydroxyquinoline, acetone: water, 4 h; (iii) 8-quinoline NaHCO3 acetone: 
H2O,  Cbz-Cl -10o C to rt, 2 h; (iv) 1. DCC/ NHS, THF, rt, 10 h; 2. 2.10, NaHCO3, THF, 
water, rt, 6 h; (v) TFA: H2O (5:2 v/v), rt, 3 h. 
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Scheme 2-2: Synthesis of L-ornithine-based trihydroxamate 
Reagents and conditions: (i) Benzaldehyde, KOH, dry CH3OH, molecular sieves 3 Å, rt, 
16 h; (ii) m-CPBA, dry CH3OH, 0o C, 4 h; (iii) 1. TFA:H2O, CH2Cl2, 40-50o C, 15 min; 2. 
1N HCl, rt, 2 h; (iv) Ac2O, CH3COOK/CH3COOH, pH 4 buffer, rt, overnight; (vi) 6% 
DIPEA in CH3OH, rt, overnight. 
2.2.2 Synthesis of trihydroxamate-based siderophore-drug conjugates 
Having the desired siderophore in hand, we attempted to couple the siderophore 
with an aryl-tetrazole containing sulfamate using HOBt, DIC and DIPEA as a base in 
DMF. However, we failed to get the desired product probably due to the competition 
between the α-amino group of isoleucine and the Nδ-hydroxyl function of the siderophore 
2.19. Therefore, protected siderophore 2.18 was coupled to the active moiety 2.20 under 
similar reaction conditions but the reaction was found to be low yielding. Moreover, 
diisopropyl urea, by-product of the reaction proved difficult to separate from the desired 
product. Therefore, we looked for other coupling conditions. The coupling reaction using 
HBTU, TEA in DMF afforded the coupled products 2.22 and 2.23 in good yield with 
straightforward purification. The coupled products were subjected to O-deacetylation 
using Hunig’s base in methanol[102] followed by hydrogenolysis using Pd/C in a mixture 
of methanol: water to provide siderophore-drug conjugates 2.26 and 2.27 (Scheme 2-3). 
However, our attempts to synthesize the SDC of aminoacyl-sulfamoyl adenosine were 
unsuccessful due to formation of a cycloadenosine derivative as a degradation product 
(Scheme 2-4). Indeed, it has been reported in literature that sulfamoyl adenosines are 
prone to form cycloadenosine.[114]  
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Scheme 2-3: Synthesis of siderophore-drug conjugates 
Reagents and conditions: (i) HBTU, TEA, dry DMF, rt, overnight (ii) 6% DIPEA in 
CH3OH, rt, overnight (iii) Pd/C, CH3OH:H2O (4:1 v/v), H2 atm. rt, 5 h. 
 
 
Scheme 2-4: An attempted synthesis of conjugate of triydroxamate siderophore with 
IleSA  
Reagent and conditions: (i) HBTU, TEA, DMF, rt, overnight. 
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2.2.3  Synthesis of a biscatecholate siderophore and its drug conjugate  
Beside the trihydroxamate-based siderophore, we also looked for an unnatural and 
relatively simple biscatecholate siderophore (2.33). This biscatecholate is known to 
promote the growth of bacteria which implies that it can form a complex with iron being 
recognized by the iron channel.[115] Moreover, SDCs of biscatecholate with β-lactam 
antibiotics proved to enhance antibacterial activity due to active uptake via the iron-
channel.[110a] As shown in Scheme 2-5, the biscatecholate siderophore was synthesized 
starting from 2,3-dihydroxy-benzoic acid (2,3-DHB) 2.30. Perbenzylation of 2.30 
followed by hydrolysis of the benzyl ester afford compound 2.32 in good yield. Active 
ester mediated coupling of 2.32 with L-ornithine.HCl (2.8) afforded the protected 
siderophore 2.33 suitable for coupling with active moiety 2.20. The HBTU mediated 
coupling of 2.33 with the active moiety 2.20, was followed benzyl deprotection, 
providing siderophore drug conjugate 2.35 (Scheme 2-5). 
Scheme 2-5: Synthesis of biscatecholate siderophore and its drug conjugate 
Reagents and conditions; (i) PhCH2Br, K2CO3, acetone reflux, 24 h; (ii) 5N NaOH, 
CH3OH, reflux, 3 h; (iii) 1. DCC, NHS, THF, rt, overnight, 2. L-Orn.HCl (2.8), NaHCO3, 
THF: H2O, rt, 6 h; (iv) HBTU, TEA, dry DMF, rt, overnight (v) Pd/C, H2 atm, CH3OH: 
H2O (4:1 v/v), rt, 2 h. 
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2.2.4 Synthesis of tris-catecholate siderophore 
 
Figure 2-2: Chemical structure of Enterobactin (2.36), its linear analogue (2.37) and 
linear analogue with amide linkage (2.38). 
 
In view of the disappointing results obtained with both the trihydroxamate and 
biscatecholate siderophores vide infra we continued to search for alternative. Enterobactin 
(Ent) (2.36, Figure 2-2) is an L-serine-based tris-catecholamide siderophore secreted by 
E. coli[116] and Salmonella typhimurium[117]. It is the strongest known iron chelator with 
an affinity constant[118] of 1052. Because of its remarkable iron-binding property, several 
modified analogues (cyclic or acyclic) of the enterobactin have been synthesized and their 
iron-binding ability has been assessed.[91a] It has been reported in the literature that the 
linear enterobactine analogue (2.37, Figure 2-2) also has comparable affinity for iron 
(complex formation constant of 1046.5).[91a, 119] Therefore we decided to synthesize the 
linear analogue of Ent allowing the free carboxylic group to be used as a handle to attach 
the active moiety. We reasoned however that the ester linkages in the linear enterobactin 
analogue may not be stable enough as these can be cleaved by extracellular esterases. We 
therefore we decided to synthesize a linear enterobactin analogue comprising amide 
linkages (2.38, Figure 2-2). Synthesis of the tris-catecholate siderophore is outlined in 
Scheme 2-6. The Nα-Cbz-asparagine 2.39 upon Hoffmann rearrangement using phenyl-
iodo diacetate (PIDA)[120] gave the β-amino-propanoic acid which upon Boc protection of 
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the β-amino group gave compound 2.41.[121] An active ester mediated coupling of 2.40 
with 2.41 afforded β-dipeptide 2.42.  
 
Scheme 2-6: Synthesis of tris-catecholate siderophore 
Reagents and conditions: (i) PIDA, EtOAc:CH3CN:H2O (2:2:1), 15o C to rt, 5 h;  (ii) 
Boc2O 10% Na2CO3 1,4-dioxane, overnight, rt  (iii) 1. DCC, NHS, THF, 0o C to rt, 
overnight; 2. 2.40, NaHCO3, THF: H2O, rt, 6 h (iv) Pd/C CH3OH, H2 atm, 6 h; (v) 1. 
2.32, DCC, NHS, THF 0o C to rt, overnight; 2. NaHCO3, THF:H2O, 6 h; (vi) 2.32, 
HBTU, TEA, DCM, rt, overnight; (vii) HBTU, TEA, CH3OH, DCM, 2 h; (viii) Pd/C, 
THF: acetic acid (3:2), H2 atm, 18h, rt; (ix) 2.32, HBTU, TEA, DMAP, dry DMF, rt, 
overnight; (x) 1. 2.32, oxalyl chloride, Toluene, 5o C, 30 min; 2. TEA, THF, 0o C to rt, 1 
h.  
 Under the same coupling conditions, the β-dipeptide was converted to the β-
tripeptide 2.43. For unclear reasons however, we failed to couple the deprotected β-
tripeptide 2.44 with 2,3-DHB (2.32) to yield appropriately protected siderophore 2.45 
using either an active ester mediated coupling with DCC/NHS in THF: water or with 
Siderophore-drug conjugates 
47 
 
HBTU/TEA in DMF. Neverthless, both conditions afforded active ester of 2.32 in almost 
quantitative yield. Therefore, to facilitate final purification and to enhance solubility of 
the deprotected tripeptide 2.44, the carboxyl terminal of the tripeptide was protected as a 
methyl ester and as shown in Scheme 2-6, deprotection of the Nβ-Cbz group by 
hydrogenolysis afforded 2.46. Acylation of the liberated amino groups was now 
attempted using either acyl chloride of 2.32 or active ester of 2.32 prepared in situ using 
using HBTU as a coupling agent. However, we failed again to get the desired product 
2.47 which upon hydrolysis of the methyl ester would have yielded the desired tris-
catecholate siderophore 2.45. 
2.2.5  Antibacterial activity of SDCs 
2.2.5.1  Disc Diffusion method 
The growth inhibitory activities of the SDCs 2.26 and 2.27 against E. coli strains 
(wt, ∆ABN and ∆Rim) and SDC 2.35 against E. coli wt were determined in MHA 
medium and M63 medium by disc diffusion method (for details see section 2.5.2.1). The 
growth medium was supplemented with and/or without 10 µg/mL of iron chelator such as 
2,2’-dipyridyl  or EDTA and with or without FeCl3 as iron source. The overnight grown 
bacteria were incubated with different concentrations of inhibitor at 37o C and the growth 
was observed over 18 h. None of the SDCs showed any growth inhibitory activity up to 5 
mM (data not shown). 
2.2.5.2  Micro broth dilution method 
The lack of inhibitory activity was further confirmed by micro broth dilution test 
in a 96 well microtiter plate. Here, the ability of the new siderophore-drug conjugates 
(2.26, 2.35) to inhibit the growth of E. coli wt were determined by measuring the optical 
density reached by identical cell cultures in the wells of microtiter plates in the presence 
of various concentrations of respective inhibitors. To facilitate the activity evaluation and 
mechanism of action studies, the LB medium was supplemented with or without 2,2’-
dipyridyl or alternatively with or without EDTA (10 µg/mL) as an iron chelator and with 
or without FeCl3 (equimolar to SDC) as an iron source. Iron chelators were added to 
make the growth medium iron deficient in order to promote the uptake of SDCs. As can 
be seen in Figure 2-3, the SDC does not exert any growth inhibitory activity. However, 
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growth inhibition was observed in a medium containing iron chelator indicating iron is an 
essential element for growth and survival of bacteria. The maximum inhibitor 
concentration used was 500 µM which upon dilution gave 25 µM of final concentration. 
 
Figure 2-3: Whole-cell antibacterial assay for SDC 2.26 using micro broth dilution 
method. 
In addition, the antibacterial activities of the plain toxic moieties and of their 
trihydroxamate siderophore conjugates were determined by monitoring the optical density 
of cell suspension of following strains: S. aureus ATCC 6538, Staphylococcus 
epidermidis RP62A (ATCC 35984), Pseudomonas aeruginosa PAO1, Sarcina lutea 
ATCC 9341 and Candida albicans CO11. Unfortunately, none of the analogues showed 
activity against the tested strains except compound 2.21, which proved active against S. 
aureus and also showed low activity against C. albicans as found earlier by Cubist 
Pharmaceuticals. In contrast, SDC 2.27 showed hardly any activity against S. aureus and 
C. albicans. Hereto, the maximum concentration tested was 500 µM which upon broth 
dilution gave final inhibitor concentration of 25 µM (Figure 2-4). 
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Figure 2-4: Growth inhibitory activity 
of compound 2.21 and its SDC 2.27 at 
25 µM against a) S. aureus and b) C. 
albicans over a time in LB medium. 
OD600 refers to the optical density of the 
cell culture measured at 600 nm. . 
2.2.5.3 In vitro evaluation of SDCs  
To rationalize the reason(s) for this disappointing lack of antibacterial activity of 
the SDCs (2.26 and 2.27), in vitro analysis was performed and the ability of the active 
moieties and their SDCs to inhibit Ile incorporation using a S30 cell extracts from E. coli 
was determined (Figure 2-5). Both compounds and their SDCs showed nice inhibitory 
activity against IleRS in a cell extract. Only in a ∆pepABN (lacking peptidases pepA, 
pepB and pepN) extract SDCs were devoid of activity as anticipated. The results thus 
indicate that SDCs are processed in the expected way to release their active moiety which 
is able to inhibit IleRS (active moieties 2.20 and 2.21 do not require processing for target 
inhibition).  
 
Figure 2-5: Inhibition of the in vitro aminoacylation reaction at 1.25 µM inhibitor 
concentration. 
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Likewise, SDC 2.35 was evaluated for its ability to inhibit IleRS under similar in 
vitro aminoacylation conditions. However, as can be seen in Figure 2-6, SDC 2.35 did not 
show any inhibitory activity against IleRS. Most likely reason for this inactivity could be 
the compound does not get processed by peptidases to release its active moiety within 15 
min (incubation time). Therefore SDC 2.35 was incubated with the S30 cell extract and 
Ile incorporation was studied at various time intervals ranging from 5 min till 3 h. It has 
been found that the SDC 2.35 is not processed by peptidases to release the active moiety 
which in turn elicit inhibitory effect. However, even after 3h of incubation time, no 
inhibitory activity was detected, showing the active moiety could not be released (Figure 
2-7).  
 
Figure 2-6: Inhibition of in vitro aminoacylation reaction at 2.50 µM inhibitor 
concentration. 
 
 
Figure 2-7: Biological acitivity of biscatecholate SDC 2.35 in S30 cell extract (E. coli 
wt) in function of time at 2.5 µM SDC concentration. 
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2.3  Discussion 
2.3.1  Trihydroxamate-based SDCs 
Siderophore-Drug Conjugates (SDCs) are meant only to facilitate the transport of 
the active moiety across the cell membrane. Therefore, the choice of the siderophore is 
determined by two important parameters. First, it should bind to iron with high affinity 
and should be recognized by the iron transport system. Secondly, upon internalization, it 
should get metabolized to release the active moiety. Therefore to prove our hypothesis, 
initial efforts were invested to synthesize L-ornithine tripeptide-based trihydroxamate as 
it is known from literature that it has strong affinity for iron (III), it is recognized by the 
iron channel and it can also undergo metabolism to release the active part.[96, 98]  Although 
no antibacterial activity was observed in whole-cell screening, newly synthesized SDCs 
did show nice in vitro activity in cell extracts (except ∆ABN cell extract). Hence, it can 
be concluded from this result that the SDCs are efficiently metabolized by cellular 
peptidases and thus release the active moiety which in turn inhibits the corresponding 
aaRS (IleRS), whereas release of the active moiety of synthetic SDC prodrug has often 
been marked as a main bottleneck.[105] Thus, failure of uptake is the main reason of the 
inactivity found for our SDCs which may be attributed to the structural differences 
between the albomycin and the newly synthesized SDCs. It has been observed by 
Vondenhoff et al. that when the McC signal peptide is coupled to aminoacyl-sulfamoyl 
adenosine, these conjugates are recognized by the YejABEF transporter and act as 
Trojan-horse inhibitors.[81, 83]  However, McC signal peptide conjugates of aryl-tetrazole 
containing sulfamates were not recognized by the YejABEF transporter. Therefore, 
authors claimed that the YejABEF transporter may be selective for only peptidyl-
adenylates or very closely resembling derivatives.[83] The same may be true for the SDCs 
that rely on FhuA and TonB complex for efficient uptake. Most probably insufficient 
recognition by FhuA or the Ton B complex which mediate the uptake of siderophores 
herein is the rate limiting step. Further studies need to resolve this issue. However, it is 
clearly shown that substitution of the adenine base with other heterocycles results in a 
lack of penetration of the bacterial membrane of all tested E. coli strains. Therefore, it 
would be highly desirable to investigate whether efficient uptake by iron channel can be 
obtained by modifying the two-carbon-linked aryl-tetrazole moiety. Our attempts to 
synthesize SDCs, by conjugation of the trihydroxamate siderophore with simple 
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aminoacyl-sulfamoyl-adenosines were not successful due to instability of these 
compounds (Scheme 2-4). It has been observed previously that aminoacyl-sulfamoyl 
adenosines are prone to form a cyclic adenosine derivative.[114] We observed a similar 
degradation product while synthesizing the trihydroxamate-based SDC of aminoacyl-
sulfamoyl adenosine. 
2.3.2  Biscatecholate-based SDC 
With disappointing results obtained with the trihydroxamate-based SDCs, we 
looked for an unnatural and relatively simple siderophore. The biscatecholate siderophore 
was chosen for its straightforward synthesis. It is known to promote growth of 
Pseudomonas aeruginosa and E. coli strains indicating the siderophore forms complex 
with iron and is recognized by the iron channel.[115] However, our attempt to improve the 
in vivo efficacy of the aryl-tetrazole sulfamate was unsuccessful. It can be concluded from 
in vitro data (Figure 2-7) that the biscatecholate-based SDC was not processed by non-
specific peptidases (pepA, pepB and pepN) and thus failed to release the active moiety. It 
has been observed previously by Kazakov et al. that mature microcin C was processed by 
these peptidases only after deformylation by peptide deformylase.[122] In other words, the 
braod-specificity peptidases cannot process microcin C if the N-terminal is protected or 
blocked. In retrospect, the N-terminal ornithine in our case is protected as a 
catecholamide which might be limiting factor to release the active moiety. However, 
when a FeCl3 solution was added to a solution of SDC, it gave a purple colour indicating 
that the SDC has the ability to complex iron cations. Whether or not our SDC can be 
recognized by the iron transport system is less relevant, as in vitro tests already show the 
lack of inhibitory activity in cell extracts derived from E. coli wt.  
2.4 Conclusions 
Although all our efforts to improve the in vivo efficacy of an aryl-tetrazole 
containing sulfamate by uptake via the iron channel were unsuccessful, two important 
conclusions can be drawn from these results. First, trihydroxamate-based SDCs (2.26 and 
2.27) are efficiently metabolized by cellular peptidases and thus release the active moiety 
which is often a bottleneck in siderophore mediated drug delivery. Therefore, the absence 
of antibacterial activity is mainly attributed to failure of uptake. This failure of uptake 
may be due to the loss of recognition at the iron channel which can be attributed to the 
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structural differences between the albomycin and the SDCs. Secondly, biscatecholate-
based SDC (2.35) being protected at its N-terminal was not metabolized by cellular 
peptidases. Thus, failure to release the active moiety is the likely reason for the absence 
of antibacterial activity. Therefore apart from the nature of the active moiety, the choice 
of siderophore is very crucial for a successful siderophore mediated drug delivery. 
However, our efforts to synthesize siderophore conjugates of aaSA analogues as the 
active moiety were unsuccessful due to their chemical instability. 
2.5 Experimental section 
2.5.1  Materials and Methods 
Reagents and solvents were purchased from commercial suppliers (Acros, Sigma-Aldrich, 
Bachem, Novabiochem) and used as provided, unless indicated otherwise. DMF and THF 
were of analytical grade and were stored over 4Å molecular sieves. All amino acids used 
were natural amino acids (L-amino acid). For reactions involving Fmoc-protected amino 
acids and peptides, DMF for peptide synthesis (low amine content) was used. All other 
solvents used for reactions were analytical grade and used as provided. Reactions were 
carried out in oven-dried glassware under a nitrogen atmosphere with stirring at room 
temperature, unless indicated otherwise. 
1H and 13C NMR spectra of the compounds dissolved in CDCl3, CD3OD, DMSO-d6 or 
D2O were recorded on a Bruker UltraShield Avance 300 MHz, 500 MHz or 600 MHz 
spectrometer. The chemical shifts are expressed as δ values in parts per million (ppm), 
using the residual solvent peaks (CDCl3: 1H 7.26 ppm; 13C, 77.16 ppm; DMSO: 1H, 2.50 
ppm; 13C, 39.52 ppm; HOD: 1H, 4.79 ppm; CD3OD: 1H, 3.31 ppm; 13C, 49.00 ppm) as a 
reference. Coupling constants are given in Hertz (Hz). The peak patterns are indicated by 
the following abbreviations: br s = broad singlet, d = doublet, m = multiplet, q = 
quadruplet, s = singlet and t = triplet. High resolution mass spectra were recorded on a 
quadrupole time-of-flight mass spectrometer (Q-Tof-2, Micromass, Manchester, UK) 
equipped with a standard ESI interface; samples were infused in 2-propanol/H2O (1:1) at 
3 µL.min-1.  
For TLC, precoated aluminium sheets were used (Merck, Silica gel 60 F254). The spots 
were visualized by UV light at 254 nm. Column chromatography was performed on ICN 
silica gel 60A 60–200 µm. Final products were purified using a PLRP-S 100Ǻ column 
connected to a Merck-Hitachi L6200A Intelligent pump. Eluent compositions are 
expressed as v/v. Purity was checked by analytical HPLC on a Inertsil ODS-3 (C-18) (4.6 
x 100 mm) column, connected to a Shimadzu LC-20AT pump using a Shimadzu SPD-
20A UV-detector. Recordings were performed simultaneously at 254 nm and 214 nm. 
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Bis(Nδ-tert-butoxycarbonyl-L-ornithinato)Cu(II) complex (2.9)[113]  
To a stirred solution of 2.8 (5.06 g, 30.0 mmol) in 2N NaOH (30 mL), a solution of 
copper acetate monohydrate (3.0 g, 15.0 mmol) in water (15 mL) was added followed by 
a solution of di-tert-butyl dicarbonate (8.51 g, 39.0 mmol) in acetone (60 mL). After 24 h, 
an additional portion of acetone (30 mL) was added and stirring was continued for 
another 20 h. The precipitate was collected and washed with a mixture of acetone:water 
(2:1v/v, 50 mL) and water (100 mL). The precipitate was dried in vacuuo to yield 6.06 g 
(11.54 mmol, 77%) of the title compound as a blue coloured solid. Melting point: 245-
246o C (lit 245.89o C) 
1H NMR: The compound proved insufficiently soluble in various duteriorated solvents. 
Nα-benzyloxycarbonyl-Nδ-tert-butoxycarbonyl-L-ornithine (2.11)[113b]  
A suspension of 2.9 (5.40 g, 10.26 mmol) in acetone (20 mL) was intensively stirred for 
15 min, water (20 mL) was added and stirring was continued for 10 min. Then, 10% 
aqueous Na2CO3 solution (40 mL) and 8-quinolinol (3.23 g, 22.57 mmol) were 
introduced. The mixture resulting after 1.5 h is called reaction mixture 1 and was 
subsequently used.  
To a solution of N-hydroxysuccinimide (2.60 g, 22.57 mmol) in water (15 mL) placed in 
a separate flask, Na2CO3 (1.2 g, 11.29 mmol) was added, followed by acetone (20 mL) 
and the mixture was cooled to -5o C. Benzyl chlorocarbonate (3.2 mL, 22.57 mmol) was 
introduced in portions to maintain this temperature. The whole mixture was left standing 
at -5o C for a half hour with occasional stirring to give reaction mixture 2. This was 
poured into the stirred reaction mixture 1. After 1 h, the precipitate of copper quinolinate 
was filtered off and washed with water. The filtrate and washings were combined and 
acetone was evaporated. The residual aqueous solution was washed with dichloromethane 
(2x25 mL), and the DCM layer was discarded. The aqueous layer was acidified with 
saturated KHSO4 to pH 2 and extracted with ethyl acetate (3x25 mL). The ethyl acetate 
layer was washed with brine, dried over sodium sulphate and evaporated to yield the 
desired compound as a pale yellow coloured oil. Acetone was added to the crude product 
and evaporated. Addition of acetone and evaporation was repeated twice to yield 6.23 g 
(17.04 mmol, 83%) the title compound as a white solid.  
1H NMR (300 MHz, CDCl3) δ 1.43 (s, 9H, Boc CH3), 1.48-1.60 (br s, 2H, Orn-γ-CH2), 
1.62-1.76 (m, 1H, Orn-β-CH2, Ha), 1.87 (br s, 1H, Orn-β-CH2, Hb), 3.10 (br s, 2H, Orn-
δ-CH2), 4.18-4.40 (m, 1H, Orn-α-CH), 5.09 (s, 2H, CH2-Ph), 5.7 (br s, 1H, CONH), 6.21 
(br s, 1H, CONH), 7.32 (br s, 5H, Ph); 13C NMR (75 MHz, CDCl3) δ  25.4, 25.9 (Orn-γ-
CH2), 28.4 (Boc CH3), 29.5 (Orn-β-CH2), 39.8, 40.8 (Orn-δ-CH2), 53.7 (Orn-α-CH), 
67.0, 67.4 (CH2-Ph), 79.6, 80.9 (Boc C(CH3)3), 128.0 (ortho-aromatic), 128.1 (para-
aromatic), 128.5 (meta-aromatic), 136.2 (ipso-aromatic), 156.3, 156.4 (CONH-Boc, 
CONH-Cbz), 176.0 (COOH); HRMS for C18H26N2O6K ([M+K]+) calcd: 405.1428 found 
405.1413. 
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Nα-benzyloxycarbonyl-Nδ-tert-butoxycarbonyl-L-ornithinyl-Nδ-tert-butoxycarbonyl-
L-ornithine (2.12)[102]  
To a solution of 2.11 (2.2 g, 6.0 mmol) and N-hydroxy succinimide (760 mg, 6.6 mmol) 
in THF (20 mL) at 0o C was added a solution of DCC (1.36 mg, 6.6 mmol) in THF (10 
mL), The reaction was stirred at room temperature for 12 h. The resulting DCU was 
filtered off and washed with THF. The THF filtrate containing the active ester was used 
in the following reaction. 
To a solution of 2.10 (1.53 g. 6.6 mmol) and NaHCO3 (1.32 g, 15.72 mmol) in a mixture 
of water/THF (30 mL/40 mL) at room temperature was added the active ester obtained 
above and reaction was stirred for 6 h. The volatiles were evaporated, and the aqueous 
residue was diluted with ethyl acetate and acidified to pH 2 with saturated KHSO4. Ethyl 
acetate layer was separated; the aqueous part was extracted further with ethyl acetate (50 
mLx3). The combined ethyl acetate layers were collected, dried over sodium sulphate and 
evaporated. The residue was subjected to silica gel column chromatography (2.5% 
AcOH/EtOAc) to afford 2.81 g (4.84 mmol, 81%) of dipeptide 2.12 as a white solid.  
1H NMR (300 MHz, DMSO-d6) δ 1.25-1.75 (m, 26H, 2xBoc CH3, Orn-β-CH2x2, Orn-γ-
CH2x2), 2.89 (br s, 4H, Orn-δ-CH2x2), 3.95-4.05 (m, 1H, Orn-α-CH), 4.09-4.2 (br s, 1H, 
Orn-α-CH), 4.68-4.82 (m, 2H, CONH), 5.02 (s, 2H, CH2-Ph), 7.25-7.40 (m, 5H, 
aromatic), 8.04 (d, 1H, J = 7.2 Hz, CONH, peptide); 13C NMR (75 MHz, DMSO-d6) 
δ 24.6 (Orn-γ-CH2), 28.4 (Boc CH3), 28.6 (Orn-β-CH2), 51.9 (Orn-α-CH), 54.3 (Orn-α-
CH), 65.5 (CH2-Ph), 77.6 (Boc C(CH3)3), 127.8 (ortho-C, aromatic), 127.9 (para-C, 
aromatic), 128.5 (meta-C, aromatic), 137.1 (ipso-C, aromatic), 155.7 (CONH Boc), 156.0 
(CONH Boc), 172.1 (CONH Cbz), 173.6 (COOH); HRMS for C28H43N4O9 ([M-H]-) 
calcd: 579.3035 found 579.3058. 
Nα-benzyloxycarbonyl-Nδ-tert-butoxycarbonyl-L-ornithinyl-Nδ-tert-butoxycarbonyl-
L-ornithinyl-Nδ-tert-butoxycarbonyl-L-ornithine (2.13)[102]  
To a solution of 2.12 (2.81 g, 4.84 mmol) and N-hydroxy succinimide (612 mg, 5.32 
mmol) in THF (20 mL) at 0o C was added a solution of DCC (1.1 g, 5.32 mmol) in THF 
(10 mL). The reaction was stirred at room temperature for 12 h. The resulting urea DCU 
was filtered off and washed with THF. The THF filtrate was used as such in the following 
reaction. To a solution of 2.10 (1.24 g. 5.32 mmol) and NaHCO3 (1.06 g, 12.58 mmol) in 
a mixture of water/THF (30 mL/40 mL) at room temperature was added the active ester 
obtained above and the reaction was stirred for 6 h. The volatiles were evaporated, and 
the aqueous residue was diluted with ethyl acetate and acidified to pH 2 with saturated 
KHSO4. The ethyl acetate layer was separated and the aqueous layer was extracted further 
with ethyl acetate (50 mLx3). The ethyl acetate layer was collected, dried over sodium 
sulphate and evaporated column purification afforded 2.70 g (3.40 mmol, 70%) of the 
tripeptide 2.13 as a white solid.  
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1H NMR (300 MHz, DMSO-d6) δ 1.30-1.72 (m, 39H, Boc-CH3x3, Orn-β-CH2x3 and 
Orn-γ-CH2x3), 2.88 (br s, 6H, Orn-δ-CH2), 3.90-4.05 (m, 2H, Orn-α-CHx2), 4.15-4.30 
(m, 1H, Orn-α-CH), 5.02 (s, 2H, 2H, CH2-Ph), 6.70-6.86 (m, 3H, CONH), 7.29-7.45 (m, 
5H,aromatic), 7.67-7.76 (m, 1H, CONH), 7.92-8.02 (m, 1H, CONH); 13C NMR (75 MHz, 
DMSO-d6) δ 26.1 (Orn-γ-CH2), 26.2 (Orn-γ-CH2), 28.4 (Boc CH3), 29.6 (Orn-β-CH2), 
52.4 (Orn-α-CH), 52.8 (Orn-α-CH), 54.5 (Orn-α-CH), 65.5 (CH2-Ph), 77.5 (Boc-
C(CH3)3), 127.8 (ortho-C, aromatic), (para-C, aromatic), 128.5 (meta-C, aromatic), 137.2 
(ipso-C, aromatic), 155.7 (CONH Boc), 156.0 (CONH Boc), 170.9 (CONH), 171.9 
(COOH); HRMS for C38H62N6O12Na ([M+Na]+) calcd: 817.4318 found: 817.4276. 
Nα-benzyloxycarbonyl-L-ornithinyl-L-ornithinyl-L-ornithine (2.14)[102]  
A solution of tripeptide 2.13 (7.8 g, 9.8 mmol) in a mixture of TFA/water (50 mL/20 mL) 
was stirred at room temperature for 3 h. The volatiles were removed and the resulting 
residue was dissolved in water (200 mL). The aqueous solution was washed with ethyl 
acetate and was concentrated to give 8.19 g (9.8 mmol, 100%) of the 2.14 as a foam.  
1H NMR (300 MHz, D2O) δ 1.60-2.0 (m, 12H, Orn-β-CΗ2x3 and Orn-γ-CH2x3), 3.01 (br 
s, 6H, Orn-δ-CH2x3), 4.14 (br s, 1H, Orn-α-CH), 4.33 (br s, 2H, Orn-α-CHx2), 5.14 (s, 
2H, CH2-Ph), 7.43 (br s, 5H, Ph); 13C NMR (75 MHz, D2O) δ 22.8, 22.9, 23.0 (Orn-γ-
CH2), 27.4, 27.5, 27.7 (Orn-β-CH2), 38.5 (Orn-δ-CH2), 52.7, 52.9, 54.1 (Orn-α-CH), 66.8 
(CH2-Ph), 114.1, 118.0 (TFA α-CF3), 162.4, 162.9 (TFA C=O), 172.7, 173.9 (CONH), 
175.4 (COOH); HRMS for C23H39N6O6 ([M+H]+) calcd: 495.2953 found 495.2935. 
Nα-benzyloxycarbonyl-Nδ-acetyl-Nδ-O-acetyl-L-ornithinyl-Nδ-acetyl-Nδ-O-acetyl-L-
ornithinyl-Nδ-acetyl-Nδ-O-acetyl-L-ornithine (2.18)[102]  
To a solution of KOH (1.18 g, 21.03 mmol) in methanol (60 mL) at room temperature 
was added tripeptide 2.14 (4.0 g, 4.78 mmol), followed by benzaldehyde (2.2 mL, 21.03 
mmol) and 3 Å molecular sieves. The reaction mixture was stirred at room temperature 
for 16 h. The molecular sieves were filtered off and washed with methanol. The filtrate 
was concentrated to give the crude imine 2.15 as a pale yellow oil which was used further 
without purification. 
1H NMR (300 MHz, CD3OD) δ 1.63-1.97 (m, 12H, Orn-β-CH2x3 and Orn-γ-CH2x3), 
3.59 (br s, 6H, Orn-δ-CH2x3), 4.15-4.28 (m, 2H, Orn-α-CHx2), 4.35-4.47 (m, 1H, Orn-α-
CH), 5.0-5.08 (m, 2H, CH2-Ph), 7.24-7.34 (m, 5H, aromatic), 7.34-7.46 (m, 9H, 
aromatic), 7.64-7.75 (m, 6H, aromatic), 8.26-8.34 (m, 3H, Imine); 13C NMR (75 MHz, 
CD3OD) δ 26.3 (Orn-γ-CH2), 26.4 (Orn-γ-CH2), 28.9 (Orn-β-CH2), 29.3 (Orn-β-CH2), 
29.9 (Orn-β-CH2), 52.9 (Orn-α-CH), 54.2 (Orn-α-CH), 54.4 (Orn-α-CH), 59.6 (Orn-δ-
CH2), 59.7 (δ-CH2), 60.2 (δ-CH2), 66.0 (CH2-Ph), 127.1, 127.3, 127.6, 127.7, 128.0, 
128.5, 129.0, 130.3, 130.4, 134.0, 135.4, 135.5, 136.4 (aromatic), 162.5, 162.8, 162.9 
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(Imine C=N), 171.3 (CONH), 173.1 (CONH), 176.8 (COOH); HRMS for C44H49N6O6 
([M-H]-) calcd: 757.3719 found 757.3704. 
To a solution of crude imine 2.15 (4.78 mmol) in methanol (40 mL) at 0o C was added a 
solution of m-CPBA (70%, 7.07 g, 28.68 mmol) in methanol (20 mL) over 2 h. The 
reaction was stirred at 0o C for additional 2 h. The resulting precipitate was filtered off 
and washed with methanol. The filtrate was concentrated at room temperature to give a 
pale yellow solid, which was partitioned between water (150 mL) and ethyl acetate (150 
mL) following adjustment to pH 2 with 1N HCl. The aqueous layer was extracted once 
again with ethyl acetate. The combined extracts were washed with brine, dried over 
sodium sulphate, filtered, and concentrated to yield crude oxaziridine 2.16 as a pale 
yellow solid. 
To a solution of crude oxaziridine 2.16 (4.78 mmol) in a mixture of TFA/water (50 
mL/10 mL) at room temperature was added CH2Cl2 (60 mL). The solution was stirred at 
50o C for 15 min. The volatiles were removed to give a light yellow oily residue. To this 
residue were added CH2Cl2 (120 mL) and 1N HCl (180 mL). The mixture was stirred at 
room temperature for 2 h, and the layers were separated. The aqueous layer was washed 
with CH2Cl2 (50 mLx2) and hexane (50 mLx2) and concentrated to give crude 
hydroxylamine.HCl 2.17 which was used further without purification 
To a solution of hydroxylamine.HCl 2.17 (4.78 mmol) in KOAc/HOAc buffer (pH 4) (15 
mL) was added KHCO3 (108 mg, 1.08 mmol). Acetic anhydride (2 mL, 1.98 mmol) was 
added drop wise at room temperature over a period of 1 h. The pH of the solution was 
maintained at 4.5-5.0 by addition of solid potassium bicarbonate during this process. The 
reaction mixture was stirred at room temperature overnight. The volatiles were removed 
to give an oily residue. To this residue were added 0.5N HCl (50 mL) and ethyl acetate 
(50 mL). The organic layer was separated and aqueous layer was extracted with ethyl 
acetate (25 mLx4). The combined organic layer was washed with brine, dried over 
sodium sulphate, filtered and concentrated to give the compound 1.75 g (3.85 mmol, 46% 
over 4 steps) as a colourless oil. 
1H NMR (300 MHz, CD3OD) δ 1.60-1.70 (m, 12H, Orn-β-CH2 and Orn-γ-CH2x3), 2.0 
(br s, 9H, N-OCOCH3 CH3x3), 2.20 (br s, 9H, N-COCH3 CH3x3), 3.71 (br s, 6H, Orn-δ-
CH2x3), 4.15 (br s, 1H, Orn-α-CH), 4.38 (br s, 2H, Orn-α-CHx2), 5.09 (s, 2H, CH2-Ph), 
7.25-7.40 (m, 5H, aromatic); 13C NMR (75 MHz, CD3OD) δ 18.2 (NCOCH3), 20.2 (Orn-
γ-CH2x3), 24.3 (N-OCOCH3), 29.8, 30.2 (Orn-β-CH2), 48.2 (Orn-δ-CH2), 53.4 54.1, 55.8 
(Orn-α-CH), 67.7 (CH2-Ph), 128.8 (ortho-C, aromatic), 129.0 (para-C, aromatic), 129.5 
(meta-C, aromatic), 138.2 (ipso-C, aromatic), 158.4 (CONH Cbz), 170.3, (CONH), 173.2, 
173.4, 173.7, 173.8, 174.5, 174.7 (CONH N-COCH3 and N-OCOCH3), 174.9 (COOH); 
HRMS for C35H50N6O15Na ([M+Na]+) calcd: 817.3226 found 817.3215. 
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Nα-benzyloxycarbonyl-Nδ-acetyl-Nδ-hydroxyl-L-ornithinyl-Nδ-acetyl-Nδ-hydroxyl-L-
ornithinyl-Nδ-acetyl-Nδ-hydroxyl-L-ornithine DIPEA salt (2.19)[102]  
A solution of hydroxamate 2.18 (500 mg, 1.37 mmol) in a methanolic 
diisopropylethylamine solution (6%, 20 mL) was stirred at room temperature for 
overnight. The volatiles were removed to give 541 mg (1.37 mmol, quantitative) of light 
yellow oil. 
1H NMR (300 MHz, CD3OD) δ 1.35 (d, 15H, J = 6.6 Hz, DIPEA CH3x5), 1.58-1.87 (m, 
12H, Orn-β-CH2x3 and Orn-γ-CH2x3), 2.04-2.14 (m, 9H, N-COCH3x3), 3.19 (m, 2H, 
DIPEA CH2-CH3), 3.52-3.76 (m, 8H, Orn-δ-CH2x3 and DIPEA CH-CH3), 4.12-4.26 (m, 
2H, Orn-α-CHx2), 4.33-4.43 (m, 1H, Orn-α-CH), 5.08 (br s, 2H, CH2-Ph), 7.34 (br s, 5H, 
aromatic); 13C NMR (75 MHz, CD3OD) δ 13.1 (DIPEA CH2-CH3), 18.1 (N-COCH3), 
20.3 (DIPEA CH-CH3), 24.2, 24.3 (Orn-γ-CH2), 30.4, 30.7, 31.0 (Orn-β-CH2), 43.6 
(DIPEA CH2-CH3), 49.8 (Orn-δ-CH2, merged with solvent), 54.7 (Orn-α-CH), 55.6 (Orn-
α-CHx2 and DIPEA CH-CH3x2), 67.6 (CH2-Ph), 128.8 (ortho-C, aromatic), 129.0 (para-
C, aromatic), 129.5 (meta-C, aromatic), 138.1(ipso-C, aromatic), 158.3 (CONH Cbz), 
173.0, 173.5, 173.7 (CONH), 174.8 (COOH); HRMS for C29H43N6O12 ([M-H]-) calcd: 
667.2944 found 667.2946. 
Trihydroxamate-based SDC (2.26) 
To a solution of 2.18 (35 mg, 0.044 mmol) was added HBTU (20 mg, 0.053 mmol) in 
DMF (2 mL) and the mixture was stirred for 15 min. In a separate vessel, 2.20 (22 mg, 
0.044 mmol) was dissolved in DMF (3 mL). Hereto, TEA (7 µL, 0.053 mmol) was added 
and both mixtures were combined and stirred at room temperature for 24 h. After 
completion of reaction, the solvent was evaporated to dryness and the residue thus 
obtained was dissolved in ethyl acetate and washed with distilled water (25 mLx2). The 
ethyl acetate layer was collected dried over sodium sulphate. The solvent was evaporated 
and column chromatography afforded 46 mg (0.036 mmol, 82%) of coupled product 2.22 
as a white solid. 
1H NMR (300 MHz, CD3OD) δ 0.88-1.08 (m, 6H, Ile-δ-CH3 and Ile-γ-CH3), 1.27 (br s, 
2H, CH2 (C-2)), 1.52-2.52 (m, 33H, Ile-γ-CH2, Ile-β-CH, Orn-β-CH2x3 and Orn-γ-
CH2x3, N-COCH3x3 and N-OCOCH3x3), 3.62-3.90 (m, 8H, Orn-δ-CH2x3, H-3 and H-5), 
4.06 (br s, 2H, H-4, H-6), 4.10-4.22 (m, 3H, H-7a, H-7b and Ile-α-CH), 4.30-4.50 (m, 
3H, Orn-α-CHx3), 4.83 (m, 2H, CH2 (C-1), merged with solvent peak), 5.10 (br s, 2H, 
CH2-Ph), 7.35 (br s, 5H, aromatic, Cbz Ph), 7.45-7.55 (m, 3H, aromatic), 8.11 (m, 2H, 
aromatic); 13C NMR (75 MHz, CD3OD) δ 11.3 (Ile-δ-CH3), 12.2 (Ile-γ-CH3), 15.5, 15.8, 
15.9 (Orn-γ-CH2x3), 20.3 (N-COCH3), 22.1 (N-OCOCH3), 25.6 (C-2), 26.0 (Ile-γ-CH2), 
34.1 (Orn-β-CH2x3), 38.1 (Ile-β-CH), 51.4 (Orn-δ-CH2), 59.9 (C-1), 61.3 (Orn-α-CH), 
67.8 (Orn-α-CH), 69.9 (Orn-α-CH), 72.6 (Ile-α-CH), 73.0 (C-7), 76.0 (CH2-Ph), 80.7 (C-
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4), 81.0 (C-3), 82.8 (C-5), 83.5 (C-6), 127.8, 128.7, 128.8, 129.0, 129.5, 130.1, 131.5, 
138.2 (aromatic), 158.5 (CONH, Cbz), 166.2 (tetrazole), 170.3, 172.3, 172.8, 173.8, 
174.4 (CONH); HRMS for C55H78N12O21SNa ([M+Na]+) calcd: 1297.5017 found 
1297.5010. 
A solution of coupled product 2.22 (35 mg, 0.027 mmol) in methanolic DIPEA (6%, 10 
mL) was stirred at room temperature overnight. After completion of reaction, the solvent 
was evaporated. The residue was subjected to silica gel chromatography to afford 15 mg 
(0.013 mmol, 50%) of 2.24 as a yellow oil. 
1H NMR (500 MHz, CD3OD) δ 0.84-0.97 (m, 6H, Ile-γ-CH3 and Ile-δ-CH3), 1.36 (d, 
15H, , J = 7.0 Hz, DIPEA CH3x5), 1.48-1.96 (m, 13H, Ile-β-CH, Ile-γ-CH2, (C-2), Orn-β-
CH2, Orn-γ-CH2x3), 2.07 (s, 9H, N-COCH3x3), 2.18-2.27 (m, 2H, Orn-β-CH2), 2.40-2.50 
(m, 2H, Orn-β-CH2), 3.21 (q, 2H, J = 8.0 Hz, DIPEA CHx2,), 3.50-3.75 (m, 8H, Orn-δ-
CH2x3 and DIPEA CH2), 3.75-3.81 (m, 2H, H-3, H-5), 3.82-3.87 (m, 1H, H-4), 4.02 (br 
s, 1H, H-6), 4.08-4.23 (m, 6H, Orn-α-CHx3, Ile-α-CH, H-7a, H-7b), 4.36-4.49 (m, 2H, 
CH2-Ph), 7.34 (br s, 5H, aromatic), 7.50 (br s, 3H, aromatic), 8.09 (br s, 2H, aromatic); 
13C NMR (125 MHz, CD3OD) δ 12.1 (DIPEA-CH2-CH3), 13.2 (Ile-δ-CH3), 16.4 (Ile-γ-
CH3), 17.4 (N-COCH3), 18.8 (Orn-γ-CH2), 20.3 (C-2), 24.2 (DIPEA CH-CH3), 25.8 (Orn-
γ-CH2), 30.3 (Orn-β-CH2), 34.2 (Ile-β-CH), 43.8 (DIPEA CH2-CH3), 49.0 (Orn-δ-CH2 
merged with solvent peak), 51.4 (C-1), 54.2 (Orn-α-CH), 55.8 (DIPEA CH-CH3 and Ile-
α-CH), 67.8 (CH2-Ph), 69.8 (C-4), 73.1 (C-7), 76.1 (C-3), 80.5 (C-5), 83.7 (C-6), 127.8, 
128.8, 128.8, 128.1, 130.1, 131.5, 138.5 (aromatic), 158.8 (CONH, Cbz), 166.1 
(tetrazole), 173.8, 179.3 (CONH); HRMS for C49H71N12O18S ([M-H]-) calcd: 1147.4735 
found 1147.4702. 
To a solution of 2.24 (15 mg, 0.013 mmol) in a mixture of methanol: water (2 mL, 
4:1v/v) was added Pd/C (10% w/w, 10 mg) and the reaction mixture was stirred at rt for 5 
h under H2 atmosphere. Subsequently, the reaction mixture was filtered off and washed 
with the mixture of methanol and water (1:1v/v). The filtrate was collected, the solvent 
was evaporated under reduced pressure and the residue was purified by HPLC to yield 10 
mg (0.01 mmol, 76%) of the desired SDC 2.26 as a white solid. 
HRMS for C41H65N12O16S ([M-H]-) calcd: 1013.4360 found 1013.4360. 
Trihydroxamat-based SDC (2.27) 
The SDC 2.27 was synthesized following the procedure as described for SDC 2.26 with 
2.21 substituting for 2.20. Yield: 20% (overall); HRMS for C55H75N12O19S ([M-H]-) 
calcd: 1239.4992 found : 1239.4967. 
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Benzyl-2,3-bis(benzyloxy)-benzoate (2.31)[123]  
A solution of 2.30 (2 g, 13.0 mmol), benzyl bromide (9.2 mL, 78.0 mmol) and potassium 
carbonate (32 g) in acetone (200 mL) was refluxed for 24 h under nitrogen atmosphere. 
After filtration, the precipitate was washed with acetone. Filtrate and washings were 
combined, concentrated under vacuum. The residue was subjected to siliga gel 
chromatography to yield 5.51 g (13.0 mmol, 100%) of 2.31 as a pale yellow oil. 
1H NMR (300 MHz, CDCl3) δ 5.06 (s, 2H, CH2-Ph), 5.11 (s, 2H, CH2-Ph), 5.30 (s, 2H, 
CH2-Ph), 7.02-7.13 (m, 2H, aromatic), 7.22-7.43 (m, 16H, aromatic); 13C NMR (75 MHz, 
CDCl3) δ 66.9 (CH2-Ph), 71.2 (CH2-Ph), 75.6 (CH2-Ph), 117.9, 122.9, 123.9, 126.8, 
126.9, 127.5, 127.8, 128.0, 128.1, 128.1, 128.3, 128.5, 128.5, 135.9, 136.5, 137.3, 148.3, 
152.8, 166.1; HRMS for C28H25O4 ([M+H]+) calcd: 425.1747 found 425.1749 
2,3-bis(benzyloxy)-benzoic acid (2.32)[123]  
A solution of 2.31 (5.51 g, 13.0 mmol) in mixture of methanol (350 mL) and 5N sodium 
hydroxide (150 mL) was refluxed for 3 h. After 3 h, methanol was evaporated and 
aqueous part was acidified to pH 2 using 3N HCl and extracted with ethyl acetate (150 
mLx4). The organic layer was collected, dried over sodium sulphate, filtered and 
evaporated to yield 4.08 g (12.21 mmol, 94%) of 2.32 as a white solid. 
1H NMR (300 MHz, CDCl3) δ 5.20 (s, 2H, CH2-Ph), 5.27 (s, 2H, CH2-Ph), 7.15-7.50 (m, 
12H, aromatic), 7.75 (m, 1H, aromatic); 13C NMR (75 MHz, CDCl3) δ 65.4 (CH2-Ph), 
77.2 (CH2-Ph), 119.0, 123.0, 124.5, 125.2, 127.0, 127.8, 128.6, 128.8, 128.9,   129.3, 
129.3, 134.6, 135.9, 147.1, 151.3, 165.0; HRMS for C21H17O4 ([M-H]-) calcd: 333.1132 
found: 333.1109 
Nα,Nδ-bis[(2,3-bis(benzyloxy)-benzoyl)-L-ornithine (2.33)[115]  
To a solution of 2.32 (2 g, 6.0 mmol) and NHS (829 mg, 7.2 mmol) in THF (20 mL) at 0o 
C was added a solution of DCC (1.49 g, 7.2 mmol) in THF (10 mL). The reaction mixture 
was stirred at room temperature for overnight. The resulting DCU was filtered off and 
washed with THF. The filtrate was used as the active ester solution in the following 
reaction. 
To a solution of 2.8 (1.51 g, 3 mmol) and sodium bicarbonate in water/THF (40 mL/30 
mL) at room temperature was added the active ester solution obtained above. The reaction 
mixture was stirred at room temperature for 6 h. The volatiles were evaporated and 
aqueous residue was diluted with ethyl acetate and acidified to pH 2 with 1N HCl. The 
layers were separated and aqueous layer was extracted with ethyl acetate (50 mLx4). The 
combined extracts were washed with brine, dried over anhydrous sodium sulphate, 
filtered and concentrated to give crude product which was purified by silica gel column to 
give 736 mg (0.96 mmol, 32%) of 2.33 as a white solid. 
Siderophore-drug conjugates 
61 
 
1H NMR (300 MHz, CDCl3) δ 1.18-1.38 (m, 3H, Orn-β-CH2, Ha and Orn-γ-CH2), 1.58-
1.72 (m, 1H, Orn-β-CH2, Hb), 2.95-3.07 (m, 1H, Orn-δ-CH2, Ha), 3.22-3.35 (m, 1H, Orn-
δ-CH2, Hb), 4.60-4.68 (m, 1H, Orn-α-CH), 5.03 (s, 2H, CH2-Ph), 5.10-5.18 (m, 6H, CH2-
Phx3), 7.11-7.16 (m, 4H, aromatic), 7.19-7.24 (m, 4H, aromatic), 7.30-7.48 (m, 15H, 
aromatic), 7.68-7.74 (m, 2H, aromatic), 8.02 (t, 2H, J = 5.7 Hz, NH), 8.53 (d, 1H, J = 7.2 
Hz, NH); 13C NMR (75 MHz, CDCl3) δ 25.3 (Orn-γ-CH2), 28.7 (Orn-β-CH2), 38.6 (Orn-
δ-CH2), 52.0 (Orn-α-CH), 71.0 (CH2Ph), 76.0 (CH2-Ph), 117.0, 117.3, 123.0, 123.1, 
124.1, 127.3, 127.5, 128.0, 128.2, 128.3, 128.4, 128.5, 128.6, 135.8, 135.9, 136.0, 136.1, 
146.6, 146.8, 151.3, 151.4, 165.4, 165.6, (aromatic) 173.4 (C=O); HRMS for C47H43N2O8 
([M-H]-) calcd: 763.3025 found 763.3023. 
Biscatecholate-based SDC (2.35) 
To a solution of 2.33 (30 mg, 0.04 mmol) in dry DMF (0.5 mL) was added HBTU (18 
mg, 0,048 mmol) and the mixture was stirred for 20 min. In a separate vessel, 2.20 (20 
mg, 0.04 mmol) and TEA (7 µL, 0.048 mmol) were dissolved in dry DMF (0.5 mL) and 
both solutions were combined. The resulting reaction mixture was stirred at room 
temperature overnight. DMF was evaporated and the residue thus obtained was dissolved 
in ethyl acetate (25 mL) and washed with water (20 mLx2). The aqueous layer was 
washed with ethyl acetate (20 mLx2). The ethyl acetate layers were combined, dried over 
anhydrous sodium sulphate, filtered and concentrated to give crude product which was 
purified by column chromatography to yield 30 mg (0.024 mmol, 61%) of 2.34 as a white 
solid. 
1H NMR (500 MHz, CD3OD) δ 0.93, (t, 3H,  J = 6.0 Hz, Ile-δ-CH3), 1.03 (d, 3H, J = 3.0 
Hz, Ile-γ-CH3), 1.23-1.30 (m, 1H, CH2 (C-2) Ha), 1.40-1.55 (m, 3H, Ile-γ-CH2, Ha and 
Orn-γ-CH2 Ha), 1.58-1.64 (m, 1H, CH2 (C-2) Hb), 1.72-1.78 (m, 1H, Orn-γ-CH2 Hb), 
1.85-1.91 (m, 1H, Ile-β-CH), 2.09-2.15 (m, 1H, Orn-β-CH2 Ha), 2.31-2.38 (m, 1H, Orn-
β-CH2 Hb), 3.10-3.17 (m, 1H, Orn-δ-CH2 Ha), 3.22-3.29 (m, 1H, Orn-δ-CH2 Hb), 3.74-
3.78 (m, 2H, H-3, H-5), 3.96-4.03 (m, 2H, H-4 and H-6), 4.19 (d, 1H, J = 6.0 Hz, Ile-α-
CH), 4.31-4.38 (m, 2H, H-7a and H-7b), 4.59-4.64 (m, 1H, Orn-α-CH), 4.70-4.80 (m, 
2H, CH2 (C-1)), 5.01-5.07 (m, 3H, CH2Ph), 5.14-5.20 (m, 5H, CH2Ph), 7.10-7.29 (m, 
29H, aromatic), 8.05-8.10 (m, 2H, aromatic); 13C NMR (125 MHz, CD3OD) δ 11.5 (Ile-
δ-CH3), 15.9 (Ile-γ-CH3), 26.0 (C-2), 26.6 (Ile-γ-CH2), 31.0 (Orn-γ-CH2), 34.1 (Orn-β-
CH2), 37.9 (Ile-β-CH), 40.1 (Orn-δ-CH2), 51.3 (C-1), 54.2 (Ile-α-CH), 60.0 (Orn-α-CH), 
72.2 (d, CH2Phx2), 72.6 (C-4), 72.9 (C-7), 76.9 (CH2Ph), 77.1 (CH2Ph), 80.9 (C-5), 82.8 
(C-6), 118.1, 122.9, 125.5 (d), 127.8, 128.7, 128.9, 129.0, 129.1, 129.2, 129.24, 129.41, 
129.44, 129.5, 129.6, 129.9, 130.0, 130.1,131.5, 137.9, 138.0, 138.1, 138.2, 147.6, 147.8, 
153.4 (d), 166.1, 167.9 (aromatic), 168.5 (CONH), 174.4 (Ile-C=O); HRMS for 
C67H71N8O14S ([M-H]-) calcd: 1243.4815 found 1243.4807. 
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To a solution of coupled product 2.34 (25 mg, 0.02 mmol) in methanol (5 mL) was added 
Pd/C (10%, 15 mg) and stirred for 4 h under hydrogen atmosphere. After 4 h, the catalyst 
was filtered off and washed with methanol. The filtrate was concentrated and the residue 
was purified by RP-HPLC to yield 6.6 mg (0.007 mmol, 37%) of desired biscatecholate 
based SDC 2.35 as a white solid. 
1H NMR (500 MHz, CD3OD) δ 0.93, (t, 3H, J = 4.5 Hz, Ile-δ-CH3), 1.02 (d, 3H, J = 3.3 
Hz, Ile-γ-CH3), 1.23-1.33 (m, 1H, CH2 (C-2) Ha), 1.57-1.65 (m, 1H, CH2 (C-2) Hb), 1.72-
1.78 (m, 2H, Ile-γ-CH2), 1.83-1.92 (m, 2H, Ile-β-CH and Orn-γ-CH2 Ha), 1.95-2.02 (m, 
1H, Orn-γ-CH2 Hb), 2.15-2.23 (m, 1H, Orn-β-CH2 Ha), 2.38-2.45 (m, 1H, Orn-β-CH2 
Hb), 3.38-3.45 (m, 1H, Orn-δ-CH2 Ha), 3.46-3.52 (m, 1H, Orn-δ-CH2 Hb), 3.77-3.82 (m, 
2H, H-3, H-5), 4.02-4.05 (m, 2H, H-4 and H-6), 4.15 (d, 1H, J = 7.5 Hz, Ile-α-CH), 4.35-
4.42 (m, 2H, H-7a and H-7b), 4.67-4.71 (m, 1H, Orn-α-CH), 4.82 (2H, CH2 (C-1) merged 
with solvent), 6.67-6.74 (m, 2H, aromatic, catechol), 6.88-6.94 (m, 2H, catechol), 7.21 (d, 
1H, J = 8.0 Hz, catechol), 7.32 (d, 1H, catechol), 7.46-7.52 (m, 3H, aromatic, tetrazole), 
8.07-8.11 (m, 2H, aromatic, aromatic); 13C NMR (125 MHz, CD3OD) δ 11.3 (Ile-δ-CH3), 
15.8 (Ile-γ-CH3), 26.0 (C-2), 26.9 (Ile-γ-CH2), 30.5 (Orn-γ-CH2), 34.1 (Orn-β-CH2), 37.7 
(Ile-β-CH), 40.0 (Orn-δ-CH2), 51.3 (C-1), 54.2 (Ile-α-CH), 60.0 (Orn-α-CH), 72.6 (C-4), 
73.1 (C-7), 76.0 (C-3), 81.0 (C-5), 82.8 (C-6),116.8, 117.1, 118.8, 119.6, 119.8, 127.8, 
128.6, 130.0, 131.5, 147.2, 147.3, 149.6, 150.2, 166.2, 170.9, 171.6, 172.4, 174.9 
(aromatic, catechol and aryl-tetrazole); HRMS for C39H47N8O14S ([M-H]-) calcd: 
883.2938 found 883.2933. 
(S)-Nβ-Benzyloxycarbonyl-L-α-2,3-diaminopropanoic acid (2.40)[120a, 124]  
A slurry of 2.39 (6 g, 22.53 mmol), ethyl acetate (100 mL), acetonitrile (100 mL), water 
(50 mL) and iodobenzene diacetate (8.73 g, 27.04 mmol) was stirred at 15o C for min. 
The temperature was allowed to rise to room temperature and the reaction was stirred for 
4.5 h during which the product separated out as a white solid. The reaction mixture was 
cooled to 5o C and the product was filtered off and washed with ethyl acetate (200 mL). 
The precipitate was dried in vacuo to afford 4.95 g (20.78 mmol, 92%) of 2.40 as a white 
solid. 
1H NMR (300 MHz, DMSO-d6/TFA) δ 2.93-3.10 (m, 1H, β-CH2-Ha), 3.17-3.30 (m, 1H, 
β-CH2-Hb), 4.21-4.38 (m, 1H, α-CH), 5.05 (s, 2H, CH2-Ph), 7.20-7.40 (m, 5H, aromatic), 
7.48-7.70 (m, 1H, CONH), 7.89 (br s, 2H, NH2); 13C NMR (75 MHz, DMSO-d6/TFA) 
δ 40.2 (β−CH2), 52.6 (α-CH), 66.7 (CH2-Ph), 110.0, 113.8, 117.6, 121.4 (TFA), 128.6 
(Ar), 129.0 (aromatic), 137.4 (ipso-C, aromatic), 157.0, 158.5, 159.0, 159.5, 160.0 (TFA), 
171.6 (COOH); HRMS for C11H13N2O4 ([M-H]-) calcd: 237.0881 found 236.0878. 
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(S)-Nα-Benzyloxycarbonyl-Nβ-tert-butyloxycarbonyl--L-α-2,3-diaminopropanoic 
acid (2.41)[121]  
To a solution of 2.40 (1.5 g, 6.3 mmol) in 10% Na2CO3 (60 mL) was added a solution of 
di-tert-butyl dicarbonate (2.1 g, 9.5 mmol) in dioxane (25 mL) over a period of 1h at 0o C. 
The reaction mixture was stirred at room temperature overnight. The reaction mixture 
was poured into 100 mL of water after which the mixture was washed with diethyl ether 
(25 mLx3). The aqueous part was acidified to pH 2 using saturated potassium hydrogen 
sulphate and the white suspension was extracted with ethyl acetate (50 mLx3). The 
combined ethyl acetate layer was dried over anhydrous sodium sulphate, filtered and 
evaporated to dryness. The product was crystallized from diethyl ether to yield 2.06 g 
(6.09 mmol, 97%) of 2.41 as a white solid. 
1H NMR (300 MHz, CDCl3) δ 1.42 (s, 9H, Boc CH3), 3.44-3.67 (m, 2H, β-CH2), 4.30-
4.48 (m, 1H, α-CH), 5.03-5.18 (m, 2H, CH2-Ph), 6.17 (br s, 1H, CONH), 6.42 (br s, 1H, 
CONH), 7.34 (s, 5H, aromatic); 13C NMR (75 MHz, CDCl3) δ 28.4 (Boc CH3), 42.4, 43.3 
(β-CH2), 54.6, 55.7 (α-CH), 67.5 (CH2-Ph), 128.3 (para-C, Ar), 128.4 (ortho-C), 128.7 
(meta-C, Ar), 136.1 (ipso-C, aromatic), 155.7, 157.0, 157.4, 158.7 (CONH), 172.9 
(COOH); HRMS for C16H21N2O6 ([M-H]-) calcd: 337.1405 found 337.1382 
Nα-Benzyloxycarbonyl -L-α-2,3-diaminopropanoyl-Nα-Benzyloxycarbonyl-Nβ-tert-
butyloxycarbonyl-L-α-2,3-diaminopropanoic acid (2.42) 
To a solution of 2.41 (2 g, 5.91 mmol) and NHS (816 mg, 7.09 mmol) in THF (25 mL) at 
0o C was added a solution of DCC (1.46 g, 7.09 mmol) in THF (15 mL). The reaction 
mixture was stirred at room temperature overnight. The resulting DCU was filtered off 
and washed with THF. The filtrate was used as active ester solution in the following 
reaction. 
To a solution of 2.40 (1.4 g, 5.91 mmol) and NaHCO3 (1.5 g, 17.73 mmol) in water/THF 
(40 mL/30 mL) at room temperature was added the active ester obtained from above. The 
reaction was stirred at room temperature for 6 h. The volatiles were evaporated and the 
aqueous residue was acidified to pH 2 using saturated KHSO4 and diluted with ethyl 
acetate (100 mL). The layers were separated and aqueous layer was washed with ethyl 
acetate (50 mLx3). The combined extracts were washed with brine, dried over anhydrous 
sodium sulphate, filtered and concentrated. The product was isolated by column 
chromatography to yield 2.92 g (5.23 mmol, 89%) of 2.42 as a white solid. 
1H NMR (300 MHz, CDCl3) δ 1.35 (s, 9H, Boc CH3), 3.25-3.50 (m, 2H, β-CH2), 3.60-
3.80 (m, 2H, β-CH2), 4.20-4.45 (m, 2H, α-CHx2), 5.08 (br s, 4H, CH2-Phx2), 7.30 (br s, 
10H, aromatic); 13C NMR (75 MHz, CDCl3) δ 28.3 (Boc CH3), 41.2 (β-CH2), 42.3 (β-
CH2), 54.2 (α-CH), 56.5 (α-CH), 67.3 (CH2-Ph), 67.5 (CH2-Ph), 80.5 (C(CH3)3), 128.4, 
128.6 (aromatic), 136.1, 136.2 (ipso-C, aromatic), 156.3, 156.9, 157.4 (CONH of Cbz and 
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Boc), 172.1 (CONH, peptide), 173.1 (COOH); HRMS for C27H33N4O9 ([M-H]-) calcd: 
557.2253 found 557.2254 
Nα-Benzyloxycarbonyl-L-α-2,3-diaminopropanoyl-Nα-Benzyloxycarbonyl- L-α-2,3-
diaminopropanoyl-Nα-Benzyloxycarbonyl-Nβ-tert-butyloxycarbonyl-L-α-2,3-
diaminopropanoic acid (2.43)[119]  
To a solution of 2.42 (558 mg, 1.0 mmol) and NHS (138 mg, 1.2 mmol) in THF (5 mL) at 
0o C was added a solution of DCC (248 mg, 1.2 mmol) in THF (5 mL). The reaction 
mixture was stirred at room temperature overnight. The resulting DCU was filtered off 
and washed with THF. The filtrate was used as an active ester solution in the following 
reaction. 
To a solution of 2.40 (238 mg, 1.0 mmol) and NaHCO3 (252 mg, 3.0 mmol) in 
water/THF (5 mL/3 mL) at room temperature was added the active ester obtained from 
above. The reaction mixture was stirred at room temperature for 6 h. The volatiles were 
evaporated and aqueous residue was diluted with ethyl acetate (50 mL) and acidified to 
pH 2 using saturated KHSO4. The layers were separated and aqueous layer was washed 
with ethyl acetate (50 mLx3). The combined extracts were washed with brine, dried over 
anhydrous sodium sulphate, filtered and concentrated. The product was isolated by 
column chromatography to yield 610 mg (0.78 mmol, 78%) of desired tripeptide 2.43 as a 
white solid. 
1H NMR (300 MHz, CDCl3) δ 1.33 (s, 9H, Boc CH3), 3.37 (br s, 3H, β-CH2), 3.65 (br s, 
3H, β-CH2), 4.17-4.50 (m, 3H, α-CHx3), 4.92-5.13 (m, 6H, CH2-Phx3), 5.56 (br s, 1H, 
CONH), 6.18 (br s, 1H, CONH), 6.51 (br s, 1H, CONH), 6.72 (br s, 1H, CONH), 7.28 (br 
s, 15H, aromatic), 7.63 (br s, CONH); 13C NMR (75 MHz, CDCl3) δ 28.7 (Boc CH3), 
42.0, 42.2, 43.0 (β-CH2), 55.3, 56.2, 57.3 (α-CH), 67.8, 68.0 (CH2-Ph), 80.7 (C(CH3)3), 
128.9, 129.0, 129.5 (aromatic), 137.9, 138.0, 138.1 (ipso-C, aromatic), 158.3, 158.6, 
158.8, 172.9, 172.9 (CONH), 173.5 (COOH); HRMS for C38H45N6O12 ([M+Na]+) calcd: 
777.3101 found 777.3087 
L-α-2,3-diaminopropanoyl-L-α-2,3-diaminopropanoyl-Nβ-tert-butyloxycarbonyl-L-
α-2,3-diaminopropanoic acid (2.44) 
To a solution of 2.43 (110 mg, 0.14 mmol) in a mixture of methanol: water (4:1 v/v, 5 
mL) was added 30 mg of Pd/C (10% w/w, 30 mg) and the mixture was stirred under 
hydrogen atmosphere for 6h. After 6h, the catalyst was filtered off and the solvent was 
evaporated to yield 48 mg (0.12 mmol, 91%) of 2.44 which was used without further 
purification. 
1H NMR (300 MHz, D2O) δ 1.44 (s, 9H, Boc-CH3), 3.35-3.45 (m, 2H, β-CH2), 3.55-3.80 
(m, 6H, β-CH2x2 and α-CHx2), 3.85-3.92 (m, 1H, α-CH); 13C NMR (75 MHz, D2O) δ 
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27.3 (Boc-CH3), 39.5, 39.6, 42.1 (β-CH2), 53.2, 53.6, 54.6 (α-CH), 81.0 (C(CH3)3); 
HRMS for C14H27N6O6 ([M-H]-) calcd: 375.1997 found 375.1989. 
Methyl-(L-α-2,3-diaminopropanoyl-L-α-2,3-diaminopropanoyl-Nβ-tert-
butyloxycarbonyl)--L-α-2,3-diaminopropanoate (2.46)[119]  
To a solution of 2.44 (100 mg, 0.13 mmol) in a mixture of dry DCM (5 mL) and dry 
DMF (0.5 mL) were added HBTU (61 mg, 0.16 mmol), methanol (1 mL) and TEA (22 
µL, 0.16 mmol). The reaction mixture was stirred at room temperature for 2 h. Next, the 
volatiles were removed and the residue was partitioned between ethyl acetate and 2N 
HCl. The aqueous part was extracted with ethyl acetate (25 mLx2). The combined 
extracts were dried over anhydrous sodium sulphate, filtered and evaporated to dryness. 
The residue was subjected to silica gel purification to yield 98 mg (0.12 mmol, 96%) of 
the intermediate Cbz protected tripeptide methyl ester as a white solid.  
1H NMR (300 MHz, CDCl3) δ 1.31 (s, 9H, Boc-CH3), 3.20-3.90 (m+s, 9H, β-CH2x3 and 
COOCH3), 4.10-4.50 (m, 3H, α-CH), 5.06 (br s, 6H, CH2Phx3), 6.26 (br s, 2H, 
CONHx2), 6.69 (br s, CONH, 7.09 (br s, 1H, CONH), 7.31 (br s, 15H, aromatic); 13C 
NMR (75 MHz, CDCl3), 28.3 (Boc-CH3), 41.4, 41.8, 42.3 (β-CH2), 53.0 (COOCH3), 
54.2, 56.0, 56.1 (α-CH), 67.2, 67.3, 67.4 (CH2Ph), 80.7 (C(CH3)3), 128.2, 128.3, 128.59, 
128.64 (aromatic), 136.1, 136.2, 136.3 (ipso-C, aromatic), 156.5, 156.6 (CONH), 171.2, 
171.8, 172.1 (CONH and COCH3); MS for C39H48N6O12Na ([M+Na]+) calcd: 815.3 found 
815.1. 
To a solution of this tripeptide methyl ester above (56 mg, 0.07 mmol) in THF: acetic 
acid (3:2 v/v, 5 mL) was added Pd/C (10%w/w, 50 mg) and the mixture was stirred at 
room temperature under H2 atmosphere for 18 h. Next, the catalyst was filtered off and 
the solvent was evaporated to dryness to yield 23 mg (0.04 mmol, 57%) of 2.46 which 
was used further without purification. However all attempts to couple catechole 2.32 with 
this tripeptide failed. 
2.5.2 Biological activity of SDCs 
2.5.2.1  Whole-cell assay by disc diffusion method 
Disc diffusion method using Muller-Hinton Agar (MHA) 
Liquid Mueller–Hinton Agar (0.75%) was mixed with bacterial suspension (29:1 
v/v) at rt. Plates were prepared by adding 4 mL of this suspension to petri plates 
containing 7 mL of solidified Mueller–Hinton Agar (1.5%). Immediately after 
solidification of the agar, 2 µL drops containing potential inhibitor compound in milliQ 
water were added and were allowed to dry. After incubation for 16 h at 37o C, the 
inhibition zones were measured. These evaluations were performed in triplicate for each 
compound-concentration combination. Maximum concentration tested was 5 mM. 
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Disc diffusion method using M63 
M63 soft Agar (0.75% of agar) was mixed with bacterial suspension (29:1 v/v) at 
rt. Plates were prepared by adding 4 mL of this suspension to petri plates containing 7 mL 
of solidified M63 hard Agar (1.5% of agar). Immediately after solidification of the agar, 2 
µL drops containing potential inhibitor compound in milliQ water were added and were 
allowed to dry. After incubation for 16 h at 37o C, the inhibition zones were measured. 
These evaluations were performed in triplicate for each compound-concentration 
combination. Maximum concentration tested was 5 mM 
2.5.2.2  MIC determination by broth dilution method 
The respective bacteria were grown overnight in LB medium and cultured again 
the following day in fresh LB medium to an OD600 of 0.1. Compounds were titrated in a 
96 well-plate using LB-medium with or without iron chelator such as 2,2’-dipyridyl or 
EDTA (final concentration of 10 µg/mL), and with or without FeCl3 (equimolar with 
SDC) which was used as iron source to promote the uptake of SDC. To each well 85 µL 
LB-medium with or without iron chelator and iron source was added to a total volume of 
90 µL followed by 10 µL of bacterial cell culture. The cultures were next incubated at 37 
°C and the OD600 was determined at two intervals after 8 h and after 18 h respectively. 
2.5.2.3  Aminoacylation experiments 
To assess the degree of inhibition of the aminoacylation reaction, in vitro tests 
were performed using the relevant S30 cell extracts. 
Preparation of S30 cell extracts: The cell extracts were prepared as described as 
per literature procedure.[78] The respective E. coli cells were grown overnight at 37o C in 
LB medium (5 mL). Next day, the overnight grown cell culture (100 µL) was transferred 
to 200 mL LB medium and allowed to attain OD600 of 0.8-1.0. Next the cell culture was 
centrifuged at 3000xg for 10 min. The supernatant was discarded and the pellet was 
resuspended in 40 mL buffer containing: Tris.HCl or Hepes.KOH (pH = 8.0) (20 mM), 
MgCl2 (10 mM), KCl (100 mM). The cell-suspension was centrifuged again at 4800 rpm 
for 15 min. This procedure was repeated 3 times. The pellet was resuspended in 1 mL of 
the following buffer Tris.HCl or Hepes.KOH (pH = 8.0) (20 mM), MgCl2 (10 mM), KCl 
(100 mM), DTT (1 mM) and kept at 0 °C. Subsequently, the cells were sonicated for 30 
sec. and left at 0°C for 10 sec. This procedure was repeated for 15-20 times. The cell 
lysate was centrifuged to a maximum speed of 15000 g for 30 min. The supernatant was 
transferred and centrifuge again for 15 min. The supernatant was transferred and divided 
over several eppendorf tubes (60 µL each) and the extract was stored at -80 oC until 
further use.  
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tRNA aminoacylation reaction: To 1 µL of solution containing inhibitor, 3 µL of 
E. coli S30 extract was added. Next, 16 µL of the following aminoacylation mixture was 
added: Tris.HCl (30mM, pH 8.0), DTT (1 mM), bulk of E. coli tRNA (5 g/l), ATP (3 
mM), KCl (30 mM), MgCl2 (8 mM), and the specified, radio labeled amino acid (40 µM). 
The aminoacylation reaction was carried out at room temperature. Depending on whether 
or not processing was needed, variable time intervals were included between the addition 
of the cell-extract and the addition of the aminoacylation mixture. The reaction products 
were precipitated in cold 10% TCA on Whatman 3MM papers, 5 min. after the 
aminoacylation mixture was added.After thorough washing with cold 10% TCA, the 
papers were washed twice with acetone and dried on a heating plate. Following the 
addition of scintillation liquid, the amount of radioactivity was determined in a 
scintillation counter. 
  
Siderophore-drug conjugates 
68 
 
 
 
Base modifications 
69 
 
3 Base substituted 5’-O-(N-isoleucyl)sulfamoyl nucleoside 
analogues as potential antibacterial agents 
 
 
 
Abstract 
Aminoacyl-sulfamoyl adenosines are well-known nanomolar inhibitors of the 
corresponding prokaryotic and eukaryotic tRNA synthetases in vitro. Inspired by the 
aryl-tetrazole containing compounds of Cubist Pharmaceuticals and the modified base as 
found in the natural antibiotic albomycin, the selectivity issue of the sulfamoylated 
adenosines prompted us to investigate the pharmacophoric importance of the adenine 
base. We therefore synthesized and evaluated several isoleucyl-sulfamoyl nucleoside 
analogues with either uracil, cytosine, hypoxanthine, guanine, 1,3-dideaza-adenine 
(benzimidazole) or 4-nitro-benzimidazole as the heterocyclic base. Based on the structure 
and antibacterial activity of microcin C, we also prepared their hexapeptidyl conjugates 
in an effort to improve their uptake potential. We further compared their antibacterial 
activity with the parent isoleucyl-sulfamoyl adenosine (Ile-SA), both in in vitro and in 
cellular assays. Surprisingly, the strongest in vitro inhibition was found for the uracil 
containing analogue 3.11f. Unfortunately, only very weak growth inhibitory properties 
were found as of low uptake. The results are discussed in the light of previous literature 
findings. 
 
This chapter was published earlier in an adapted form as:  
“Base substituted 5’-O-(N-isoleucyl)sulfamoyl nucleoside analogues as potential 
antibacterial agents.” B. Gadakh, G. Vondenhoff, E. Lescrinier, J. Rozenski, M. Froeyen 
and A. Van Aerschot, Bioorg. Med. Chem, 2014, 22(10), p-2875-2886 
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3.1  Introduction 
5’-O-(N-aminoacyl)-sulfamoyl adenosines are well-known inhibitors of the 
corresponding aaRSs in vitro but lack selectivity due to their structural similarity with aa-
AMP. Several modifications have been attempted in order to increase the selectivity of 
these analogues. For instance, Cubist Pharmaceuticals reported aryl-tetrazole containing 
sulfamate derivatives which displayed up to 3000-fold selectivity for bacterial aaRS over 
their human counterpart. However, further development was halted due to their lack of in 
vivo activity and high serum albumin binding.[8, 61] Moreover, the natural antibiotic such 
as albomycin has a modified pyrimidine base and mupirocin has no base moiety at all. 
Thus, high selectivity of aryl-tetrazole containing sulfamates[8, 61] and the excellent 
efficacy of albomycin against Streptococcus pneumonia,[96] both deviating from the 
adenine base structure while yet acting as aa-AMP analogues, prompted us to investigate 
the pharmacophoric importance of the adenine base for the well-known aminoacyl 
sulfamoyl adenosine (aaSA) inhibitors. We therefore intended to evaluate a series of 
aaSA analogues with different natural or unnatural heterocyclic bases substituting for the 
adenine ring. Towards this end, we designed, synthesized, and evaluated several 
isoleucyl-sulfamoyl nucleoside analogues with either uracil (U), cytosine (C), 
hypoxantine (I), guanine (G), 1,3-dideaza-adenine [4-amino-benzimidazole (4-ABI)] or 
4-nitro-benzimidazole (4-NBI) as the heterocyclic base. We further compared their 
antibacterial activity with the parent Ile-SA, both in vitro and in cellular assays. 
3.2  Chemistry 
The corresponding series of isoleucyl sulfamate analogues were prepared combining 
different literature procedures. The required nitrobenzimidazole heterocycle was 
synthesized starting from o-phenylene diamine 3.1 via its selenium complex 3.2[125] 
followed by nitration,[126] reduction,[127] and cyclization[128] using triethyl orthoformate 
yielding 4(7)-nitrobenzimidazole 3.5 (Scheme 3-1). The heterocyclic base was further 
reacted with tetra-O-acetyl ribofuranose using stannic chloride[128] followed by 
deprotection of the acetyl moieties using methanolic ammonia yielding the 4-nitro 
benzimidazole nucleoside analogue 3.7a. All sulfamoylated nucleoside analogues (natural 
and unnatural ones) were further synthesized following literature procedures which  
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Scheme 3-1: Synthesis of 1-(β-D-ribofuranosyl)-4-nitrobenzimidazole 
Reagents and conditions: (i) ethanol, selenium dioxide, reflux 10 min, 99%; (ii) conc. 
H2SO4 and conc. HNO3 from 0o C to rt in 30 min, 100%; (iii) conc. HCl, aq. HI (57%), 3 
h, 54%; (iv) triethyl orthoformate, reflux, 4 h then formic acid relux 3 h, 87%; (v) tetra-O-
acetyl ribofuranose, SnCl4 (1M solution in DCM), dry ACN, 25o C, 16 h, 80%; (vi) 7N 
ammonia in methanol, rt, overnight, 90%. 
 
 
Scheme 3-2: Synthetic scheme for assembly of 5'-O-(N-isoleucyl)-sulfamoyl adenosine 
and its different base analogues (3.11a-g). 
Reagents and conditions: (i) TBDMSCl, imidazole, dry DMF, 50 oC, 3 d, 92-98%; (ii) 
TFA-Water, THF, 0 oC, 6 h, 90-99%; (iii) ClSO2NCO, formic acid, DMA, 63-80%; (iv) 
Boc-Ile-OSu, DBU, DMF, rt, 6 h, (v) TFA:water (5:2), rt, 3 h, (vi) TEA.3HF, THF, rt, 
overnight 28-65% (over 3 steps); (vii) Pd/C, methanol: water, H2 atm, rt, 6 h, 40%. 
 
involved persilylation of the nucleoside followed by selective removal of the 5’-TBDMS 
protection and reaction of the liberated 5’-hydroxyl group with in situ formed sulfamoyl 
 chloride.[82] Finally, the isoleucyl sulfam
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Scheme 3-3: Strategy for synthesis of th
conjugates (3.12a-g). 
Reagents and conditions: 
TFA/water/thioanisole (90:7.5:2.5), rt, 2 h, 6
 
3.3  Biological evaluation
Figure 3-1: In vitro aminoacylation reaction in presence of the respective aaSA 
analogues 3.11a-g using E. coli wt 
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Figure 3-2: Broth dilution antibacterial activity test against E. coli wt in LB medium at 
different concentrations of the hexapeptidyl conjugates 3.12a-g. 
A) 
 
B) 
 
Figure 3-3: Broth dilution antibacterial test against E. coli Ara-Yej (BW39758) strain in 
LB medium containing 5 mM L-arabinose at different concentrations of the hexapeptidyl 
conjugates 3.12a-g as determined after incubation for 8 h (panel A) and after 18 h (panel 
B). 
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The obtained analogues were evaluated for inhibition of isoleucine incorporation 
under in vitro aminoacylation experiment (Figure 3-1). The remarkable order of 
inhibitory activity found for the different sulfamates surprisingly showed the strongest 
inhibition for the U analogue 3.11f followed by I > adenine= C > 4-ABI > 4-NBI > G. 
Excited with the results from our in vitro aminoacylation experiments, we evaluated the 
analogues 3.11a-g for their ability to inhibit the growth of microorganisms by a disc 
diffusion method (data not shown).  
In line with previous results[81] none of the analogues showed growth inhibitory 
activity (maximum concentration tested was 5 mM). Hexapeptidyl (formyl-MRTGNA-
OH) conjugates of these analogues likewise were evaluated for their growth inhibitory 
properties. Unfortunately, none of conjugates 3.12a-g displayed any activity against E. 
coli wt (Figure 3-2). Upon evaluation with the E. coli Ara-Yej inducer strain 
(BW39758)[81] transient inhibition could be seen after 8 h incubation for the adenosine 
conjugate 3.12b and to a lower extent for the purines 3.12d and 3.12g. The uracil 
conjugate 3.12f however was devoid of inhibitory activity (panel A, Figure 3-3). 
3.4  Discussion 
Several non-hydrolysable analogues of aa-AMP have been reported in literature as 
inhibitors of aaRS with the aaSAs displaying nanomolar affinity for the corresponding 
aaRS in vitro. These inhibitors however lack selectivity for bacterial aaRSs as compared 
to their human orthologs due to structural similarity with aa-AMP. Visual inspection of 
the compounds reported by Cubist Pharmaceuticals, and of albomycin and mupirocin 
reveals that these structures vary from aaSA analogues in having a heterocyclic base or a 
modified base or no base moiety at all as in mupirocin respectively. These observations 
prompted us to re-investigate the pharmacophoric importance of the adenine base in 
aaSAs. IleRS, being extensively studied as aaRS target before (e.g. the mupirocin studies 
and the Cubist Pharmaceuticals inhibitor program), was chosen to study the effect of 
different bases substituting for adenine. Hereto, isoleucyl-sulfamoyl nucleoside analogues 
comprising either a natural base like G, I, U or C, or the unnatural base 4-NBI or 4-ABI 
(the latter corresponding to 1,3-dideaza adenine) were envisaged. The natural nucleobase 
containing analogues were prepared to investigate the effect of pyrimidine versus purine 
analogues, whereas the sulfamates containing an unnatural base aimed at evaluating the 
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importance of N1 and N3 of the adenine ring, respectively. All analogues were 
synthesized as outlined in Scheme 3-2.  
From the in vitro aminoacylation experiments it can be concluded that these 
molecules act as IleRS inhibitors (Figure 3-1). The remarkable order of inhibitory activity 
found for the different sulfamates showed the strongest inhibition for the U analogue 
3.11f followed by I > adenine= C > 4-ABI > 4-NBI > G. This implies that the adenine 
base or a purine ring per se is not a prerequisite for aaRS inhibition. Furthermore, U and 
C analogues proved to be either more or equally active respectively, as compared to the 
adenine base. The latter is rather unexpected in view of their small size occupying only 
part of the active site. While I is well tolerated, addition of the C-2 amino moiety as in the 
G analogue resulted in a significant decrease in activity possibly due to steric clashes. The 
unnatural 1,3-dideaza-adenine containing analogues displayed lower activity, most 
probably in view of loss of the reported H-bonding of the adenine N3 position with a His 
residue of the active site.[129] The 4-NBI analogue 3.11a proved less active compared to 
its reduced counterpart, the 4-ABI (1,3-dideaza adenine) analogue suggesting the possible 
interaction of the amine with the synthetase active site. In contrast, in the reported 
IleRS.IleAMS of Nakama et al. (with IleAMS being a close analogue to IleSA with 
nitrogen substituting for the 5’-oxygen), the adenine N6 atom is too far to allow hydrogen 
bonding.[129]  
The strong in vitro inhibition shown by both pyrimidine containing compounds is 
rather unexpected in view of the omnipresent and more spacious adenosine being used in 
the majority of biochemical processes. We therefore tried to get some insight into the 
binding pocket of IleRS, and made an attempt to carry out some molecular simulations 
with the synthesized inhibitors using a homology modeled IleRS. The E. coli IleRS 
structure being not available in the protein databank, a homology model was created 
using the I-tasser server[130] starting from the E. coli MetRS structure (1PG0); (see 
experimental section). The newly developed inhibitors were then superimposed onto the 
original inhibitor present in 1PG0 (Figure 3-4). 
Base modifications 
76 
 
 
Figure 3-4: Homology model for E. coli IleRS based on the 1PG0 structure including its 
interactions with the sulfamoylated adenosine analogue 3.11b. 
In using a homology model for our analysis, we cannot use a classical program to 
dock the inhibitors into the binding site of tRNA synthetase. Numerous amino acid side 
chains, in addition to the many flexible dihedrals from the inhibitors, would have to be 
adjusted to accommodate the inhibitors. Unfortunately, the noise on the calculation of the 
interaction energy values for the different inhibitors proved too large to allow for a clear 
classification. 
Despite the exciting results from the in vitro aminoacylation experiments, no 
growth inhibitory activity on microorganisms was found for the analogues 3.11a-g by a 
disc diffusion method up to maximum concentration tested of 5 mM. This lack of activity 
corresponds with the general lack of activity in a whole-cell assay as shown before[81] and 
can be related to limited cell-penetration in accordance with the lack of in vivo efficacy 
for the IleSA analogue 3.11b. Hence with the microcin C strategy in mind, hexapeptidyl 
conjugates of these analogues were prepared in an effort to improve the uptake of these 
compounds via a Trojan-horse mechanism. Hence, the conjugates 3.12a-g were evaluated 
against E. coli wt (Figure 3-2) or E. coli Ara-Yej inducer (BW39758) strain (Figure 3-3) 
in a broth dilution test. The latter strain upon arabinose induction shows an increased 
expression of the transporter.[81] Unfortunately, only some transient antibacterial activity 
was noticed for purine derivatives 3.12b, 3.12d and 3.12g following incubation with the 
inducer strain (panel A, figure 3-3), while no antibacterial activity could be recorded for 
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the in vitro strongly active uracil derivative 3.12f. As it has been shown previously that 
the hexapeptide is effectively metabolized by non-specific peptidases failure of uptake is 
the likely reason for the low activity of these hexapeptidyl conjugates. Hence, being the 
only different part of these constructs, the heterocyclic base might play an important role 
for recognition by the transporter as was seen with the tetrazole analogues when coupled 
to the peptidic carrier.[83]  
3.5  Conclusions 
A series of isoleucyl-sulfamoylated nucleoside analogues comprising different 
base substitution was synthesized in an effort to evaluate the pharmacophoric importance 
of the adenine ring for recognition by IleRS. Upon in vitro evaluation in a cellular extract, 
surprisingly the uracil containing analogue 3.11f was shown to be endowed with the 
highest inhibitory properties. To promote their bacterial uptake, these polar sulfamoylated 
analogues were converted into their respective hexapeptidyl conjugates in analogy with 
the natural Trojan-horse antibiotic microcin C. Unfortunately, only weak inhibitory 
properties could be noticed for the adenosine analogue 3.12b and not for the conjugate 
3.12f comprising the uracil moiety. 
3.6 Experimental section 
3.6.1  Materials and Methods:  
Analogous to the procedure as described in section 2.5.1 In addition, signal assignment 
for 1H and 13C in the conjugate compounds 3.12a-g were obtained using [1H,1H]-DQF-
COSY,[131] [1H,13C]-HSQC[132] and [1H,13C]-HMBC[133] spectra were recorderd on Bruker 
Avance II 600 with a TCI gradient cryoprobe. 
2,1,3-benzoselenadiazole (3.2) 
An amount of 3.1 (10.5 g, 97.1 mmol) and selenium dioxide (11.85 g, 106.8 mmol) were 
refluxed in absolute ethanol (100 mL) for 10 min. The reaction mixture was cooled to rt 
and ethanol was evaporated in vacuo. The product was precipitated from water to yield 
17.6 g (96.1 mmol, 99% yield) of 3.2 as a faint pink coloured solid: 1H NMR (300 MHz, 
CD3OD) δ 7.46-7.52 (m, 2H, Ar), 7.76-7.83 (m, 2H, Ar); 13C NMR (75 MHz, CD3OD) δ 
124.2, 130.6, 161.6 (C=N); HRMS for C6H5N2Se ([M+H]+) calcd: 184.9612 found 
184.9616. 
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4-nitro-2,1,3-benzoselenadiazole (3.3)[126]  
A mixture of 9.1 mL of conc. nitric acid and 18.2 mL of conc. sulphuric acid was added 
to a solution of 3.2 (16.7 g, 91.2 mmol) in conc. sulphuric acid (36.5 mL) at 0 oC. The 
solution was allowed to stir at room temperature for 30 min and then poured into excess 
ice water. The precipitate was filtered off and washed with distilled water to yield 20.8 g 
(91.2 mmol, quantitative) of the title compound 3.3 as yellow solid: 1H NMR (300 MHz, 
DMSO-d6) δ 7.72-7.78 (dd, 1H, J = 7.5 Hz and 8.7 Hz, H-meta to nitro), 8.29 (d, 1H, J = 
8.7 Hz, H-para to nitro), 8.46 (d, 1H, J = 7.5 Hz, H-ortho to nitro); 13C NMR (75 MHz, 
DMSO-d6) δ 126.4, 126.8, 129.4, 140.5, 149.9, 159.9; HRMS for C6H4N3O2Se ([M+H]+) 
calcd: 229.9463 found 229.9668. 
3-nitro-1,2-phenylenediamine (3.4)[128]  
To a suspension of 3.3 (18 g, 79 mmol) in conc. hydrochloric acid (225 mL), 70 mL of 
aqueous hydroiodic acid (57% w/v, 70 mL) was added dropwise at room temperature 
with vigorous stirring. The reaction mixture was stirred further at room temperature for 3 
h. A 5% aqueous sodium hydrogen sulphide solution (400 mL) was added to the dark-red 
reaction mixture. This was then warmed to 80 oC and filtered hot and afterwards cooled to 
4 oC. The needle like salt of the diamine crystallized out. The product was neutralized 
with 30% NaOH to pH 8 and extracted with ethyl acetate (6x100 mL). The ethyl acetate 
layer was collected, dried over Na2SO4, filtered off and evaporated to yield 6.5 g (42.44 
mmol, 54%) of the title compound 3.4 as a red solid: 1H NMR (300 MHz, CD3OD) δ 
6.47-6.56 (dd, 1H, J = 7.5 Hz and 8.7 Hz, Ar), 6.87-6.92 (dd, 1H, J = 1.2 Hz and 7.5 Hz, 
Ar), 7.48-7.53 (dd, 1H, J = 1.2 Hz and 8.7 Hz, Ar); 13C NMR (75 MHz, CD3OD) δ 116.4, 
117.0, 120.6 (quaternary carbon not detected); HRMS for C6H7N3O2Na ([M+Na]+) calcd: 
176.0431 found 176.1058. 
4(7)-nitro-benzimidazole (3.5)[128]  
A mixture of 3.4 (6 g, 39.2 mmol) and triethyl orthoformate (150 mL) was refluxed at 
145 oC for 4 h. The solution was evaporated to dryness with a rotary evaporator and the 
residue obtained was dissolved in formic acid (150 mL) and refluxed for 3 h at 110 oC. 
When the reaction was completed, the excess formic acid was removed in vacuo and the 
residue was dissolved in methanol (150 mL) and treated with activated charcoal by 
overnight stirring at room temperature. The charcoal was removed by filtration through 
celite and the filtrate was evaporated to dryness. The residue obtained was subjected to 
silica gel column chromatography to afford 5.54 g (34 mmol, 87 %) of 3.5 as a yellow 
solid: 1H NMR (300 MHz, DMSO-d6) δ 7.43 (t, 1H, J = 8.1 Hz, H-5/6), 8.16 (d, 2H, J = 
8.1 Hz, H-4/7 and H-6/5), 8.45 (s, 1H, H-2), 8.47 (bs, 1H, NH); 13C NMR (75 MHz, 
DMSO-d6) δ 118.9 (C-5/6), 121.2 (C-4/7), 126.6 (C-6/5), 145.3 (C-2); HRMS for 
C7H4N3O2 ([M-H]-) calcd: 162.0309 found 162.0314. 
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1-(2’,3’,5’-tri-O-acetyl-β-D-ribofuranosyl)-4-nitrobenzimidazole (3.6)[128]  
The compound 3.5 (1.2 g, 7.36 mmol) and 1’,2’,3’,5’-tetra-O-acetyl-β-D-ribofuranose  
(2.81 g, 8.83 mmol) were dissolved in 30 mL of dry acetonitrile. A solution of stannic 
chloride (1M in DCM, 22.1 mL, 22.1 mmol) was added and the reaction mixture was 
stirred at 25 oC for 16 h. The reaction mixture was diluted with DCM and then poured 
under stirring into 30 mL of ice cooled saturated sodium bicarbonate. The resulting 
suspension was filtered through celite and the layers were separated. The organic layer 
was further washed with brine and was dried over Na2SO4, filtered off and evaporated. 
The residue was purified by silica gel column chromatography to yield 2.5 g (5.93 mmol, 
80%) of the title compound 3.6 as pale yellow solid: 1H NMR (500 MHz, CDCl3) δ 2.10 
(s, 3H, COCH3), 2.16 (s, 3H, COCH3), 2.18 (s, 3H, COCH3), 4.39-4.44 (m, 1H, H-5’a), 
4.45-4.50 (m, 1H, H-5’b), 4.51-4.55 (m, 1H, H-4’), 5.51 (t, 1H, J = 5.0 Hz, H-3’), 5.56 (t, 
1H, 5.5 Hz, H-2’), 6.15 (d, 1H, J = 5.5 Hz, H-1’), 7.44 (t, 1H, J = 8.0 Hz, H-6), 7.97 (d, 
1H, J = 8.0 Hz, H-7), 8.19 (d, 1H, J = 8.0 Hz, H-5), 8.40 (s, 1H, H-2); 13C NMR (125 
MHz, CDCl3) δ 19.5 (COCH3), 19.6 (COCH3), 19.9 (COCH3), 61.7 (C-5’), 69.1 (C-3’), 
72.5 (C-2’), 79.7 (C-4’), 86.5 (C-1’), 116.3 (C-5), 119.2 (C-7), 122.1 (C-6), 134.2 (C-9), 
136.9 (C-4), 138.8 (C-8), 142.8 (C-2), 168.5 (COCH3), 168.7(COCH3), 169.1 (COCH3); 
HRMS for C18H19N3O9Na ([M+Na]+) calcd: 444.1014 found 444.1012. 
1-β-D-(4-nitro-benzimidazol-1-yl)-ribofuranoside (3.7a) 
The acylated precursor 3.6 (2.5 g, 5.93 mmol) was dissolved in methanolic ammonia (7N, 
25 mL) at 0 oC. The reaction mixture was allowed to warm to room temperature and 
stirred overnight. Then the mixture was evaporated to dryness and the residue was 
partitioned between water and ether. The aqueous layer was evaporated to yield 1.4 g 
(4.74 mmol, 90%) of the title compound 3.7a as a pale yellow solid which was used 
further without purification: 1H NMR (500 MHz, DMSO-d6) δ 3.62-3.66 (m, 1H, H-5’a), 
3.67-3.72 (m, 1H, H-5’b), 4.03 (q, 1H, J = 3.0 Hz, H-4’), 4.14 (q, 1H, J = 5.0 Hz, H-3’), 
4.38 (q, 1H, J = 6.0 Hz, H-2’), 5.19 (t, 1H, J = 5.5 Hz, 5’-OH), 5.27 (d, 1H, J = 4.5 Hz, 
3’-OH), 5.56 (d, 1H, J = 6.0 Hz, H-1’), 7.48 (t, 1H, J = 8.0 Hz, H-6), 8.08 (d, 1H, J = 8.0 
Hz, H-7), 8.27 (d, 1H, J = 8.0 Hz, H-5), 8.77 (s, 1H, H-2); 13C NMR (125 MHz, DMSO-
d6) δ 61.1 (C-5’), 70.1 (C-3’), 74.1 (C-2’), 86.0 (C-4’), 89.1 (C-1’), 118.7 (C-7), 118.8 
(C-5), 122.3 (C-6), 135.5 (C-9), 136.9 (C-8), 138.8 (C-4), 145.8 (C-2); HRMS for 
C12H14N3O6 ([M+H]+) calcd: 296.0877 found 296.0880. 
General procedure for synthesis of 2’,3’,5’-tri-O-TBDMS nucleosides (3.8a-f)[134]  
To a stirred solution of the nucleoside (1 mmol) and imidazole (8 mmol) in DMF (5 mL) 
was added TBDMSCl (4 mmol). The reaction mixture was stirred at 50 oC for 3 days. 
After completion of reaction, DMF was evaporated and the residue was partitioned 
between ethyl acetate (50 mL) and saturated NaHCO3 (50 mL). The layers were separated 
and the aqueous layer was extracted with ethyl acetate (50 mLx3). The combined organic 
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layers were washed with brine, dried over sodium sulfate, filtered and evaporated to yield 
an oily residue which was purified by silica gel chromatography yield persilyated 
derivatives in 92-98% yield. 
1-β-D-(4-nitro-benzimidazol-1-yl)-2’,3’,5’-tri-O-TBDMS-ribofuranoside (3.8a) 
1H NMR (500 MHz, CDCl3) δ -0.68 (s, 3H, CH3-Si), -0.16 (s, 3H, CH3-Si), 0.12 (s, 3H, 
CH3-Si), 0.13 (s, 3H, CH3-Si), 0.17 (s, 3H, CH3-Si), 0.19 (s, 3H, CH3-Si), 0.71 (s, 9H, tBu 
CH3), 0.96 (s, 9H, tBu CH3), 0.98 (s, 9H, tBu CH3), 3.84-3.87 (dd, 1H, J = 2.0 Hz and 
11.5 Hz, H-5’a), 3.95-3.99 (dd, 1H, J = 2.0 Hz and 11.5 Hz, H-5’b), 4.16-4.18 (m, 1H, H-
4’), 4.23 (d, 1H, J = 4.5 Hz, H-3’), 4.40-4.44 (dd, 1H, J = 4.5 Hz and 7.5 Hz, H-2’), 5.93 
(d, 1H, J = 8.0 Hz, H-1’), 7.35 (t, 1H, J = 8.0 Hz, H-6), 8.13 (d, 1H, J = 8.0 Hz, H-7), 
8.18 (d, 1H, J = 8.0 Hz, H-5), 8.34 (s, 1H, H-2); 13C NMR (125 MHz, CDCl3) δ -6.7 
(CH3-Si), -6.3 (CH3-Si), -6.2 (CH3-Si), -5.5 (CH3-Si), -5.4 (CH3-Si), -5.3 (CH3-Si), 16.9 
(tBu C(CH3)3), 17.2 (tBu C(CH3)3), 17.7 (tBu C(CH3)3),  24.8 (tBu, CH3), 25.0 (tBu, CH3), 
25.21 (tBu, CH3), 62.6 (C-5’), 72.0 (C-3’), 74.9 (C-2’), 86.7 (C-4’), 88.3 (C-1’), 117.8 (C-
7), 118.9 (C-5), 121.3 (C-6), 134.7 (C-9), 136.9 (C-8), 138.5 (C-4), 144.2 (C-2); HRMS 
for C30H56N3O6Si3 ([M+H]+) calcd: 638.3471 found 638.3482. 
2’,3’,5’-tri-O-TBDMS-guanosine (3.8c)[135]  
1H NMR (300 MHz, DMSO-d6) δ -0.28 (s, 3H, CH3-Si), -0.08 (s, 3H, CH3-Si), 0.09-0.12 
(ms, 12H, 4xCH3-Si), 0.73 (s, 9H, tBu CH3), 0.9 (2s, 18H, tBu CH3), 3.68-3.73 (dd, 1H,  J 
= 3.9 Hz, and 11.4 Hz, H-5’a), 3.82-3.88 (dd, 1H,  J = 5.4 Hz, 11.4 Hz, H-5’b), 3.93-3.95 
(m, 1H, H-4’), 4.17 (d, 1H, J = 4.2 Hz,  H-3’), 4.56-4.61 (dd, 1H, J = 4.5 Hz and 6.9 Hz, 
H-2’), 5.74 (d, 1H, J = 7.2 Hz, H-1’), 6.45 (bs, 2H, NH2), 7.89 (s, 1H, H-8), 10.61 (bs, 
NH); 13C NMR (75 MHz, DMSO-d6) δ -5.39 (3xCH3-Si), -4.67 (CH3-Si), -4.64 (CH3-Si), 
-4.55 (CH3-Si), 17.7 (tBu C(CH3)3), 17.9 (tBu C(CH3)3), 18.2 (tBu C(CH3)3), 25.6 (tBu 
CH3), 25.9 (tBu CH3), 26.0 (tBu CH3), 63.1 (C-5’), 72.9 (C-3’), 75.4 (C-2’), 85.4 (C-4’), 
85.8 (C-1’), 116.7 (C-5), 135.0 (C-8), 151.8 (C-4), 153.9 (C-2), 156.8 (C-6); HRMS calcd 
for C28H56N5O5Si3 ([M+H]+) calcd: 626.3584 found: 626.3582. 
2’,3’,5’-tri-O-TBDMS-inosine (3.8d)[136]  
1H NMR (300 MHz, DMSO-d6) δ -0.53 (s, 3H, CH3-Si), -0.13 (s, 3H, CH3-Si), -0.02 (s, 
3H, CH3-Si), 0.01 (2s, 6H, 2xCH3-Si), 0.74 (s, 9H, tBu, CH3), 0.94 (s, 9H, tBu, CH3), 3.71 
(d, 1H, J = 12.6 Hz, H-5’), 3.94 (d, 1H, J = 12.9 Hz, H-5’), 4.15 (bs, 1H, H-4’), 4.37 (d, 
1H, J = 4.2 Hz, H-3’), 4.82-4.92 (m, 1H, H-2’), 3.78 (d, 1H, J = 7.5 Hz, H-1’), 7.90 (s, 
1H, H-8), 8.43 (s, 1H, H-2); 13C NMR (75 MHz, DMSO-d6) δ -5.7 (CH3-Si), -4.52 (CH3-
Si), -4.47 (CH3-Si), -4.4 (CH3-Si), 17.9 (tBu C(CH3)3), 18.2 (tBu C(CH3)3), 25.8 (tBu 
CH3), 25.9 (tBu CH3), 62.9 (C-5’), 73.9 (C-3’), 74.8 (C-2’), 89.2 (C-4’), 91.0 (C-1’), 
126.7 (C-5), 140.9 (C-8), 146.3 (C-2), 147.9 (C-4), 159.6 (C-6); HRMS for 
C28H55N4O5Si3 ([M+H]+) calcd: 611.3475 found 611.3472. 
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2’,3’,5’-tri-O-TBDMS-cytidine (3.8e)[134b]  
1H NMR (300 MHz, DMSO-d6) δ -0.01 (s, 6H, 2xCH3-Si), 0.06 (s, 3H, CH3-Si), 0.07 (s, 
3H, CH3-Si), 0.09 (s, 3H, CH3-Si), 0.10 (s, 3H, CH3-Si), 0.83 (s, 9H, tBu CH3), 0.88 (s, 
9H, tBu CH3), 0.91 (s, 9H, tBu CH3), 3.67-3.75 (m, 1H, H-5’a), 3.85-3.95 (m, 2H, H-5’b, 
H-4’), 4.04 (t, 1H, J = 4.2 Hz, H-3’), 4.10 (t, 1H, J = 4.5 Hz, H-2’), 5.71 (d, 1H, J = 7.5 
Hz, H-5), 5.82 (d, 1H, J = 4.5 Hz, H-1’), 7.17 (bs, 2H, NH2), 7.79 (d, 1H, J = 7.5 Hz, H-
6); 13C NMR (75 MHz, DMSO-d6) δ -5.7 (CH3-Si), -5.6 (CH3-Si), -5.0 (2xCH3-Si), -4.8 
(CH3-Si), -4.6 (CH3-Si), 17.6 (tBu C(CH3)3), 17.7 (tBu C(CH3)3), 18.0 (tBu C(CH3)3), 
25.6 (tBu CH3), 25.7 (tBu CH3), 25.8 (tBu CH3), 61.9 (C-5’), 71.0 (C-3’), 75.2 (C-2’), 
83.6 (C-4’), 87.8 (C-5), 93.8 (C-1’), 140.4 (C-6), 155.1 (C-2), 165.4 (C-4); HRMS for 
C27H56N3O5Si3 ([M+H]+) calcd: 586.3522 found 586.3522. 
2’,3’,5’-tri-O-TBDMS-uridine (3.8f) 
1H NMR (300 MHz, DMSO-d6) δ -0.02 (s, 3H, CH3-Si), 0.03 (s, 3H, CH3-Si), 0.09 (s, 
3H, CH3-Si), 0.09-0.11 (m, 9H, 3xCH3-Si), 0.84 (s, 9H, tBu CH3), 0.89 (s, 9H, tBu CH3), 
0.91 (s, 9H, tBu CH3), 3.68-3.75 (dd, 1H, J = 2.4 Hz and 11.4 Hz, H-5’a), 3.83-3.90 (dd, 
1H, J = 3.9 Hz and 11.4 Hz, H-5’b), 3.93-3.97 (m, 1H, H-4’), 4.05-4.09 (m, 1H, H-3’), 
4.20-4.25 (m, 1H, H-2’), 5.64 (d, 1H, J = 7.8 Hz, H-5), 5.82 (d, 1H, J = 5.7 Hz, H-1’), 
7.77 (d, 1H, J = 8.1 Hz, H-6), 11.40 (s, 1H, NH); 13C NMR (75 MHz, DMSO-d6) δ -5.7 
(CH3-Si), -5.6 (CH3-Si), -5.04 (CH3-Si), -5.0 (CH3-Si), -4.8 (CH3-Si), -4.7 (CH3-Si), 17.6 
(tBu C(CH3)3), 17.7 (tBu C(CH3)3), 18.0 (tBu C(CH3)3), 25.5 (tBu CH3), 25.7 (tBu CH3), 
25.8 (tBu CH3), 62.3 (C-5’), 71.7 (C-3’), 74.4 (C-2’), 84.7 (C-4’), 86.9 (C-1’), 101.9 (C-
5), 139.9 (C-6), 150.6 (C-2), 162.8 (C-4); HRMS for C27H53N2O6Si3 ([M-H]-) calcd: 
585.3218 found 585.3218. 
General procedure for 5’-desilylation (3.9a-f)[137]  
To a stirred solution of the persilylated nucleoside (200 mg) in THF (4 mL) was added 
aqueous TFA (2 mL, TFA:water 1:1) at 0 oC. After stirring for 6 h at 0 oC, the reaction 
mixture was neutralized with saturated aqueous NaHCO3 and diluted with ethyl acetate 
(80 mL). The layers were separated and the organic phase was washed with water (10 
mL) and brine (10 mL), dried over anhydrous Na2SO4, filtered and evaporated at reduced 
pressure. The residue was subjected to silica gel chromatography to provide the 2’,3’-
disilylated products as a white solid in 90-99% yield. 
1-(β-D-ribofuranosyl)-4-nitro-2’,3’-di-O-TBDMS-benzimidazole (3.9a) 
1H NMR (300 MHz, CDCl3) δ -0.54 (s, 3H, CH3-Si), -0.09 (s, 3H, CH3-Si), 0.15 (s, 6H, 
2xCH3-Si), 0.72 (s, 9H, tBu CH3), 1.0 (s, 9H, tBu CH3), 4.07-4.13 (m, 2H, H-5’a and H-
5’b), 4.26 (bs, 1H, H-4’), 4.41 (d, 1H, J = 3.3 Hz, H-3’), 4.74-4.80 (dd, 1H, J = 4.8 Hz 
and 7.2 Hz, H-2’), 6.03 (d, 1H, J = 6.6 Hz, H-1’), 7.43 (t, 1H, J = 8.4 Hz, H-6), 7.92 (d, 
1H, J = 8.4 Hz, H-7), 8.22 (d, 1H, J = 8.1 Hz, H-5), 9.19 (s, 1H, H-2); 13C NMR (75 
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MHz, CDCl3) δ -5.4 (CH3-Si), -4.4 (2xCH3-Si), -4.3 (CH3-Si), 17.9 (tBu C(CH3)3), 18.3 
(tBu C(CH3)3), 25.8 (tBu CH3), 26.0 (tBu CH3), 62.0 (C-5’), 74.2 (C-3’), 78.3 (C-2’), 87.9 
(C-4’), 89.5 (C-1’), 117.3 (C-7), 120.0 (C-5), 122.6 (C-6), 136.4 (C-9), 136.6 (C-8), 139.1 
(C-4), 145.5 (C-2); HRMS for C24H41N3O6Si2Na ([M+Na]+) calcd: 546.2426 found 
546.2420. 
2’,3’-di-O-TBDMS-adenosine (3.9b)[92c]  
1H NMR (300 MHz, DMSO-d6) δ -0.38 (s, 3H, CH3-Si), -0.10 (s, 3H, CH3-Si), 0.10 (s, 
3H, CH3-Si), 0.12 (s, 3H, CH3-Si), 0.72 (s, 9H, tBu CH3), 0.92 (s, 9H, tBu CH3), 3.55-
3.63 (m, 1H, H-5’a), 3.70-3.80 (m, 1H, H-5’b), 3.95-4.02 (m, 1H, H-4’), 4.29-4.35 (m, 
1H, H-3’), 4.75-4.83 (m, 1H, H-2’), 5.94 (d, 1H, J = 6.3 Hz, H-1’), 8.35 (s, 1H, H-2), 
8.60 (s, 1H, H-8); 13C NMR (75 MHz, DMSO-d6) δ -5.7 (CH3-Si), -4.9 (CH3-Si), -4.8 
(CH3-Si), -4.7 (CH3-Si), 17.5 (tBu C(CH3)3), 17.8 (tBu C(CH3)3), 25.5 (tBu CH3), 25.7 
(tBu CH3), 61.0 (C-5’), 72.6 (C-3’), 74.8 (C-2’), 86.9 (C-4’), 87.5 (C-1’), 119.1 (C-5), 
141.2 (C-8), 148.6 (C-4), 148.8 (C-2), 153.2 (C-6); HRMS for C22H42N5O4Si2 ([M+H]+) 
calcd: 496.2770 found 496.2771. 
2’,3’-di-O-TBDMS-guanosine (3.9c)[135]  
1H NMR (300 MHz, DMSO-d6) δ -0.36 (s, 3H, CH3-Si), -0.09 (s, 3H, CH3-Si), 0.11 (s, 
3H, CH3-Si), 0.13 (s, 3H, CH3-Si), 0.72 (s, 9H, tBu CH3), 0.92 (s, 9H, tBu CH3), 3.53-
3.64 (m, 1H, H-5’a), 3.68-3.78 (m, 1H, H-5’b), 3.93-4.0 (m, 1H, H-4’), 4.27-4.32 (m, 1H, 
H-3’), 4.73 (dd, 1H, J = 4.2 Hz and 6.6 Hz, H-2’), 5.24 (t, 1H, J = 6.0 Hz, 5’-OH), 5.90 
(d, 1H, J = 6.9 Hz, H-1’), 8.11 (H-8), 8.39 (NH); 13C NMR (75 MHz, DMSO-d6) δ -5.7 
(CH3-Si), -4.84 (CH3-Si), -4.76 (CH3-Si), -4.7 (CH3-Si), 17.5 (tBu C(CH3)3), 17.8 (tBu 
C(CH3)3), 25.4 (tBu CH3), 25.7 (tBu CH3), 61.0 (C-5’), 72.7 (C-3’), 75.2 (C-2’), 86.7 (C-
4’), 86.8 (C-1’), 124.5 (C-5), 138.9 (C-8), 146.0 (C-4), 148.2 (C-2), 156.5 (C-6); HRMS 
for C22H42N5O5Si2 ([M+H]+) calcd: 512.2718 found 512.2715. 
2’,3’-di-O-TBDMS-inosine (3.9d) 
1H NMR (300 MHz, CDCl3) δ -0.53 (s, 3H, CH3-Si), -0.13 (s, 3H, CH3-Si), -.02 (s, 3H, 
CH3-Si), 0.01 (2s, 6H, 2xCH3-Si), 0.74 (s, 9H, tBu, CH3), 0.94 (s, 9H, tBu, CH3), 3.71 (d, 
1H, J = 12.6 Hz, H-5’), 3.94 (d, 1H, J = 12.9 Hz, H-5’), 4.15 (bs, 1H, H-4’), 4.37 (d, 1H, 
J = 4.2 Hz, H-3’), 4.82-4.92 (m, 1H, H-2’), 5.78 (d, 1H, J = 7.5 Hz, H-1’), 7.90 (s, 1H, H-
2), 8.43 (s, 1H, H-8); 13C NMR (75 MHz, CDCl3) δ -5.7 (CH3-Si), -4.52 (CH3-Si), -4.47 
(CH3-Si), -4.4 (CH3-Si), 17.9 (tBu C(CH3)3), 18.2 (tBu C(CH3)3), 25.8 (tBu CH3), 25.9 
(tBu CH3), 62.9 (C-5’), 73.9 (C-3’), 74.8 (C-2’), 89.2 (C-4’), 91.0 (C-1’), 126.7 (C-5), 
140.9 (C-8), 146.3 (C-2), 147.9 (C-4), 159.6 (C-6); HRMS for C22H41N4O5Si2 ([M+H]+) 
calcd: 497.2610 found 497.2608. 
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2’,3’-di-O-TBDMS-cytidine (3.9e) 
1H NMR (600 MHz, DMSO-d6) δ -0.01 (s, 3H, CH3-Si), 0.01 (s, 3H, CH3-Si), 0.06 (s, 
3H, CH3-Si), 0.08 (s, 3H, CH3-Si), 0.82 (s, 9H, tBu CH3), 0.88 (s, 9H, tBu CH3), 3.51-
3.56 (m, 1H, H-5’a), 3.65-3.70 (m, 1H, H-5’b), 3.86 (q, 1H, J = 3.6 Hz, H-4’), 4.10 (t, 
1H, J = 4.2 Hz, H-3’), 4.19 (t, 1H, J = 4.8 Hz, H-2’), 5.19-5.21 (m, 1H, 5’-OH) 5.75 (d, 
1H, J = 7.2 Hz, H-5) 5.77 (d, 1H, J = 4.8 Hz, H-1’) 7.20-7.35 (m, 2H, NH2), 7.91 (d, 1H, 
J = 7.2 Hz, H-6); 13C NMR (150 MHz, DMSO-d6) δ -4.9 (2xCH3-Si), -4.8 (CH3-Si), -4.6 
(CH3-Si), 17.7 (tBu C(CH3)3), 17.8 (tBu C(CH3)3), 25.7 (tBu CH3), 25.8 (tBu CH3), 60.1 
(C-5’), 71.4 (C-3’), 74.9 (C-2’), 84.5 (C-4’), 88.3 (C-5), 94.0 (C-1’), 141.5 (C-6), 155.0 
(C-2), 165.2 (C-4); HRMS for C22H42N3O5Si2 ([M-H]-) calcd: 472.2657 found 472.2652. 
2’,3’-di-O-TBDMS-uridine (3.9f)[92c]  
1H NMR (300 MHz, DMSO-d6) δ -0.03 (s, 3H, CH3-Si), 0.02 (s, 3H, CH3-Si), 0.08 (s, 
3H, CH3-Si), 0.09 (s, 3H, CH3-Si), 0.83 (s, 9H, tBu CH3), 0.88 (s, 9H, tBu CH3), 3.52-
3.70 (m, 2H, H-5’a and H-5’b), 3.85-3.90 (m, 1H, 5’-OH), 4.10-4.17 (m, 1H, H-3’), 4.25 
(t, 1H, J = 5.7 Hz, H-2’), 5.24 (d, 1H, J = 4.8 Hz, H-4’) 5.68 (d, 1H, J = 8.4 Hz, H-5) 5.81 
(d, 1H, J = 6.0 Hz, H-1’) 7.93 (d, 1H, J = 8.1 Hz, H-6), 11.34 (s, 1H, NH); 13C NMR (75 
MHz, DMSO-d6) δ -5.0 (CH3-Si), -4.9 (CH3-Si), -4.8 (CH3-Si), -4.6 (CH3-Si), 17.6 (tBu 
C(CH3)3), 17.7 (tBu C(CH3)3), 25.59 (tBu CH3), 25.64 (tBu CH3), 60.4 (C-5’), 71.9 (C-
3’), 74.6 (C-2’), 85.5 (C-4’), 86.9 (C-1’), 102.0 (C-5), 140.3 (C-6), 150.8 (C-2), 163.0 (C-
4); HRMS for C21H39N2O6Si2 ([M-H]-) calcd: 471.2352 found 471.2343. 
General procedure for synthesis of the respective 5’-O-sulfamoyl nucleosides (3.10a-
f) 
Formic acid (2.5 mmol) was added to ice cooled chlorosulfonyl isocyanate (2.5 mmol) 
and allowed to stir at 0 oC for 5 min. The resulting solid was dissolved in dry acetonitrile 
(2 mL) and cooled to 0 oC. The obtained sulfamoyl chloride was then added to an ice 
cooled solution of the respective nucleoside (1 mmol) in dimethyl acetamide (5 mL) and 
allowed to stir at room temperature for 1 h. After 1 h, TEA (1.5 mL, excess) was added 
and stirring was continued for an additional 10 min. Subsequently, methanol (2 mL) was 
added and the mixture was stirred for an additional 15 min. Finally, the solvent was 
evaporated to dryness and the residue was dissolved in ethyl acetate and washed with 
saturated NaHCO3. The organic layer was further washed with water and brine. The 
organic layer was collected, dried over Na2SO4, filtered and evaporated. The residue was 
subjected to silica gel chromatography to afford sulfamoylated nucleoside in 63-80% 
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1-(2’,3’-di-O-TBDMS)-5’-O-sulfamoyl-β-D-ribofuranosyl)-4-nitro-benzimidazole 
(3.10a) 
1H NMR (500 MHz, CDCl3) δ -0.50 (s, 3H, CH3-Si), -0.10 (s, 3H, CH3-Si), 0.13 (s, 6H, 
2xCH3-Si), 0.71 (s, 9H, tBu CH3), 0.95 (s, 9H, tBu CH3), 4.31-4.36 (m, 2H, H-5’a and H-
5’b), 4.41-4.45 (m, 2H, H-4’, H-3’), 4.55-4.59 (dd, 1H, J = 2.5 Hz, 11.0 Hz, H-2’), 5.97 
(d, 1H, J = 6.5 Hz, H-1’), 6.68 (bs, 2H, NH2), 7.40 (t, 1H, J = 8.0 Hz, H-6), 7.85 (d, 1H, J 
= 8.0 Hz, H-7), 8.15 (d, 1H, J = 8.0 Hz, H-5), 8.59 (s, 1H, H-2); 13C NMR (125 MHz, 
CDCl3) δ -6.4 (CH3-Si), -5.6 (CH3-Si), -5.5 (CH3-Si), -5.3 (CH3-Si), 16.9 (tBu C(CH3)3), 
17.1 (tBu C(CH3)3), 24.8 (tBu CH3), 25.0 (tBu CH3), 67.9 (C-5’), 71.9 (C-2’), 76.0 (C-3’), 
82.9 (C-4’), 88.0 (C-1’), 116.5 (C-7), 119.1 (C-5), 121.8 (C-6 ),134.9 (C-9), 135.8 (C-8), 
138.1 (C-4), 143.7 (C-2); HRMS for C24H43N4O8SSi2 ([M+H]+) calcd: 603.2334 found 
603.2325. 
2’,3’-di-O-TBDMS-5’-O-sulfamoyl-adenosine (3.10b) 
1H NMR (300 MHz, DMSO-d6) δ -0.37 (s, 3H, CH3-Si), -0.08 (s, 3H, CH3-Si), 0.13 (s, 
3H, CH3-Si), 0.15 (s, 3H, CH3-Si), 0.71 (s, 9H, tBu CH3), 0.93 (s, 9H, tBu CH3), 4.15-
4.21 (m, 1H, H-3’), 4.27-4.34 (m, 1H, H-2’), 4.36-4.44 (m, 2H, H-5’a and H-5’b), 4.94-
4.94 (dd, 1H, J = 4.5 Hz, 6.6 Hz, H-4’), 5.96 (d, 1H, J = 6.9 Hz, H-1’), 7.31 (s, 2H, NH2), 
7.64 (s, 2H, NH2), 8.16 (s, 1H, H-8), 8.36 (s, 1H, H-2); 13C NMR (75 MHz, DMSO-d6) δ 
-5.6 (CH3-Si), -4.9 (CH3-Si), -4.8 (CH3-Si), -4.7 (CH3-Si), 17.5 (tBu C(CH3)3), 17.7 (tBu 
C(CH3)3), 25.4 (tBu CH3), 25.7 (tBu CH3), 68.0 (C-5’), 72.4 (C-2’), 73.7 (C-3’), 82.8 (C-
4’), 87.0 (C-1’), 119.3 (C-5), 139.8 (C-8), 149.4 (C-4), 152.7 (C-2), 156.1 (C-6); HRMS 
for C22H43N6O6SSi2 ([M+H]+) calcd: 575.2498 found 575.2530. 
2’,3’-di-O-TBDMS-5’-O-sulfamoyl-guanosine (3.10c) 
1H NMR (300 MHz, DMSO-d6) δ -0.28 (s, 3H, CH3-Si), -0.06 (s, 3H, CH3-Si), 0.12 (s, 
3H, CH3-Si), 0.14 (s, 3H, CH3-Si), 0.73 (s, 9H, tBu CH3), 0.92 (s, 9H, tBu CH3), 4.12-
4.17 (m, 1H, H-3’), 4.21-4.35 (m, 3H, H-2’, H-5’a and H-5’b), 4.75-4.81 (dd, 1H, J = 4.5 
Hz, 7.2 Hz, H-4’), 5.76 (d, 1H, J = 7.5 Hz, H-1’), 6.47 (bs, 2H, SONH2), 7.66 (s, 2H, 2-
NH2), 7.91 (s, 1H, H-8), 10.69 (s, 1H, NH); 13C NMR (75 MHz, DMSO-d6) δ -5.6 (CH3-
Si), -4.9 (CH3-Si), -4.7 (2xCH3-Si), 17.5 (tBu C(CH3)3), 17.7 (tBu C(CH3)3), 25.5 (tBu 
CH3), 25.7 (tBu CH3), 68.1 (C-5’), 72.7 (C-2’), 74.0 (C-3’), 83.0 (C-4’), 85.8 (C-1’), 
116.8 (C-5), 135.6 (C-8), 151.5 (C-4), 153.7 (C-2), 156.7 (C-6); HRMS for 
C22H43N6O7SSi2 ([M+H]+) calcd: 591.2447 found 591.2455. 
2’,3’-di-O-TBDMS-5’-O-sulfamoyl-inosine (3.10d) 
1H NMR (300 MHz, CDCl3) δ -0.33 (s, 3H, CH3-Si), -0.08 (s, 3H, CH3-Si), 0.11 (s, 3H, 
CH3-Si), 0.15 (s, 3H, CH3-Si),0.76 (s, 9H, tBu CH3), 0.94 (s, 9H, tBu CH3), 4.30-4.42 (m, 
2H, H-5’a and H-5’b), 4.48-4.52 (m, 1H, H-4’), 4.65-4.75 (m, 1H, H-3’), 4.75-4.80  (m, 
1H, H-2’), 5.82 (d, 1H, J = 5.4 Hz, H-1’), 7.01 (bs, 2H, NH2), 8.01 (s, 1H, H-8), 8.42 (s, 
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1H, H-2); 13C NMR (75 MHz, CDCl3) δ -5.1 (CH3-Si), -4.7 (CH3-Si), -4.6 (CH3-Si), -4.3 
(CH3-Si), 17.9 (tBu C(CH3)3), 18.2 (tBu C(CH3)3), 25.8 (tBu CH3), 26.0 (tBu CH3), 69.0 
(C-5’), 72.3 (C-2’), 74.8 (C-3’), 83.3 (C-4’), 90.0 (C-1’), 124.8 (C-5), 140.8 (C-8), 146.1 
(C-2), 148.2 (C-4), 158.3 (C-6); HRMS for C22H41N5O7SSi2 ([M+H]+) calcd: 576.2338 
found 576.2347. 
2’,3’-di-O-TBDMS-5’-O-sulfamoyl-cytidine (3.10e) 
1H NMR (300 MHz, DMSO-d6) δ 0.00 (s, 3H, CH3-Si), 0.02 (s, 3H, CH3-Si), 0.08 (s, 3H, 
CH3-Si), 0.10 (s, 3H, CH3-Si),0.83 (s, 9H, tBu CH3), 0.88 (s, 9H, tBu CH3), 4.04-4.18 (m, 
3H, H-5’a, H-5’b and H-4’), 4.22-4.32 (m, 2H, H-2’ and H-3’), 5.73-5.80 (m, 2H, H-5 
and H-1’), 7.21-7.38 (m, 2H, SONH2), 7.63 (d, 1H, J = 7.5 Hz, H-6), 7.68 (s, 2H, NH2); 
13C NMR (75 MHz, DMSO-d6) δ -5.0 (CH3-Si), -4.9 (CH3-Si), -4.8 (CH3-Si), -4.6 (CH3-
Si), 17.6 (tBu C(CH3)3), 17.7 (tBu C(CH3)3), 25.67 (tBu CH3), 25.69 (tBu CH3), 67.5 (C-
5’), 71.2 (C-3’), 74.0 (C-2’), 81.0 (C-4’), 88.9 (C-5), 94.3 (C-1’), 141.1 (C-6), 154.8 (C-
2), 165.2 (C-4); HRMS for C21H43N4O7SSi2 ([M+H]+) calcd: 551.2385 found 551.2380. 
2’,3’-di-O-TBDMS-5’-O-sulfamoyl-uridine (3.10f) 
1H NMR (300 MHz, CDCl3) δ 0.07 (s, 3H, CH3-Si), 0.08 (s, 3H, CH3-Si), 0.10 (s, 3H, 
CH3-Si), 0.11 (s, 3H, CH3-Si),0.88 (s, 9H, tBu CH3), 0.91 (s, 9H, tBu CH3), 4.12 (t, 1H, J 
= 4.2 Hz, H-5’a) 4.24 (q, 1H, J = 3.9 Hz, H-4’), 4.28 (dd, 1H, J = 3.6 Hz and 11.1 Hz, H-
5’b), 4.48-4.54 (m, 2H, H-2’ and H-3’), 5.53 (d, 1H, J = 4.5 Hz, H-1’), 5.62 (bs, 2H, 
SONH2), 5.77 (d, 1H, J = 8.1 Hz, H-5), 7.50 (d, 1H, J = 8.1 Hz, H-6), 9.70 (bs, 1H, NH); 
13C NMR (75 MHz, CDCl3) δ -5.8 (CH3-Si), -5.59 (CH3-Si), -5.56 (CH3-Si), -5.2 (CH3-
Si), 17.10 (tBu C(CH3)3), 17.15 (tBu C(CH3)3), 24.90 (tBu CH3), 24.93 (tBu CH3), 67.4 
(C-5’), 70.5 (C-3’), 72.6 (C-2’), 81.1 (C-4’), 92.1 (C-1’), 101.6 (C-5), 141.1 (C-6), 149.7 
(C-2), 162.7 (C-4); HRMS for C21H41N3O8SSi2Na ([M+Na]+) calcd: 574.2045 found 
574.2043. 
General procedure for synthesis of 5’-O-(N-L-isoleucyl)-sulfamoyl nucleosides 
(3.11a-f) 
To a solution of the respective 2’,3’-di-O-(tert-butyldimethylsilyl)-5’-O-sulfamoyl 
nucleoside (1.0 mmol) and Nα-Boc-L-isoleucine N-hydroxysuccinimide ester (1.1 equiv) 
in DMF (3 mL) was added DBU (1.1 equiv) and the reaction mixture was stirred at rt for 
6-8h. Next, the volatiles were removed in vacuo and the residue was purified by silica gel 
chromatography (Et3N 1%, MeOH 2.5-10% in CH2Cl2). The coupled product was next 
treated with TFA/H2O (5/2 v/v) for 2 h at rt, after which the volatiles were evaporated and 
coevaporated twice with EtOH and once with EtOH and Et3N (2 mL), to neutralize any 
remaining acid. The compound was carefully dried and dissolved in THF (2 mL) and 
Et3N.3HF (0.5 mL). After 3 h, another 0.4 mL of Et3N.3HF was added and the reaction 
mixture was stirred further for 22 h. The reaction mixture was evaporated and the residue 
was purified by flash chromatography (5 to 50% CH2Cl2:MeOH) and finally by HPLC 
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using PLRP-S 100 Å column and acetonitrile:water as mobile phase to yield isoleucyl-
sulfamoyl nucleoside as white solid in 28-65% yield. 
1-[5’-O-(N-L-isoleucyl-sulfamoyl-β-D-ribofuranosyl)]-4-nitro-benzimidazole (3.11a) 
1H NMR (500 MHz, D2O) δ 0.74 (t, 3H, J = 10.0 Hz, Ile-δ-CH3), 0.88 (d, 3H, J = 10.0 
Hz, Ile-γ-CH3), 1.05-1.15 (m, 1H, Ile-γ-CH2 Ha), 1.32-1.41 (m, 1H, Ile-γ-CH2 Hb), 1.79-
1.85 (m, 1H, Ile-β-CH), 3.46 (d, 1H, J = 5.0 Hz, Ile-α-CH), 4.38-4.45 (m, 2H, H-5’a and 
H-5’b), 4.45-4.50 (m, 2H, H-3’ and H-4’), 4.61 (t, 1H, J = 5.0 Hz, H-2’), 6.09 (d, 1H, J = 
5.0 Hz, H-1’), 7.44 (t, 1H, J = 10.0 Hz, H-6), 8.03 (d, 1H, J = 10.0 Hz, H-7), 8.12 (d, 1H, 
J = 10.0 Hz, H-5) 8.60 (s, 1H, H-2); 13C NMR (75 MHz, D2O) δ 10.4 (Ile-δ-CH3), 14.4 
(Ile-γ-CH3), 23.6 (Ile-δ-CH2), 37.0 (Ile-β-CH), 60.3 (Ile-α-CH), 67.7 (C-5’), 69.8 (C-3’), 
73.5 (C-2’), 82.5 (C-4’), 88.8 (C-1’), 118.7 (C-7), 120.2 (C-5), 123.0 (C-6), 134.5 (C-9), 
135.6 (C-8), 137.3 (C-4), 145.0 (C-2), 178.4 (C=O, Ile); HRMS for C18H24N5O9S ([M-H]-
) calcd: 486.1300 found 486.1301. 
5’-O-(N-L-isoleucyl)-sulfamoyl-adenosine (3.11b) 
1H NMR (300 MHz, D2O) δ 0.87 (t, 3H, J = 7.5 Hz, Ile-δ-CH3), 0.98 (d, 3H, J = 6.9 Hz, 
Ile-γ-CH3), 1.02-1.28 (m, 1H, Ile-γ-CH2 Ha), 1.40-1.53 (m, 1H, Ile-γ-CH2 Hb), 1.95-2.07 
(m, 1H, Ile-β-CH), 3.76 (d, 1H, J = 4.2 Hz, Ile-α-CH), 4.43-4.51 (m, 3H, H-5’a, H-5’b 
and H-4’), 4.56 (t, 1H, J = 5.1 Hz, H-3’), 4.75-4.78 (m, 1H, merged with D2O peak, H-
2’), 6.13 (d, 1H, J = 5.1 Hz, H-1’), 8.24 (s, 1H, H-8), 8.42 (s, 1H, H-2); 13C NMR (75 
MHz, D2O) δ 11.5 (Ile-δ-CH3), 15.1 (Ile-γ-CH3), 24.7 (Ile-δ-CH2), 37.0 (Ile-β-CH), 60.7 
(Ile-α-CH), 68.9 (C-5’), 70.8 (C-3’), 74.7 (C-2’), 82.9 (C-4’), 87.9 (C-1’), 119.1 (C-5), 
140.4 (C-8), 149.5 (C-4), 153.1 (C-2), 155.8 (C-6), 175.6 (C=O, Ile); HRMS for 
C16H24N7O7S ([M-H]-) calcd: 458.1463 found 458.1461. 
5’-O-(N-L-isoleucyl)-sulfamoyl-guanosine (3.11c) 
1H NMR (600 MHz, D2O) δ 0.83 (t, 3H, J = 7.2 Hz, Ile-δ-CH3), 0.94 (d, 3H, J = 7.2 Hz, 
Ile-γ-CH3), 1.01-1.19 (m, 1H, Ile-γ-CH2 Ha), 1.34-1.43 (m, 1H, Ile-γ-CH2 Hb), 1.92-1.99 
(m, 1H, Ile-β-CH), 3.89 (d, 1H, J = 4.2 Hz, Ile-α-CH), 4.35-4.40 (m, 3H, H-5’a, H-5’b 
and H-4’), 4.50 (t, 1H, J = 4.2 Hz, H-3’), 4.70-4.75 (m, 1H, H-2’), 5.92 (d, 1H, J = 6.0 
Hz, H-1’), 8.03 (s, 1H, H-8); 13C NMR (125 MHz, D2O) δ 10.5 (Ile-δ-CH3), 14.1 (Ile-γ-
CH3), 23.7 (Ile-δ-CH2), 36.0 (Ile-β-CH), 59.7 (Ile-α-CH), 68.0 (C-5’), 69.8 (C-3’), 73.2 
(C-2’), 81.9 (C-4’), 86.6 (C-1’), 115.9 (C-5), 137.1 (C-8), 151.4 (C-4), 153.6 (C-2), 158.7 
(C-6), 174.7 (C=O, Ile); HRMS for C16H24N7O8S ([M-H]-) calcd: 474.1412 found 
474.1407. 
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5’-O-(N-L-isoleucyl)-sulfamoyl-inosine (3.11d) 
1H NMR (300 MHz, D2O) δ 0.74 (t, 3H, J = 7.5 Hz, Ile-δ-CH3), 0.86 (d, 3H, J = 7.2 Hz, 
Ile-γ-CH3), 1.01-1.17 (m, 1H, Ile-γ-CH2 Ha), 1.25-1.40 (m, 1H, Ile-γ-CH2 Hb), 1.82-1.95 
(m, 1H, Ile-β-CH), 3.62 (d, 1H, J = 4.2 Hz, Ile-α-CH), 4.29-4.38 (m, 3H, H-5’a, H-5’b 
and H-4’), 4.43 (t, 1H, J = 4.2 Hz, H-3’), 4.62-4.70 (m, 1H, merged with solvent peak, H-
2’), 6.02 (d, 1H, J = 5.1 Hz, H-1’), 8.11 (s, 1H, H-8), 8.27 (s, 1H, H-2); 13C NMR (75 
MHz, D2O) δ 10.6 (Ile-δ-CH3), 14.1 (Ile-γ-CH3), 23.7 (Ile-δ-CH2), 36.1 (Ile-β-CH), 59.8 
(Ile-α-CH), 67.8 (C-5’), 69.9 (C-3’), 73.9 (C-2’), 82.1 (C-4’), 87.4 (C-1’), 123.4 (C-5), 
139.2 (C-8), 146.1 (C-2), 148.4 (C-4), 158.5 (C-6), 175.0 (C=O, Ile); HRMS for 
C16H23N6O8S ([M-H]-) calcd: 459.1303 found 459.1304. 
5’-O-(N-L-isoleucyl)-sulfamoyl-cytidine (3.11e) 
1H NMR (300 MHz, D2O) δ 0.91 (t, 3H, J = 7.5 Hz, Ile-δ-CH3), 1.02 (d, 3H, J = 7.2 Hz, 
Ile-γ-CH3), 1.17-1.33 (m, 1H, Ile-γ-CH2 Ha), 1.41-1.56 (m, 1H, Ile-γ-CH2 Hb), 1.99-2.10 
(m, 1H, Ile-β-CH), 3.76 (d, 1H, J = 4.2 Hz, Ile-α-CH), 4.23-4.37 (m, 4H, H-5’a, H-5’b H-
4’and H-3’), 4.44-4.51 (m, 1H, H-2’), 5.95 (d, 1H, J = 3.3 Hz, H-1’), 6.10 (d, 1H, J = 7.5 
Hz, H-5) 7.83 (d, 1H, J = 7.8 Hz,  H-6); 13C NMR (75 MHz, D2O) δ 10.6 (Ile-δ-CH3), 
14.2 (Ile-γ-CH3), 23.8 (Ile-δ-CH2), 36.1 (Ile-β-CH), 59.8 (Ile-α-CH), 67.6 (C-5’), 68.9 
(C-3’), 73.7 (C-2’), 80.9 (C-4’), 89.5 (C-5), 96.1 (C-1’), 141.0 (C-6), 157.3 (C-2), 165.8 
(C-4), 174.8 (C=O, Ile); HRMS for C15H26N5O8S ([M+H]+) calcd: 436.1496 found 
436.1495. 
5’-O-(N-L-isoleucyl)-sulfamoyl-uridine (3.11f) 
1H NMR (300 MHz, D2O) δ 0.93 (t, 3H, J = 7.5 Hz, Ile-δ-CH3), 1.02 (d, 3H, J = 6.9 Hz, 
Ile-γ-CH3), 1.18-1.34 (m, 1H, Ile-γ-CH2 Ha), 1.42-1.56 (m, 1H, Ile-γ-CH2 Hb), 1.98-2.11 
(m, 1H, Ile-β-CH), 3.75 (d, 1H, J = 3.9 Hz, Ile-α-CH), 4.38-4.48 (m, 5H, H-5’a, H-5’b, 
H-4’ H-3’, H-2’), 5.92 (m, 2H, H-1’ and H-5), 7.84 (d, 1H, J = 8.1 Hz, H-6); 13C NMR 
(75 MHz, D2O) δ 10.7 (Ile-δ-CH3), 14.2 (Ile-γ-CH3), 23.8 (Ile-δ-CH2), 36.1 (Ile-β-CH), 
59.7 (Ile-α-CH), 67.7 (C-5’), 69.2 (C-3’), 73.3 (C-2’), 81.4 (C-4’), 88.5 (C-1’), 102.2 (C-
5), 141.2 (C-6), 151.3 (C-2), 165.8 (C-4), 174.8 (C=O, Ile); HRMS for C15H23N4O9S ([M-
H]-) calcd: 435.1191 found 435.1192. 
5’-O-(N-L-isoleucyl)-sulfamoyl-1,3-dideaza-adenosine (3.11g) 
To a solution of 3.11a (50 mg, 0.1 mmol) in dry methanol (5 mL) was added Pd/C (10% 
w/w, 20 mg) and the mixture was stirred under H2 atmosphere at room temperature for 7 
h. Next, the catalyst was filtered off and the solvent was evaporated to dryness. The 
product was purified by silica gel column chromatography and finally by HPLC to yield 
19 mg (0.04 mmol, 40%) of title compound as faint brown solid. 
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1H NMR (500 MHz, D2O) δ 0.80 (t, 3H, J = 7.5 Hz, Ile-δ-CH3), 0.95 (d, 3H, J = 7.0 Hz, 
Ile-γ-CH3), 1.12-1.24 (m, 1H, Ile-γ-CH2 Ha), 1.37-1.46 (m, 1H, Ile-γ-CH2 Hb), 1.95-2.02 
(m, 1H, Ile-β-CH), 3.71 (d, 1H, J = 4.0 Hz, Ile-α-CH), 4.41-4.46 (m, 3H, H-5’a, H-5’b, 
H-4’), 4.48-4.51 (m,1H, H-3’), 4.67 (t, 1H, J = 6.0 Hz, H-2’), 6.04 (d, 1H, J = 6.5 Hz, H-
1’), 6.78 (d, 1H, J = 7.5 Hz, H-1), 7.17 (d, 1H, J = 7.5 Hz, H-3), 7.23 (t, 1H, J = 8.0 Hz, 
H-2), 8.34 (s, 1H, H-8); 13C NMR (125 MHz, D2O) δ 10.5 (Ile-δ-CH3), 14.1 (Ile-γ-CH3), 
23.7 (Ile-δ-CH2), 36.0 (Ile-β-CH), 59.8 (Ile-α-CH), 68.1 (C-5’), 69.7 (C-3’), 72.8 (C-2’), 
82.0 (C-4’), 88.2 (C-1’), 101.7 (C-3), 108.3 (C-1), 124.7 (C-2), 132.1 (C-5), 133.0 (C-6), 
137.5 (C-4), 140.5 (C-8), 174.8 (C=O Ile); HRMS for C18H26N5O7S ([M-H]-) calcd: 
456.1558 found 456.1560. 
General procedure for synthesis of nucleoside sulfamate-hexapeptidyl conjugates 
(3.12a-g)[81] 
The peptide formyl-methionyl-arginyl-(2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-
sulfonyl)-threonyl(tBu)-glycyl-asparaginyl-(trityl)-alanyl-OH was synthesized on a 2-
chlorotrityl chloride resin using standard Fmoc-based solid phase peptide chemistry. The 
protected hexapeptide was cleaved from the resin using a mixture of 
HOAc/trifluoroethanol/DCM (1/1/8, v/v) in 30 min. Following RP-HPLC purification, 
the peptide (20 mg, 16.13 µmol, 1.0 eq.) and HOBt (9 mg, 64.52 µmol, 4.0 eq.) were 
dissolved in DMF (500 µL) and DIC (10 µL, 64.52 µmol, 4.0 eq.) was added. This 
mixture was stirred for 1 h at rt under argon atmosphere. Following addition of DIPEA 
(7.5 µL, 40.33 µmol, 2.5 eq.), the mixture was added to the nucleoside sulfamate 
analogue 3.11a-g (32.26 µmol, 2.0 eq.) and stirred for 16 h at rt under argon. Next, the 
volatiles were evaporated and the residue was taken up in a mixture of CH3CN/water. 
This was purified on a PoraPak Rxn RP 6 cc Vac Cartridge 80µm particle (Waters®) 
column with a CH3CN gradient of 25 to 100% in water). The fractions containing the 
product were evaporated and the protected conjugate was subsequently deprotected using 
a mixture of 90% TFA, 7.5% H2O and 2.5% thioanisole. The reaction mixture was poured 
in chilled diethyl ether and centrifuged. Supernatant was decanted and the residue was re-
suspended in chilled diethyl ether and centrifuged. A small amount of TEA (500 µL) was 
added for final washing. The product was dissolved in CH3CN/water and purified by RP-
HPLC (solvent A: 25 mM TEAB in H2O; solvent B: 25 mM TEAB in CH3CN; see 
supporting file for HPLC analysis of all final compounds). Overall yield for coupling, 
deprotection and tedious HPLC purification is generally low and affords about 6-12% 
yield. 
fMRTGNAI-S[(4-nitrobenzimidazole)-β-ribofuranoside] (3.12a) 
1H NMR (600 MHz, D2O) δ 0.73 (t, 3H, J = 7.2 Hz, Ile-δ-CH3), 0.81 (d, 3H, J = 6.6 Hz, 
Ile-γ-CH3), 1.00-1.10 (m, 1H, Ile-γ-CH2, Ha), 1.14-1.21 (m, Thr-γ-CH3, TEA-CH3), 1.27-
1.39 (d+m, 4H, J = 7.2 Hz, Ala-β-CH3 and Ile-γ-CH2, Hb), 1.55 (m, 2H, Arg-γ-CH2), 
1.67-1.88 (m, 3H, Ile β-CH and 2H, Arg-β-CH2), 1.95-2.07 (m+s, 5H, Met-β-CH2 and 
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Met-SCH3), 2.53 (m, 2H, Met-γ-CH2), 2.37 (dd, 1H, J = 8.4 Hz and 15.6 Hz, Asn-β-CH2, 
Ha), 2.78 (dd, 1H, J = 4.8 Hz, and 16.2 Hz, Asn-β-CH2, Hb), 3.00 (m, TEA-CH2), 3.10 
(m, 2H, Arg-δ-CH2), 3.87 (d, 1H, J = 16.9 Hz,  Gly-α-CH2, Ha), 3.94-4.00 (m, 2H,  Ile-
α-CH and Gly-α-CH2, Hb), 4.19-4.28 (m, 2H, Thr-β-CH, Ala-α-CH), 4.31-4.41 (m, 4H, 
Thr-α-CH, Arg-α-CH and H-5’a and H-5’b), 4.42-4.46 (m, 2H, H-3’and H-4’), 4.49 (dd, 
1H, J = 5.9 Hz and 8.2 Hz, Met-α-CH), 4.64-4.68 (m, 2H, H-2’ and Asn-α-CH), 6.13 (d, 
1H, J = 6.7 Hz, H-1’), 7.54 (t, 1H, J = 8.3 Hz, H-6), 8.08 (s, 1H, CHO), 8.16 (d, 1H, J = 
8.3 Hz,  H-7), 8.26 (d, 1H, J = 8.3 Hz,  H-5), 8.68 (s, 1H, H-2); 13C NMR (150 MHz, 
D2O) δ 8.9 (ΤΕΑ-CH3), 10.1 (Ile-δ-CH3), 13.8 (Met-SCH3), 14.7 (Ile-γ-CH3), 16.1 (Ala-
β-CH3), 18.3 (Thr-γ-CH3), 24.0 (Ile-γ-CH2), 24.1 (Arg-γ-CH2), 27.7 (Arg-β-CH2), 28.7 
(Met-γ-CH2), 30.1 (Met-β-CH2), 35.9 (Asn-β-CH2), 36.6 (Ile-β-CH), 40.1 (Arg-δ-CH2), 
42.2 (Gly-α-CH2), 45.6 (TEA-CH2), 49.5 (Ala-α-CH), 49.9 (Asn-α-CH), 51.1 (Met-α-
CH), 53.0 (Arg-α-CH), 58.6 (Thr-α-CH), 60.2 (Ile-α-CH), 66.9 (Thr-β-CH), 68.0 (C-5’), 
70.0 (C-3’), 73.4 (C-2’), 82.8 (C-4’), 88.7 (C-1’), 119.0 (C-7), 120.5 (C-5), 123.2 (C-6), 
134.8 (C-8), 135.9 (C-9), 137.7 (C-4), 145.4 (C-2), 156.2 (Arg-Cζ), 163.9 (CHO), 170.9 
(Gly-CO), 171.8 (Asn-CO), 172.0 (Thr-CO), 173.0 (Met-CO), 173.3 (Arg-CO), 174.0 
(Ala-CO and Asn-Cγ), 179.1 (Ile-CO); HRMS for C43H66N15O18S2 ([M-H]-) calcd: 
1144.4158 found 1144.4150. 
fMRTGNAI-SA (3.12b) 
1H NMR (600 MHz, D2O) δ 0.85 (t, 3H, J = 7.2 Hz, Ile-δ-CH3), 0.90 (d, 3H, J = 6.6 Hz, 
Ile-γ-CH3), 1.13-1.24 (m, Thr-γ-CH3, TEA-CH3 and Ile-γ-CH2, Ha), 1.36 (d, 3H, J = 7.2 
Hz, Ala-β-CH3), 1.43-1.52 (m, 1H, Ile-γ-CH2, Hb), 1.61 (m, 2H, Arg-γ-CH2), 1.71-1.92 
(m, 3H, Ile β-CH and 2H, Arg-β-CH2), 1.96-2.08 (m+s, 5H, Met-β-CH2 and Met-SCH3), 
2.55 (m, 2H, Met-γ-CH2), 2.70 (dd, 1H, J = 8.4 Hz and 15.6 Hz, Asn-β-CH2, Ha), 2.79 
(dd, 1H, J = 4.8 Hz, and 16.2 Hz, Asn-β-CH2, Hb), 3.08-3.21 (m, TEA-CH2 and Arg-δ-
CH2), 3.97 (d, 1H, J = 16.9 Hz,  Gly-α-CH2, Ha), 3.98 (d, 1H, J = 16.9 Hz,  Gly-α-CH2, 
Hb), 4.06 (d, 1H, J = 6.9 Hz, Ile-α-CH), 4.21 (m, 1H, Thr-β-CH ), 4.26-4.46 (m, 7H, Ala-
α-CH, Thr-α-CH, Arg-α-CH, H-3’, H-4’  and H-5’a and H-5’b), 4.50 (dd, 1H, J = 5.9 
Hz, and 8.2 Hz, Met-α-CH), 4.67 (dd, 1H, J = 5.2 Hz and 8.9 Hz, Asn-α-CH), 4.72 (m, 
1H, H-2’), 6.09 (d, 1H, J = 5.9 Hz, H-1’), 8.08 (s, 1H, CHO) , 8.22 (s, 1H, H-2), 8.42 (s, 
1H, H-8); 13C NMR (150 MHz, D2O) δ 7.9 (ΤΕΑ-CH3), 9.8 (Ile-δ-CH3), 13.8 (Met-
SCH3), 14.4 (Ile-γ-CH3), 16.0 (Ala-β-CH3), 18.4 (Thr-γ-CH3), 24.1 (Ile-γ-CH2), 24.3 
(Arg-γ-CH2), 27.6 (Arg-β-CH2), 28.7 (Met-γ-CH2), 30.1 (Met-β-CH2), 35.4 (Asn-β-CH2), 
35.9 (Ile-β-CH), 40.1 (Arg-δ-CH2), 42.1 (Gly-α-CH2), 46.3 (TEA-CH2), 49.5 (Ala-α-
CH), 50.0 (Asn-α-CH), 51.1 (Met-α-CH), 53.2 (Arg-α-CH), 58.8 (Thr-α-CH), 60.4 (Ile-
α-CH), 66.9 (Thr-β-CH), 68.0 (C-5’), 70.2 (C-3’), 73.7 (C-2’), 82.8 (C-4’), 86.5 (C-1’), 
139.4 (C-8), 148.8 (C-4), 152.7 (C-2), 155.2 (C-6), 156.4 (Arg-Cζ), 163.9 (CHO), 170.9 
(Gly-CO), 172.0 (Asn-CO and Thr-CO), 173.1 (Met-CO), 173.4 (Arg-CO), 174.0 (Ala-
Base modifications 
90 
 
CO and Asn-Cγ), 179.6 (Ile-CO); HRMS for C41H68N17O16S2 ([M-H]-) calcd: 1116.4320 
found 1116.4305. 
fMRTGNAI-SG (3.12c) 
1H NMR (600 MHz, D2O) δ 0.77 (t, 3H, J = 7.2 Hz, Ile-δ-CH3), 0.82 (d, 3H, J = 6.6 Hz, 
Ile-γ-CH3), 1.05 (m, 1H, Ile-γ-CH2, Ha), 1.16 (d, J = 6.3 Hz, 3H, Thr-γ-CH3), 1.24 (t, J = 
3.6 Hz, TEA-CH3), 1.32 (d, 3H, J = 7.2 Hz, Ala-β-CH3), 1.36 (m, 1H, Ile-γ-CH2, Hb), 
1.58 (m, 2H, Arg-γ-CH2), 1.69-1.89 (m, 3H, Ile β-CH and Arg-β-CH2), 1.94-2.08 (m+s, 
5H, Met-β-CH2 and Met-SCH3), 2.45-2.57 (m, 2H, Met-γ-CH2), 2.70 (dd, 1H, J = 8.4 Hz 
and 15.6 Hz, Asn-β-CH2, Ha), 2.80  (dd, 1H, J = 4.8 Hz and 16.2 Hz, Asn-β-CH2, Hb), 
3.11 (t, 2H, J = 6.6 Hz, Arg-δ-CH2), 3.16 (q, J = 7.8 Hz, TEA-CH2), 3.89 (d, 1H, J = 6.6 
Hz and 16.6 Hz, Gly-α-CH2, Ha), 3.95-4.02 (m, 2H, Ile-α-CH and Gly-α-CH2, Hb), 4.18-
4.24 (m, 1H, Thr-β-CH), 4.25-4.31 (m, 3H, H-5’a and H-5’b, Ala-α-CH), 4.33-4.37 (m, 
2H, J = 4.4 Hz, Thr-α-CH, H-4’), 4.37-4.43 (m, 2H, Arg-α-CH, H-3’), 4.49 (dd, 1H, J = 
5.9 Hz and 8.2 Hz, Met-α-CH), 4.66-4.72 (m, 2H, Asn-α-CH and H-2’), 5.89 (d, 1H, J = 
6.6 Hz, H-1’), 8.00 (s, 1H, H-8), 8.08 (s, 1H, CHO); 13C NMR (150 MHz, D2O) 
δ 7.3 (ΤΕΑ-CH3), 10.0 (Ile-δ-CH3), 13.6 (Met-SCH3), 14.5 (Ile-γ-CH3), 15.9 (Ala-β-
CH3), 18.2 (Thr-γ-CH3), 23.8 (Ile-γ-CH2), 23.9 (Arg-γ-CH2), 27.7 (Arg-β-CH2), 28.7 
(Met-γ-CH2), 29.8 (Met-β-CH2), 35.8 (Asn-β-CH2), 36.5 (Ile-β-CH), 40.1 (Arg-δ-CH2), 
42.1 (Gly-α-CH2), 46.0 (TEA-CH2), 49.5 (Ala-α-CH), 49.9 (Asn-α-CH), 51.1 (Met-α-
CH), 53.0 (Arg-α-CH), 58.6 (Thr-α-CH), 60.2 (Ile-α-CH), 66.9 (Thr-β-CH), 68.1 (C-5’), 
70.0 (C-3’), 73.1 (C-2’), 82.0 (C-4’), 85.9 (C-1’), 116.2 (C-5), 136.3 (C-8), 151.4 (C-4), 
156.0 (Arg-Cζ), 163.7 (CHO), 170.6 (Gly-CO), 171.5 (Asn-CO), 171.7 (Thr-CO), 173.1 
(Met-CO), 173.2 (Arg-CO), 173.7 (Ala-CO), 173.8 (Asn-Cγ), 179.1 (Ile-CO); HRMS for 
C41H66N17O17S2 ([M-H]-) calcd: 1132.4269 found 1132.4274. 
fMRTGNAI-SI (3.12d) 
1H NMR (600 MHz, D2O) δ 0.75 (t, 3H, J = 7.2 Hz, Ile-δ-CH3), 0.81 (d, 3H, J = 6.6 Hz, 
Ile-γ-CH3), 1.04-1.10 (m, Ile-γ-CH2, Ha, TEA-CH3), 1.16 (d, 3H, J = 6.3 Hz, Thr-γ-
CH3),1.29-1.37 (d+m, 4H, J = 7.2 Hz, Ala-β-CH3 and Ile-γ-CH2, Ha), 1.55 (m, 2H, Arg-γ-
CH2), 1.69-1.77 (m, 2H, Ile-β-CH and Arg-β-CH2, Ha), 1.79-1.87 (m, 1H, Arg-β-CH2, 
Hb), 1.94-2.08 (m+s, 5H, Met-β-CH2 and Met-SCH3), 2.45-2.57 (m, 2H, Met-γ-CH2), 
2.67-2.76 (m, TEA-CH2 and Asn-β-CH2, Ha), 2.80  (dd, 1H, J = 4.8 Hz and 16.2 Hz, 
Asn-β-CH2, Hb), 3.10 (t, 2H, J = 6.6 Hz, Arg-δ-CH2), 3.87 (d, 1H, J = 16.8 Hz, Gly-α-
CH2, Ha), 3.95-4.01 (m, 2H, Ile-α-CH and Gly-α-CH2, Hb), 4.18-4.24 (m, 1H, Thr-β-
CH), 4.25-4.31 (m, 3H, H-5’a and H-5’b, Ala-α-CH), 4.33 (d, 1H, J = 4.4 Hz, Thr-α-
CH), 4.36-4.43 (m, 3H, Arg-α-CH, H-3’, H-4’), 4.48 (dd, 1H, J = 5.9 Hz and 8.2 Hz, 
Met-α-CH), 4.67-4.73 (m, 2H, Asn-α-CH and H-2’), 6.03 (d, 1H, J = 6.6 Hz, H-1’), 8.08 
(s, 1H, CHO), 8.11 (s, 1H, H-2), 8.25 (s, 1H, H-8); 13C NMR (150 MHz, D2O) 
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δ 9.1 (ΤΕΑ-CH3), 10.1 (Ile-δ-CH3), 13.8 (Met-SCH3), 14.7 (Ile-γ-CH3), 16.1 (Ala-β-
CH3), 18.4 (Thr-γ-CH3), 24.2 (Ile-γ-CH2 and Arg-γ-CH2), 27.5 (Arg-β-CH2), 28.8 (Met-γ-
CH2), 30.0 (Met-β-CH2), 35.9 (Asn-β-CH2), 36.6 (Ile-β-CH), 40.0 (Arg-δ-CH2), 42.2 
(Gly-α-CH2), 45.5 (TEA-CH2), 49.6 (Ala-α-CH), 50.0 (Asn-α-CH), 51.3 (Met-α-CH), 
53.2 (Arg-α-CH), 58.8 (Thr-α-CH), 60.4 (Ile-α-CH), 66.9 (Thr-β-CH), 68.2 (C-5’), 70.3 
(C-3’), 73.5 (C-2’), 82.2 (C-4’), 86.1 (C-1’), 123.0 (C-5), 137.3 (C-8), 149.8 (C-4), 153.6 
(C-2), 156.2 (Arg-Cζ), 164.0 (CHO), 167.3 (C-6), 170.9 (Gly-CO), 171.8 (Asn-CO), 
172.1 (Thr-CO), 173.3 (Met-CO), 173.6 (Arg-CO), 174.0 (Ala-CO), 174.1 (Asn-Cγ), 
179.4 (Ile-CO); HRMS for C41H65N16O17S2 ([M-H]-) calcd: 1117.4160 found 1117.4186. 
fMRTGNAI-SC (3.12e) 
1H NMR (600 MHz, D2O) δ 0.82 (t, 3H, J = 7.2 Hz, Ile-δ-CH3), 0.88 (d, 3H, J = 6.6 Hz, 
Ile-γ-CH3), 1.07-1.15 (m, 1H, Ile-γ-CH2, Ha), 1.15-1.24 (m, Thr-γ-CH3 and  TEA-CH3), 
1.35 (d, 3H, J = 7.2 Hz, Ala-β-CH3), 1.37-1.44 (m, 1H, Ile-γ-CH2, Hb), 1.61 (m, 2H, Arg-
γ-CH2), 1.75 (m, 1H, Ile-β-CH), 1.84 (m, 2H, Arg-β-CH2), 1.96-2.09 (m+s, 5H, Met-β-
CH2 and Met-SCH3), 2.55 (m, 2H, Met-γ-CH2), 2.70 (m, 1H, Asn-β-CH2, Ha) , 2.80  (dd, 
1H, J = 4.8 Hz and 16.2 Hz, Asn-β-CH2, Hb), 3.07 (m, TEA-CH2),  3.16 (t, 2H, J = 6.6 
Hz, Arg-δ-CH2), 3.89 (d, 1H,  J = 5.4 Hz, Gly-α-CH2, Ha), 3.95-4.04 (m, 2H, Ile-α-CH 
and Gly-α-CH2, Hb), 4.18-4.25 (m, 2H, H-2’ and Thr-β-CH), 4.27-4.33 (m, 4H, H-5’a, 
H-5’b, H-3’ and Ala-α-CH), 4.34-4.45 (m, 3H, Thr-α-CH, Arg-α-CH and H-4’), 4.50 
(dd, 1H, J = 5.9 Hz and 8.2 Hz, Met-α-CH), 4.68 (dd, 1H, J = 5.2 Hz and 8.9 Hz, Asn-α-
CH), 5.92 (d, 1H, J = 3.2 Hz, H-1’), 6.03 (d, 1H, J = 7.5 Hz, H-5), 7.82 (d, 1H, J = 7.5 
Hz,  H-6), 8.09 (s, 1H, CHO); 13C NMR (150 MHz, D2O) δ 8.3 (ΤΕΑ-CH3), 10.3 (Ile-δ-
CH3), 13.8 (Met-SCH3), 14.8 (Ile-γ-CH3), 16.2 (Ala-β-CH3), 18.4 (Thr-γ-CH3), 24.2 (Ile-
γ-CH2 and Arg-γ-CH2), 27.5 (Arg-β-CH2), 28.8 (Met-γ-CH2), 30.0 (Met-β-CH2), 35.9 
(Asn-β-CH2), 36.7 (Ile-β-CH), 40.1 (Arg-δ-CH2), 42.2 (Gly-α-CH2), 46.0 (TEA-CH2), 
49.6 (Ala-α-CH), 50.0 (Asn-α-CH), 51.3 (Met-α-CH), 53.2 (Arg-α-CH), 58.8 (Thr-α-
CH), 60.4 (Ile-α-CH), 66.9 (Thr-β-CH), 67.2 (C-5’), 69.0 (C-3’), 73.8 (C-2’), 81.1 (C-4’), 
89.1 (C-1’), 96.2 (C-5), 140.9 (C-6), 156.3 (Arg-Cζ), 157.4 (C-4), 164.0 (CHO), 165.8 
(C-2), 170.9 (Gly-CO), 171.9 (Asn-CO), 172.1 (Thr-CO), 173.4 (Met-CO), 173.6 (Arg-
CO), 174.1 (Ala-CO and Asn-Cγ), 179.4 (Ile-CO); HRMS for C40H66N15O17S2 ([M-H]-) 
calcd: 1092.4208 found 1092.4196. 
fMRTGNAI-SU (3.12f) 
1H NMR (600 MHz, D2O) δ 0.83 (t, 3H, J = 7.2 Hz, Ile-δ-CH3), 0.89 (d, 3H, J = 6.6 Hz, 
Ile-γ-CH3), 1.07-1.16 (m, 1H, Ile-γ-CH2, Ha), 1.18 (d, 3H, J = 8.4 Hz, Thr-γ-CH3), 1.19-
1.27  (t, J = 3.6 Hz, TEA-CH3), 1.36 (d, 3H, J = 7.2 Hz, Ala-β-CH3), 1.37-1.44 (m, 1H, 
Ile-γ-CH2, Hb), 1.61 (m, 2H, Arg-γ-CH2), 1.7-1.92 (m, 3H, Ile-β-CH and 2H, Arg-β-
CH2), 1.98-2.09 (m+s, 5H, Met-β-CH2 and Met-SCH3), 2.55 (m, 2H, Met-γ-CH2), 2.70 
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(dd, 1H, J = 8.4 Hz and 15.6 Hz, Asn-β-CH2, Ha), 2.80 (dd, 1H, J = 4.8 Hz, and 16.2 Hz, 
Asn-β-CH2, Hb), 3.17 (m, TEA-CH2 and Arg-δ-CH2), 3.89 (d, 1H, J = 16.9 Hz,  Gly-α-
CH2, Ha), 3.98 (d, 1H, J = 16.9 Hz,  Gly-α-CH2, Hb), 4.01 (d, 1H, J = 6.9 Hz, Ile-α-CH), 
4.19-4.37 (m, 8H, Thr-β-CH, Ala-α-CH, Thr-α-CH, Arg-α-CH, H-3’, H-4’, H-5’a-and 
H-5’b), 4.41 (dd, 1H, J = 5.9 Hz and 8.2 Hz, Met-α-CH), 4.51 (dd, 1H, J = 6.0 Hz, and 
8.3 Hz, H-2’), 4.68 (dd, 1H, J = 5.2 Hz and 8.9 Hz, Asn-α-CH), 5.88 (d, 1H, J = 7.6 Hz,  
H-5), 5.94 (d, 1H, J = 5.3 Hz, H-1’), 7.79 (d, 1H, J = 7.6 Hz, H-6), 8.09 (s, 1H, CHO); 
13C NMR (150 MHz, D2O) δ 7.9 (ΤΕΑ-CH3), 10.2 (Ile-δ-CH3), 13.8 (Met-SCH3), 14.8 
(Ile-γ-CH3), 16.2 (Ala-β-CH3), 18.4 (Thr-γ-CH3), 24.2 (Ile-γ-CH2), 24.3 (Arg-γ-CH2), 
27.6 (Arg-β-CH2), 28.8 (Met-γ-CH2), 30.0 (Met-β-CH2), 35.9 (Asn-β-CH2), 36.6 (Ile-β-
CH), 40.1 (Arg-δ-CH2), 42.2 (Gly-α-CH2), 46.3 (TEA-CH2), 49.5 (Ala-α-CH), 50.0 
(Asn-α-CH), 51.3 (Met-α-CH), 53.2 (Arg-α-CH), 58.8 (Thr-α-CH), 60.4 (Ile-α-CH), 
66.8 (Thr-β-CH), 67.6 (C-5’), 69.4 (C-3’), 73.4 (C-2’), 81.5 (C-4’), 88.2 (C-1’), 102.4 (C-
5), 140.8 (C-6), 156.3 (Arg-Cζ), 152.8 (C-2), 164.0 (CHO), 167.4 (C-4), 170.9 (Gly-CO), 
171.9 (Asn-CO), 172.1 (Thr-CO), 173.3 (Met-CO), 173.6 (Arg-CO), 174.0 (Ala-CO and 
Asn-Cγ), 179.5 (Ile-CO); HRMS for C40H65N14O18S2 ([M-H]-) calcd: 1093.4048 found 
1093.4047. 
fMRTGNAI-S(4-ABI) (3.12g) 
1H NMR (600 MHz, D2O) δ 0.76 (t, 3H, J = 7.2 Hz, Ile-δ-CH3), 0.84 (d, 3H, J = 6.6 Hz, 
Ile-γ-CH3), 1.05-1.11 (m, 1H, Ile-γ-CH2, Ha), 1.16 (d, 4H, J = 6.3 Hz, 3H, Thr-γ-CH3), 
1.22 (t, J = 3.6 Hz, TEA-CH3), 1.30 (d, 3H, J = 7.2 Hz, Ala-β-CH3), 1.36-1.40 (m, 1H, 
Ile-γ-CH2, Hb), 1.51-1.60 (m, 2H, Arg-γ-CH2), 1.60-1.72 (m, 1H, Ile-β-CH), 1.77-1.85 
(m, 2H, Arg-β-CH2), 1.94-2.08 (m+s, 5H, Met-β-CH2 and Met-SCH3), 2.47-2.58 (m, 2H, 
Met-γ-CH2), 2.97  (dd, 1H, J = 8.4 Hz and 15.6 Hz, Asn-β-CH2, Ha), 2.78 (dd, 1H, J = 
4.8 Hz, and 16.2 Hz, Asn-β-CH2, Hb), 3.05-3.15 (m, Arg-δ-CH2 and TEA-CH2), 3.87 
(dd, 1H, J = 6.6 Hz and 16.6 Hz, Gly-α-CH2, Ha), 3.94-4.03 (m, 2H, Ile-α-CH and Gly-
α-CH2, Hb), 4.17-4.23 (m, 1H, Thr-β-CH), 4.23-4.29 (m, 1H, Ala-α-CH), 4.30-4.43 (m, 
6H, Thr-α-CH, Arg-α-CH, H-3’, H-4’, H-5’a and H-5’b), 4.48 (t, 1H, J = 7.2 Hz, Met-α-
CH), 4.64-4.68 (m, 2H, Asn-α-CH and H-2’), 5.99 (d, 1H, J = 6.0 Hz, H-1’), 6.73 (d, 1H, 
J = 7.2 Hz,  H-5), 7.15-7.21 (d+tr, 2H, H-6, and H-7), 8.01 (s, 1H, CHO), 8.31 (s, 1H, H-
2); 13C NMR (150 MHz, D2O) δ 8.0 (ΤΕΑ-CH3), 10.1 (Ile-δ-CH3), 13.8 (Met-SCH3), 
14.8 (Ile-γ-CH3), 16.1 (Ala-β-CH3), 18.4 (Thr-γ-CH3), 24.2 (Ile-γ-CH2 and Arg-γ-CH2), 
27.5 (Arg-β-CH2), 28.8 (Met-γ-CH2), 30.0 (Met-β-CH2), 35.9 (Asn-β-CH2), 36.6 (Ile-β-
CH), 40.0 (Arg-δ-CH2), 42.2 (Gly-α-CH2), 46.2 (TEA-CH2), 49.6 (Ala-α-CH), 49.9 
(Asn-α-CH), 51.3 (Met-α-CH), 53.2 (Arg-α-CH), 58.7 (Thr-α-CH), 60.4 (Ile-α-CH), 
66.9 (Thr-β-CH), 68.1 (C-5’), 70.0 (C-3’), 72.6 (C-2’), 82.3 (C-4’), 88.2 (C-1’), 102.1 (C-
7), 108.5 (C-5), 124.8 (C-6), 132.2 (C-9), 133.0 (C-8) 137.4 (C-4), 140.7 (C-2), 156.2 
(Arg-Cζ), 164.0 (CHO), 170.9 (Gly-CO), 171.8 (Asn-CO), 172.1 (Thr-CO), 173.3 (Met-
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CO), 173.6 (Arg-CO), 174.0 (Ala-CO), 174.1 (Asn-Cγ), 179.4 (Ile-CO); HRMS for 
C43H68N15O16S2 ([M-H]-) calcd: 1114.4415 found 1114.4412. 
3.6.2  Model building and analysis 
With the E coli Ile-tRNA synthetase structure being not available in the protein 
databank, a homology model was created using the I-tasser server.[130] The sequence of 
the enzyme was taken from the uniprot database (enzyme code EC=6.1.1.5 and uniprot id 
P00956). As single 3D template structure, we used the E coli methionyl-tRNA synthetase 
structure (1PG0) belonging to the same class I of tRNA synthetases. This structure 
contains a methionyl adenylate analogue inhibitor similar to the seven inhibitors used in 
this study, and therefore was used as template for our adenylate inhibitor. Additionally, 
the threonyl sulfamoyl adenosine inhibitor found in structure 3UH0[138] was used to 
complete part of the sulfamoyl tail in our inhibitor structures. The six inhibitors having 
different bases were built by superimposing the respective base onto the adenosine using 
quatfit. The homology model of E coli Ile-tRNA synthetase was then superimposed onto 
structure 1PG0 using dali.[139]  
All seven inhibitors were then superimposed onto the original inhibitor present in 
1PG0 resulting in seven complexes of E coli Ile-tRNA synthetase with inhibitor. As no 
interactions were seen between the base atoms of the pyridine inhibitors and the enzyme 
pocket, the uridine and cytosine inhibitors were repositioned with the base coinciding 
with the six-membered ring of the adenine base. The complexes were prepared for use in 
the AMBER software.[140] The parameters for enzyme structure were taken from the 
ff99bsc0 force field.[141] The seven ligand molecules were parameterized with 
Antechamber using the gaff force field.[142] Some patches were introduced to the 
parameters to get the right conformation for the base atoms and the sulfamoyl group after 
energy minimization. The molecular mechanics energy of the complexes was minimized 
using 500 steps. Then the mm/pbsa method[143] was applied on the minimized complexes 
to obtain the binding energies for the different inhibitors. Visual inspection[144] together 
with a ligplot analysis[145] was used for interpretation. 
3.6.3 Biological activity experiments 
3.6.3.1  Whole cell activity determinations 
The respective bacteria were grown overnight in Luria Broth (LB) medium and 
cultured again the following day in fresh LB medium or LB-medium containing 5 mM 
(L)-arabinose. Compounds were titrated in a 96-well plate using either LB-medium +/- 5 
mM (L)-arabinose to dilute the compounds. To each well, 85 µL LB-medium +/- 5 mM 
(L)-arabinose was added to a total volume of 90 µL. Next, 10 µL of bacterial cell culture 
grown to a OD600 of 0.1 was added. The cultures were next placed into a Tecan Infinite 
M200® incubator and shaken at 37 °C, subsequently the OD600 was determined after 18 
h. The broth dilution tests were performed in duplicates. 
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Bacterial strains used for the evaluations: E. coli Ara-Yej (BW39758), expressing 
the YejABEF transporter upon L-arabinose induction; E. coli wt used as wild type 
control. The antibacterial activities of all compounds were determined by monitoring the 
optical density of suspensions of cell-cultures. 
3.6.3.2  Aminoacylation experiments 
To assess the degree of inhibition of the aminoacylation reaction, in vitro tests 
were perform using the relevant S30 cell extracts. 
Preparation of S30 cell extracts. Cells were grown in 50 mL LB-medium. After 
centrifugation at 3000 g for 10 min the supernatant was discarded and the pellet was 
resuspended in 40 mL buffer containing: Tris.HCl or Hepes.KOH (pH = 8.0; 20 mM), 
MgCl2 (10 mM), KCl (100 mM). The cell suspension was centrifuged again at 3000 g. 
This procedure was repeated twice. The pellet was resuspended in 1 mL of the following 
buffer Tris.HCl or Hepes.KOH (pH = 8.0; 20 mM), MgCl2 (10 mM), KCl (100 mM), 
DTT (1 mM) and kept at 0 °C. Subsequently, the cells were sonicated for 10 s and left at 
0 °C for 10 min. This procedure was repeated 5-8 times. The lysate was centrifuged at 
15000 g for 30 min at +4 °C.  
tRNA aminoacylation reaction: To 1 µL of solution containing inhibitor, 3 µL of 
E. coli S30 extracts was added. Next, 16 µL of the following aminoacylation mixture was 
added: Tris.HCl (30 mM, pH 8.0), DTT (1 mM), bulk of E. coli tRNA (5 g/l), ATP (3 
mM), KCl (30 mM), MgCl2 (8 mM), and the specified, 14C-radiolabeled amino acid (40 
µM, 200 µCi/mmol). The reaction products were precipitated in cold 10% TCA on 
Whatman 3MM papers, 5 min. after the aminoacylation mixture was added. The 
aminoacylation reaction was carried out at room temperature. Depending on whether or 
not processing was needed, variable time intervals were included between the addition of 
the cell extract and the addition of the aminoacylation mixture. After thorough washing 
with cold 10% TCA, the papers were washed twice with acetone and dried on a heating 
plate. Following the addition of scintillation liquid (12 mL), the amount of radioactivity 
was determined in a Tri-card 2300 TR (time resolved) liquid scintillation counter. 14C-
Radiolabeled amino acids and scintillation liquid were purchased from Perkin Elmer.
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4 5'-(N-aminoacyl)-sulfonamido-5'-deoxyadenosine: 
attempts for a stable alternative to aminoacyl-
sulfamoyl adenosines 
 
 
 
 
 
 
Abstract 
Upon synthesis of aminoacyl-sulfamoyl adenosines (aaSAs) and their peptidyl 
conjugates, we observed that aminoacyl-sulfamoyl adenosines are prone to form a 
cycloadenosine derivative by attack of the adenine N3 on the C-5’of the ribose. In an 
effort to reduce this side reaction, we aimed to prepare aminoacyl-sulfonamide (aa-SoA) 
as a more stable alternative to aaSA derivatives. We hypothesized that deletion of the 5’-
oxygen in aaSA analogues renders the C-5’ less electrophilic which in turn should 
improve the stability in comparison to aminoacyl sulfamate analogues. We therefore 
synthesized six aa-sulfonamides and further compared their activity against the respective 
aaSA analogue. It was shown however that these compounds are not able to inhibit the 
corresponding aaRS, except for the aspartyl derivative. We in addition tested the 
intermediate sulfamate (SA) and sulfonamide (SoA) (without any attached amino acid) 
for inhibitory activity. The obtained results will be discussed in comparison with their 
corresponding aaSA analogues. 
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4.1  Introduction 
Despite of numerous aaRS inhibitors reported in the literature, none of them 
(except mupirocin) developed into a clinically useful antibiotic.[146] Therefore, in recent 
years, more efforts have been directed towards the rational design of aaRS inhibitors 
based on the natural reaction intermediate (aa-AMP).[16] In fact, the idea to explore non-
hydrolysable analogues of aa-AMP is also derived from natural antibiotics and examples 
include microcin C (1.17),[78, 80, 82] agrocin 84 (1.14)[54b, 54c] and ascamycin (1.15a)[55] 
(Figure 1-5). Here, microcin C and agrocin 84 possess an acyl-phosphoramidate linkage 
as a replacement for the labile acyl-phosphate whereas ascamycin comprises a stable 
sulfamate linkage. These antibiotics have been discussed in section 1.3.1 (Chapter 1). 
Among several non-hydrolysable mimics of aa-AMP, aaSA analogues are proved to be 
the strongest inhibitor of the corresponding aaRS in vitro. However, they could be not 
pursued as potential antibiotics due to their lack of selectivity and the poor in vivo 
efficacy. Moreover, synthesis of aaSA analogues remained problematic due to the cyclic 
degradation formed during synthesis. It has been reported that the aaSAs are prone to 
form a cycloadenosine derivative as a side product. This degradation results in poor yield 
of the reaction.[114] In our attempts to promote the uptake of aaSA analogues, we 
consistently observed the formation of cycloadenosine as a side product.[83] Similar 
problems were also encountered by Van de Vijver et al. and Vodenhoff G. et al. while 
studying dipeptidyl- and hexapeptidyl-conjugates of sulfamoyl adenosines 
respectively.[81, 114b, 147] Therefore, in this chapter we investigated aaSoA as a potentially 
more stable alternative to aaSA analogues. We hypothesized that eliminating the 5’-
oxygen of aaSA may render the C-5’ of ribose less susceptible to electrophilic attack by 
N3 of the adenine, and thus could yield more stable analogues which hopefully retain the 
inhibitory activity with equal potency as compared to aaSA analogues. General structures 
of an aaSA (4.1) analogue along with the proposed aa-sulfonamide (4.2a) have been 
given in Figure 4-1. 
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Figure 4-1: General structures of aaSA analogue and proposed aaSoA analogue. 
4.2 Design 
As mentioned above, among the different non-hydrolysable mimics of aa-AMP, 
aaSAs proved to be excellent inhibitors of the corresponding aaRS in vitro. However, 
these analogues could not be pursued further due to their lack of selectivity and poor cell 
penetration. Several modifications have been attempted to address these issues. For 
example, a series of aryl-tetrazole containing sulfamate derivatives reported by Cubist 
Pharmaceuticals showed 3000-fold selectivity for pathogen aaRS over human aaRS. 
Despite their high selectivity and excellent inhibitory potency in vitro, these analogues 
could not reach the clinic due to their high serum albumin binding and poor cell 
penetration.[8, 61] In chapter 1, we attempted to improve the in vivo efficacy of aryl-
tetrazole containing sulfamates by coupling them with a trihydroxamate siderophore (iron 
carrier) but without success.[83] Along the same lines, we also coupled aryl-tetrazole 
containing sulfamates with the McC hexapeptide (a transport module) in an attempt to 
improve their in vivo efficacy by a Trojan-horse mechanism.[83] Unexpectedly, both these 
conjugates (either siderophore or McC hexapeptide) failed to cross the cell membrane. 
We therefore concluded that the adenine base may be playing a vital role in recognition 
by the transporter (being either an iron channel or the YejABEF peptide transporter). 
Hence, the conjugates of different aminoacyl-sulfamoyl adenosines would seem 
interesting target compounds, as they should be recognized by the transporter and once 
internalized could act by a Trojan-horse mechanism. However, trihydroxamate-aaSA 
conjugates could not be synthesized due to their instability (Scheme 2-4, chapter 2). 
Moreover, synthesis of McC hexapeptidyl-aaSA conjugates is low yielding in part as of 
formation of a cyclic degradation product by the nucleophilic attack of the adenine N3 on 
the sugar 5’-carbon.[81, 83] Similar problems were encountered by Van de Vijver et al. 
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when studying dipeptidyl-sulfamoyladenosine as potential antibiotics,[147] and aaSA 
analogues as immunosuppressant[114b] and by Vondenhoff et al. while synthesizing 
hexapeptidyl conjugates of aaSA.[81] We therefore aimed to improve the stability of the 
aaSA analogues and hypothesized that deletion of the 5’-oxygen of adenosine would 
render the C-5’ less electrophilic and less prone to attack by N3 of adenine. In general, 
sulfonamides are known to exhibit enzyme inhibitory activity in view of their non-
hydrolysable properties.[148] Therefore, deletion of the 5’-oxygen could yield aaSoAs 
(4.2a) with improved stability and hopefully equal potency as compared to aaSAs. 
To test our hypothesis, six aaSoAs 4.21-4.26 were synthesized and evaluated for 
their ability to inhibit the corresponding aaRS. Herein, sulfonamides 4.21-4.23 are 
targeting IleRS, LeuRS and TyrRS respectively belonging to class I of the synthetases, 
whereas sulfonamides 4.24-4.26 are targeting GlyRS, SerRS and AspRS respectively 
from class II of the synthetases. Isoleucyl- (4.21) and leucyl- (4.22) sulfonamides were 
selected for their straightforward synthesis while tyrosyl sulfonamide (4.23) was selected 
for its aromatic side chain. All three aaRSs have been targeted in the past of different 
medicinal chemistry efforts for inhibition of various microorganisms. Glycyl-sulfonamide 
4.24 was selected for its small size and specifically for the considerable sequence 
divergence of the hetero-tetramer structure as found in eubacteria compared to the 
dimeric structure of human GlyRS.[149] Seryl-(4.25) and Aspartyl- (4.26) sulfonamide 
were selected for their polar side chain and as they already figured as targets in our 
previous efforts for developing antibiotics based on either microcin C or albomycin.[83] In 
addition, the intermediates in the synthesis of aaSoA (sulfonamide 4.27) and aaSAs 
(sulfamate 4.29) which lack an attached amino acid were also evaluated for their 
inhibitory properties.  
4.3  Chemistry 
Retro synthetic analysis of aa-sulfonamide reveals that the target aa-sulfonamide 
(4.2a) can be synthesized starting from an appropriately protected 5’-sulfonic acid 
derivative (4.5) via 5’-sulfonamido-5’-deoxyadenosine (4.3) (Figure 4-2). Active ester 
mediated coupling of 4.3 with an appropriately protected amino acid (4.4) could yield the 
desired aminoacyl-sulfamoyl adenosines (4.2a). Therefore, initial efforts have been 
directed towards synthesis of derivative 4.3. 
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Figure 4-2: Retrosynthetic analysis of aminoacyl-sulfonamide (4.2a). 
As shown in Scheme 4-1, under Mitsunobu reaction conditions, the 5’-hydroxyl of 
adenosine (4.6) was converted to a good leaving group (iodo derivative, 4.7) which upon 
nucleophilic substitution using sodium sulphite (Na2SO3) gave sodium-5’-
deoxyadenosine-5’-sulfonate (4.8).  Further benzoylation of the compound 4.8 using 
pyridine as a base and DMF as a solvent gave compound 4.9. However, converting 5’-
sulfonate into a 5’-sulfonamide 4.10 proved to be cumbersome (Scheme 4-2). Our initial 
unsuccessful attempts for converting sulfonate 4.9 into sulfonamide are summarized in 
Table 4-1. 
Scheme 4-1: Synthesis of protected sodium-5'-deoxy-adenosine-5'-sulfonate. 
Reagents and conditions:  (i) PPh3, I2, pyridine, rt, 2 h, (ii) Na2SO3, water: methanol, 
reflux, 18 h; (iii) BzCl, pyridine, DMAP, DMF, rt, 24 h. 
 
Scheme 4-2: Attempted synthetic strategy in obtaining the 5’-sulfonamide scaffold. 
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Table 4-1: Summary of unsuccessful attempts to convert sodium sulfonate into 
sulfonamide 
Entry Reaction conditions R’ R  
1. 1. SOCl2 (1.5 eq.), 2 drops of DMF, Toluene, 0o 
C addition, reflux for 18 h,  
2. methanolic NH3 0o C to rt 24 h 
H H Reaction mixture 
turned black upon 
heating 
(degradation) 
2. 1. SOCl2 (2 eq.), 3 drops of DMF, DCM, rt for 
18 h 
2. Methanolic ammonia, 0o C to rt, 24 h 
H H After 1st step, MS 
for SM-Bz was 
observed 
Degradation 
3. 1. SOCl2 (1.5 eq.), 3 drops of DMF, DCM, rt for 
20 h 
2. Boc carbamate, TEA, DCM 
Boc Bz MS for SM-Bz 
was observed 
No reaction 
4. 1. SOCl2 as solvent, 40o C, 20h 
Evaporation under reduced press 
Then dissolved in dry DCM 
2. methanolic ammonia, 0o C to rt 2 d 
H H Degradation 
5. 1. SO2Cl2, PPh3, DCM, 0o C to rt, 4h 
2. BnNH2, TEA, 0o C to rt 4h 
PhCH2- Bz Degradation 
6. 1.Sulfuryl chloride (5 eq.), 15-crown-5 ether (0.2 
eq.), dry DCM 0o C to rt, 4h,  
2. TEA, BnNH2 
PhCH2- Bz Degradation 
7. 1. SOCl2 (4 eq), 15-crown-5 (0.2 eq), 1 drop of 
DMF, DCM, 0°C addition, react for 1h at 0°C, 
bring to rt and react overnight, 
2. Benzylamine (1.5 eq), triethylamine (7.5 eq), 
DCM, 0°C addition, react for 1h at 0°C and 1h at 
rt 
PhCH2- Bz Degradation 
8. Cyanuric chloride (1 eq.), 15-crown-5 ether (0.2 
eq.), TEA (1 eq.), dry aetone reflux  20 
h,Solvent was evaporated, and residue was 
dissolved in dry DCM and added to methanolic 
ammonia   
H H Degradation 
9. 1. Oxalyl chloride (1eq.), DCM, 5-15o C, 1h, 
2. TEA, BnNH2, addition at 0o C and 2 h at rt 
PhCH2- Bz No reaction 
10. 1. PPh3, Br2, CH3CN 
2. BnNH2, TEA 
PhCH2- Bz Degradation 
11. 1. triphosgene, dry DCM 
2. methanolic ammonia 
H H Degradation 
 
Thionyl chloride being widely used as a chlorinating agent was attempted to 
activate the sodium sulfonate 4.9 into sulfonyl chloride,[150] which upon reaction with 
ammonia could afford the desired sulfonamide. Optimization of the reaction conditions 
was attempted by changing the solvent, the number of equivalents of thionyl chloride, the 
reaction temperature (0o C, 40o C and reflux conditions) and the nucleophile (ammonia, 
Boc-carbamate or benzylamine). However, none of these efforts yielded the desired 
Sulfonamides 
101 
 
sulfonamide (entry 1 to 4, Table 4-1) and rather degradation of the starting material was 
observed at higher equivalents of thionyl chloride or at higher temperature. Therefore, 
sulfuryl chloride,[151] cyanuric chloride[152] or oxalyl chloride were used as mild 
chlorinating agents (entry 5, 7 to 9). Unfortunately, these reagents likewise led to 
degradation of the starting sulfonate. It was clear from these experiments that the low 
nucleophilic reactivity of the sodium sulfonatewas at the heart of the problem for this 
failure. Therefore, we added 15-crown-5 ether to complex sodium and to increase the 
nucleophilicity of the sulfonate. Despite using crown ether, we again failed to obtain the 
desired sulfonamide using either sulfuryl chloride or thionyl chloride (entry 6 and 7 
respectively) as a chlorinating agent. We therefore chose to use harsh reaction conditions 
such as triphenylphosphine with liquid bromine[153] or triphosgene[150b] (entry 10 and 11 
respectively) with the hope to activate the sodium sulfonate into sulfonyl chloride but 
without success. 
All of the above attempts failing to convert the sodium sulfonate into the desired 
sulfonamide, we decided to first prepare the tetrabutyl ammonium (TBA) salt instead. 
Previously, analogous tetrabutyl ammonium sulfonates have been successfully converted 
into a sulfonamide.[154] Synthesis of the tetrabutyl ammonium sulfonate is depicted in 
Scheme 4-3. As shown, adenosine (4.6) was first protected by an isopropylidene moiety 
to afford compound 4.11. Next, the acetylated 5’-thio-5’-deoxyadenosine (4.12) was 
synthesized in almost quantitative yield by coupling thioacetic acid via a Mitsunobu 
reaction.[155] The isopropylidene protecting group was next removed by treatment with 
aqueous formic acid to afford compound 4.13. Further, 2’,3’-hydroxyl and 6-amino 
groups were protected as acetates. However, attempted oxidation of the protected 
thioacetyl derivative 4.14 to the tetrabutyl ammonium sulfonate 4.15 yielded over 
oxidized product with concomitant N6-oxidation even with a milder oxidizing agent like 
oxone (potassium peroxymonosulfate).[151b, 156] Moreover, purification of the desired 
product remained challenging due to partial or complete deprotection of the acetyl group 
during the oxidation step.  
We therefore needed to look for an alternative strategy. It has been recently 
reported in the literature that aryl benzyl thioether or aryl thiols can be converted to the 
corresponding sulfonyl chlorides via oxidative chlorination using 1,3-dichloro-5,5-
dimethyl hydantoin (DCDMH).[157] We attempted a similar protocol on the corresponding 
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nucleoside benzyl thioether (4.17) as well as on the thiol 4.20. Nucleoside 5’-benzyl 
thioether was prepared via 5’-chloroadenosine derivative (4.16)[158] or directly using a 
Mitsunobu reaction (Scheme 4-4) on adenosine as per literature procedure.[155] In both 
cases, the yield for the reaction to obtain our starting benzyl thioether 4.17 was very low 
(<40%). Moreover the reaction converting benzyl thioether to sulfonamide 4.19 was 
likewise low yielding (~30%).  Therefore we decided to use the thiol 4.20 which was 
synthesized in almost quantitative yield starting from 2’,3’-isopropylidene adenosine 
(4.11) and thioacetic acid using Mitsunobu reaction condition followed by deprotection of 
the acetyl group. Overall synthesis of the sulfonamide 4.19 via 5’-nucleoside thiol 4.20 is 
depicted in Scheme 4-5. Although the yield for the oxidative chlorination (formation of 
the intermediate sulfonyl chloride) was very low (~32%), we continued with this 
protocol.  
 
Scheme 4-3: Attempted synthesis of the tetrabutyl ammonium-5’-deoxyadenosine-5’-
sulfonate. 
Reagents and  conditions:  (i) Dimethoxy propane, Acetone, PTSA, rt, 16 h; (ii) DEAD, 
PPh3,AcSH; (iii) HCOOH, water, rt, 44 h; (iv) Ac2O, Pyridine, 0o C to rt, 24 h; (v) H2O2, 
TBA acetate, AcOH, 40o C, 12 h (vi) oxone, TBA acetate, glacial acetic acid, rt, 5 h. 
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Scheme 4-4: Synthesis of the 5’-sulfonamido-5’-deoxyadenosine intermediate 4.19 via 
the corresponding nucleoside benzylthio ether 
Reagents and conditions: (i) SOCl2, acetonitrile, pyridine, 0o C to 5o C, 4 h; (ii) BnSH, 
NaH, DMF, rt, overnight; (iii) PTSA, acetone, DMP, rt, overnight (iv) PPh3, DEAD, 
BnSH, THF, 0o C 1 h; (v) (a) DCDMH, ACN:AcOH:H2O (40:1.5:1), 0o C, 2 h, (b) aq. 
ammonia, 0o C to rt, overnight. 
 
 
Scheme 4-5: Synthesis of 5’-sulfonamido-5’-deoxyadenosine intermediate via nucleoside 
thiol. 
Reagents and conditions (i) PPh3, DEAD, thiolacetic acid, THF, 0o C, 1.5 h; (ii) 
methanolic ammonia/aq. ammonia (1:1) 0o C to rt, overnight; (iii) (a) CH3CN/AcOH/H2O 
(40:1.5:1v/v), DCDMH, 1 h; (b) liquid ammonia, 0o C to rt, 1 h. 
Having the sulfonamide in hand, aa-sulfonamides were synthesized analogously to 
a literature procedure[82] but using orthogonal protecting groups for the side chain with 
respect to the α-amino group (Scheme 4-6). The aaSoA 4.21-4.26 were obtained by 
coupling of the respective N-hydroxy succinimide ester of appropriately protected amino 
acids with the sulfonamide 4.19 using DBU as a base in DMF. The Boc, tBu and 
acetonide protecting groups were cleaved by acidolysis followed by hydrogenolysis of the 
Sulfonamides 
104 
 
obtained intermediate in a mixture of methanol-water containing catalytic acetic acid and 
affording target compounds 4.21-4.26. Similarly, acidolysis of intermediate 4.19 afforded 
the sulfonamide 4.27.  
N
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Scheme 4-6: Synthesis of the desired aa-sulfonamides. 
Reagents and conditions: (i) Boc/Cbz-aa-(tBu/Bn)-OSu, DBU, DMF, 6-8 h; (ii) for 
isopropylidene, Boc and tBu group deprotection; TFA/water (5/2 v/v), rt, 2.5 h (iii) Pd/C, 
methanol, cat. acetic acid, H2 atm. rt, overnight. 
Analogously, an intermediate sulfamate 4.29 was synthesized as outlined in 
Scheme 4-7.  As the synthesis of aaSAs has been well described before, it will not be 
discussed here.[92c, 159]  
 
 
Scheme 4-7: Synthesis of sulfamate (4.29). 
Reagent and conditions: (i) Et3N.3HF. THF, rt 24 h. 
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4.4  Antibacterial assay 
The antibacterial activities of all newly synthesized aa-sulfonamides against E. 
coli K-12 BW28357, S. aureus (ATCC6538), Sarcina lutea (ATCC 9341) and C. 
albicans CO11 were determined by measuring the optical density reached by the cell 
suspension in the wells of microtiter plates in the presence of various concentrations of 
the respective inhibitors. These four strains were selected to cover the spectrum of 
activity going from Gram-negative (E. coli) to Gram-positive strains (S. aureus and S. 
lutea), and to fungi (C. albicans). All strains were grown on LB medium. As can be seen 
from Figure 4-3, only the  sulfamate 4.29 showed growth inhibitory activity against all 
tested strains (panel H) and aspartyl-sulfonamide 4.26 was active only against E. coli K-
12 (panel F). The likely reason for inactivity could be the lack of cell-penetration of these 
analogues (similar to aaSA analogues) or loss of affinity of the compound due to deletion 
of the 5’-oxygen. It has been reported in the literature that ascamycin could not penetrate 
the cell membrane whereas its dealanyl analogue is able to penetrate the cell membrane 
and showed broad-spectrum of antibacterial activity. The sulfamate analogue (4.29) 
which closely resembles the dealanyl ascamycin (except chloro substitution at C-2) 
analogously showed broad spectrum of activity against all tested strains. However, only 
the AspSoA analogue 4.26 showed selective toxicity against E. coli indicating that these 
analogues apparently can be transported across the cell membrane and resulting to the 
loss of recognition by the respective aaRS enzymes. The results of broth dilution test are 
summarized in Figure 4-3 and Table 4-2. 
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C) D)
 
E) 
 
 
F) 
G) 
 
H) 
Figure 4-3: Broth dilution tests to 
determine MIC of newly synthesized aa-
sulfonamides along with the intermediate 
SoA and SA. 
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Table 4-2: MIC50 values of aaSoAs, SoA and SA analogues against different 
microorganisms 
  MIC50 (µM) 
SN Compound* E. coli wt S. aureus S. lutea C. albicans 
1. 4.21 >100 >100 >100 >100 
2. 4.22 >100 >100 >100 >100 
3. 4.23 >100 >100 >100 >100 
4. 4.24 >100 >100 >100 >100 
5. 4.25 >100 >100 >100 >100 
6. 4.26 ~ 50 µM >100 >100 >100 
7. 4.27 >100 >100 >100 >100 
8. 4.29 ~75 µM ~1 µM ~50 µM ~10 µM 
*Maximum inhibitor concentration tested was 100 µM. 
 
To understand the reason(s) for this disappointing lack of antibacterial activity of 
all newly synthesized aaSoAs and to investigate the probable mode of action of the 
sulfamate 4.29, in vitro aminoacylation experiments were performed. Hereto, the ability 
of all compounds to inhibit the corresponding aaRS in E. coli wt extract was determined. 
As shown earlier for aaSA analogues, the intracellular target for the respective aaSA 
analogue is determined by the amino acid moiety attached to sulfamoyl adenosine. 
Therefore, aaSoAs were evaluated for their ability to inhibit the incorporation of the 
corresponding amino acid. The respective aaSA analogues were used as a control to 
compare the activity of the newly synthesized aaSoAs. Moreover, the plain SoA 4.27 and 
sulfamate 4.29 were included in the evaluation against all six aaRSs (Figure 4-4).  
From the in vitro experiments, it can be concluded that deletion of the 5’-oxygen 
of the sulfamate leads to a significant reduction in the inhibitory activity of these 
analogues as compared to the respective aaSA analogue (with notable exception as found 
for the AspSoA, 4.26). Removal of the amino acid part of the aaSoA and aaSA analogues 
provided SoA 4.27 and sulfamate 4.29 respectively, but these lead to further reduction in 
inhibitory activity against all tested aaRSs as noted in our test panel. To our surprise, the 
sulfamate 4.29 which showed antibacterial activity against all tested strains was found to 
be inactive against all six aaRS under in vitro aminoacylation experiment implying that 
the sulfamate (aaSA but lacking amino acid part) has a different mode of action. As 
reported earlier, ascamycin is a natural antibiotic which has a narrow spectrum of activity 
and showed selective toxicity against Xanthomonas species whereas its dealanyl analogue 
is a broad spectrum antibiotic. Ascamycin and its dealanyl analogue are known to act by 
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inhibiting polyuridylate directed polyphenylalanine synthesis. We therefore, we tested 
4.27 and 4.29 for their ability to inhibit phenylalanine incorporation using PheSA as a 
control. The results of these in vitro aminoacylation experiments are summerized in 
Figure 4-4. 
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G) PheRS inhibition
 
 
 
Figure 4-4: in vitro aminoacylation 
experiments using E. coli wt S30 cell 
extracts at 2.5 µM final concentration of 
respective inhibitor: panel A) IleRS, B) 
LeuRS, C) GlyRS, D) SerRS, E) TyrRS 
F) AspRS G) PheRS inhibition. The 
respective aaSA analogues were used as 
a positive control. 
4.5 Discussion 
As shown before, synthesis of aaSA analogues is cumbersome due to their 
chemical instability. Therefore, aaSoAs have been put forward as a more stable 
alternative to aaSA analogues. It can be seen from broth dilution test results that only the 
sulfamate analogue 4.29 is active against all tested strains whereas AspSoA 4.26 is active 
against E. coli wt. The likely reason for the lack of inhibitory activity of the other aaSoA 
could be either lack of cell penetration or lack of affinity for their hypothesized target. 
However, unlike aaSA analogues, aspartyl-sulfonamide did show some activity against E. 
coli wt at a higher micromolar concentration (~50 µM) indicating that this analogue is 
able to cross the cell membrane (at least Gram-negative bacteria). Therefore, the loss of 
activity most likely should be attributed to a loss of binding affinity for the target.  
To find out the reason for this lack of antibacterial activity and to study the mode 
of action of the sulfamate 4.29, in vitro aminoacylation experiments were carried out. 
These showed that the newly synthesized aaSoA (except 4.26) lack inhibitory activity 
against their hypothesized target. Moreover, the compounds 4.29 and 4.27 were inactive 
against all tested aaRS. Therefore, we assumed that AspSoA 4.26 may act by inhibiting 
AspRS whereas loss of affinity for the respective aaRS is the most likely reason for 
inactivity of all other aaSoAs. However, the broad-spectrum activity of the sulfamate 4.29 
remained unexplained. It has been reported that ascamycin is a natural antibiotic 
structurally resembling AlaSA and showing selective toxicity against Xanthomonas 
species (due to the presence of an ascamycin dealanylating enzyme, Xc-aminopeptidases) 
whereas its dealanyl analogue exhibits broad-spectrum antibacterial activity.[55] These 
results illustrated that the intact ascamycin could not penetrate the cell-membrane but 
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after dealanylation, becomes permeable and displaying antibacterial activity. Both 
ascamycin and dealanyl ascamycin are known to act by inhibiting polyuridylate directed 
polyphenylalanine synthesis. Therefore, sulfamate 4.29 and SoA 4.27 were evaluated for 
their ability to inhibit phenylalanine incorporation under in vitro aminoacylation 
conditions. PheSA was used as a positive control (panel G, Figure 4-4). From these 
experiments, we concluded that the sulfamate 4.29 although closely resembling to 
dealanyl-ascamycin exercise its inhibitory effect via a different mode of action than by 
inhibiting PheRS. Further research is needed to resolve this issue. 
There are several reasons which can be proposed for the loss of activity of aaSoAs 
as compared to their respective aaSA analogues. Most likely reason could be the 
shortened linker length of aaSoA as compared to aaSA analogues which in turn could 
lead to the loss of H-bonding with the α-amino group of aaSoAs. We recently established 
that the α-amino group is an important recognition point at the active site of aaRS when 
studying N-methylation which annihilated the inhibitory activity.[160] Alternatively, 
deletion of the 5’-oxygen provides aaSoA which possibly fail to mimic the 
stereoelectronic properties of the sulfamate. It has been reported in the literature that the 
distance between amino acid and the sugar moiety is crucial for tight binding.[39c] 
Moreover, the degree of puckering in the ribose ring also plays an important role to 
achieve the desired accuracy in the aminoacylation reaction.[25] Elimination of the 5’-
oxygen leads to a decreased distance between the sugar and the amino acid which may 
result in steric clashes at the amino acid binding site of aaRS.  
Recently, Pope et al. developed a binding model for mupirocin bound to IleRS. 
Based on this model they have designed IleRS inhibitors combining the structural features 
of mupirocin and IleSA.[39c] They further optimized the length and polarity of the linker 
for IleRS inhibition. According to their data, the distance between the sugar and the Ile 
moiety is crucial for tight binding. An increased distance herein resulted in significant 
reduction in inhibitory activity. Moreover, replacement of the linking oxygen by a 
methylene or by a nitrogen atom reduced the potency dramatically. They concluded that 
the stereoelectronic properties of the sulfamate are optimal to mimic the acyl-phosphate 
intermediate in the aminoacylation reaction.[39c] Furthermore, replacement of the 
sulfamate oxygen with –NHO- or substituting the sulfamate linkage with an ester or 
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amide groups yielded analogues with either increased or decreased distance between the 
sugar and the amino acid, both leading to a significant decrease in potency.[58b, 60] 
Moreover, replacement of the sulfamate oxygen with nitrogen also lead to a significant 
loss in activity implying that sulfamide analogues although having the same length, failed 
to mimic the negative charge density of the acyl phosphate of aa-AMP. Our results are in 
good agreement with the literature. However, whether it is the overall length or the charge 
around the sulfonamide linkage which are the main culprit for the affinity loss of these 
analogues remains to be determined. Therefore, the study of homoadenosine analogues 
(4.2b, Figure 4-1) occupying the same length as that of aaSA analogues is warranted.  
To our surprise, only aspartic acid derivative 4.26 displayed some selective 
toxicity against E. coli wt in a whole-cell assay and also showed AspRS inhibition in the 
in vitro aminoacylation experiment. In order to get some insight into the binding mode of 
the AspSoA in the active site of AspRS, we performed some molecular simulation on E. 
coli AspRS (PDB code 1c0a).[75] It can be seen from the ligplot of the AspSoA (Figure 4-
5a) and AspSA (Figure 4-5b), and superimposition of both analogues at the active site 
(Figure 4-5c) that the binding mode of AspSA and AspSoA are quite analogous. No steric 
clashes were observed during docking of the AspSoA within the active site of AspRS.  
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Figure 4-5a: Aspartyl-sulfonamide bound to AspRS from E. coli wt (upper panel: ligplot 
and lower panel: interactive hydrophobic surface). 
 
 
Figure 4-5b: AspSA bound to AspRS from E. coli wt (upper panel: ligplot showing 
interaction and lower panel: interactive hydrophobic surface). 
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Figure 4-5c: Superimposition of AspSoA and AspSA in the active site of aaRS 
4.6  Conclusions 
Very few examples of nucleoside sulfonamides have been reported in the literature 
probably due to difficulties in their synthesis. We also encountered similar difficulties in 
the synthesis of the SoA intermediate. Among the several attempts undertaken, oxidative 
chlorination using DCDMH seems a promising and straightforward strategy for the 
synthesis of nucleoside sulfonamides. The reaction conditions needs to be further 
optimized to improve the yields of the desired sulfonamides. 
Several aaSoA analogues have been synthesized and evaluated for antibacterial activity. 
Unfortunately, no inhibitory activity was observed for these aaSoAs analogues (except for 
the AspSoA) either in in vitro or in whole-cell assays. From the in vitro experiments it 
can be concluded that the loss of affinity for the target is the most likely reason for 
inactivity of these analogues. However, whether it is the overall length or the charge 
around the sulfonamide which is the main culprit for the affinity loss remains unclear. 
Interestingly, the SA core structure did show broad-spectrum antibacterial activity in a 
whole-cell assay, but is acting via a different mechanism and not via inhibition of an 
aaRS enzyme. 
4.7  Experimental section 
4.7.1  Materials and Methods  
Analogous to the procedures described in section 2.5.1 
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Sodium-5’-deoxyadenosine-5’-sulfonate (4.8) 
Adenosine 4.5 (2.14 g, 8.0 mmol) and triphenylphosphine (3.04, 12.0 mmol) were 
suspended in dry pyridine (20 mL) and stirred for 15 min at room temperature. Hereto, 
suspension, iodine (3.14 g, 12.0 mmol) was added and reaction mixture was stirred for an 
additional 2 h at room temperature. Next, the solvent was evaporated and the crude 
product obtained was used as such without purification. The crude product was dissolved 
in a mixture of methanol: water (30: 50 mL). To this sodium sulphite (3.0 g, 24 mmol) 
was added and the mixture was heated to reflux under inert atmosphere for 24 h. Next, the 
methanol was evaporated under reduced pressure and water layer was washed with ethyl 
acetate (2x100 mL). The aqueous layer was collected and evaporated to dryness. The 
obtained residue was suspended in the minimum amount of methanol and filtered through 
celite and celite was washed with methanol. The filtrate was collected and evaporated to 
dryness. The yellow residue was subjected to silica gel column chromatography to yield 
1.39 g (3.93 mmol, 49%) of the sulfonate derivative as a pale yellow solid. 
1H NMR (300 MHz, D2O) δ 3.34-3.36 (m, 2H, H-5’), 4.36 (t, 1H, J = 5.1 Hz, H-3’), 4.42-
4.45 (m, 1H, H-4’), 5.99 (d, 1H, J = 5.1 Hz, H-1’), 8.12 (s, 1H, H-8), 8.22 (s, 1H, H-2), 
H-2’ merged in solvent signal; 13C NMR (75 MHz, D2O) δ 53.2 (C-5’), 72.5 (C-3’), 78.8 
(C-2’), 79.8 (C-4’), 87.5 (C-1’), 139. 9 (C-8), 148.5 (C-4), 152.5 (C-2), 155.2 (C-6); 
HRMS for C10H12N5Na2O6S ([M+Na]+) calcd: 376.0299 found 376.0298. 
Sodium-2,3-di-O-acetyl-N6,N6-diacetyl-5’-deoxyadenosine-5’-sulfonate (4.9) 
To a solution of 4.8 (525 mg, 1.49 mmol) and DMAP (20 mg, catalytic) in a mixture of 
dry pyridine and DMF (1:1, 18 mL) at 0o C was added benzoyl chloride (1.1 mL, 9.0 
mmol) over a period of 10 min. The reaction mixture was allowed to warm to room 
temperature and stirred for 24 h. Next, the solvent was evaporated and the residue was 
purified by column chromatography to yield 1.01 g (1.31 mmol, 89%) of the title 
compound as a pale yellow viscous oil. 
1H NMR (300 MHz, DMSO-d6) δ 3.35 (m, 2H, H-5’), 4.78 (m, 1H, H-4’), 6.29 (m, 1H, 
H-1’), 6.5 (m, 2H, H-2’ and H-3’), 7.33-8.02 (28H, Ar), 8.71 (bs, 1H, H-8), 9.01 (bs, 1H, 
H-2); 13C NMR (75 MHz, DMSO-d6) δ 53.5 (C-5’), 72.9 (C-3’), 73.9 (C-2’), 80.2 (C-4’), 
85.4 (C-1’), 127.3-133.9 (aromatic signals), 146.3 (C-8), 151.0 (C-4), 152.0 (C-2), 152.6 
(C-6,), 164.2, 164.7, 172.0 (C=O); HRMS for C38H28N5O10S ([M-Na]-) calcd: 746.1557 
found 746.1558 
2’,3’-O-isopropylidene adenosine (4.11)[161]  
PTSA (7.1 g, 37.42 mmol) was added to a suspension of 4.6 (10 g, 37.42 mmol) in 
acetone (300 mL). Followed by addition of dimethoxy propane (20 mL) the mixture was 
and allowed to stir at room temperature for overnight. The reaction was monitored by 
TLC (1:9 MeOH:DCM). After completion of reaction, the reaction was quenched by 
Sulfonamides 
115 
 
adding saturated NaHCO3 (till pH= 8). The acetone was evaporated under reduced 
pressure and the aqueous layer was washed with ethyl acetate (150 mL x4). The organic 
layer and washings were collected, dried over anhydrous sodium sulphate, filtered and 
evaporated to dryness. The product was subjected to column chromatography to yield 9.5 
g (30.93 mmol, 83%) of the title compound as a white solid. 
1H NMR (300 MHz, DMSO-d6) δ 1.33 (s, 3H, CH3), 1.55 (s, 3H, CH3), 3.48-3.60 (m, 2H, 
H-5’a and H-5’b), 4.92-5.0 (m, 1H, H-4’), 5.24 (t, 1H, J = 5.4 Hz, H-3’), 5.32-5.38 (m, 
1H, H-2’), 6.13 (d, 1H, J = 3.0 Hz, H-1’), 7.35 (bs, 1H, 6-NH2), 8.16 (s, 1H, H-8), 8.35 (s, 
1H, H-2); 13C NMR (75 MHz, DMSO-d6) δ 25.2 (CH3), 27.1 (CH3), 54.9 (C-5’), 81.4 (C-
3’), 83.2 (C-2’), 86.4 (C-4’), 89.6 (C-1’), 113.1 (C(CH3)3), 119.1 (C-5), 139.7 (C-8), 
148.8 (C-4), 152.6 (C-2), 156.2 (C-6); HRMS for C13H18N5O4 ([M+H]+) calcd: 308.1353 
found 308.1352. 
5’-deoxy-2’,3’-O-isopropylidene-5’-thioacetyl-adenosine (4.12)[155]  
To an ice-cold solution of triphenylphosphine (3.76 g, 14.32 mmol) in dry THF (20 mL), 
diethyl azodicarboxylate (2.2 mL, 14.32 mmol) was added over 5 min. After stirring for 
30 min, 4.11 (2.0 g, 6.51 mmol) was added, and stirring was continued for 10 min. To the 
resulting yellow suspension a solution of thioacetic acid (1.0 mL, 14.32 mmol) in dry 
THF (5 mL) was added drop wise and stirring was continued for another 1.5 h at 0°C. 
During this time the yellow suspension cleared, and an orange solution was obtained. At 
the end of the reaction the solvent was removed under reduced pressure, and the resulting 
yellowish residue was purified by flash chromatography on silica gel. The column was 
eluted with CHCl3:THF (4:1 v/v) followed by a gradient of 2-10% methanol in CHCl3. 
The product containing fractions were evaporated to afford 2.35 g (6.43 mmol, 99%) of 
the title compound as a white solid. 
1H NMR (300 MHz, CDCl3) δ 1.39 (s, 3H, CH3), 1.60 (s, 3H, CH3), 2.34 (s, 3H, COCH3), 
3.19 (dd, 1H, J = 6.9 Hz and 13.5 Hz, H-5’a), 3.30 (dd, 1H, J = 6.9 Hz and 13.5 Hz, H-
5’b), 4.35 (dt, 1H, J = 3.3 Hz, H-4’), 4.98 (dd, 1H, J = 3.0 Hz, H-3’), 5.53 (dd, 1H, J = 
6.6 Hz and 2.1 Hz, H-2’), 5.66 (bs, 2H, 6-NH2), 6.06 (d, 1H, J = 2.1 Hz, H-1’), 7.90 (s, 
1H, H-8), 8.37 (s, 1H, H-2); 13C NMR (75 MHz, CDCl3) δ 24.5 (CH3), 26.2 (CH3), 29.7 
(COCH3), 30.4 (C-5’), 82.9 (C-3’), 83.4 (C-2’), 85.3 (C-4’), 90.1 (C-1’), 113.7 (C(CH3)3), 
139.2 (C-8), 152.4 (C-2), 154.7 (C-6), 193.7 (CO), C-4 and C-5 not detected; HRMS for 
C15H20N5O4S ([M+H]+) calcd: 366.1230 found 366.1227. 
5’-deoxy-2’,3’-O-isopropylidene-5’-thioacetyl-adenosine (4.13) 
A solution of 4.12 (490 mg, 1.39 mmol) in a mixture of formic acid and water (25 mL, 
1:1 v/v) was stirred at room temperature for 44 h. The progress of the reaction was 
monitored by TLC (10% MeOH:DCM). Next, the solvent was evaporated under reduced 
pressure, and traces of formic acid were removed by coevaporating five times with absol. 
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ethanol. The obtained white powder was purified by silica gel chromatography to afford 
329 mg (1.01 mmol, 75%) as a white solid. 
1H NMR (300 MHz, DMSO-d6) δ 2.33 (s, 3H, SCOCH3), 3.14-3.18 (m, 2H, H-5’), 3.90-
3.94 (m, 1H, H-4’), 4.09-4.10 (m, 1H, H-3’), 4.79 (q, 1H, J = 5.0 Hz, H-2’), 5.37 (d, 1H, 
J = 4.5 Hz, 3’-OH), 5.51 (d, 1H, J = 5.5 Hz, 2’-OH), 5.87 (d, 1H, J = 6.0 Hz, H-1’), 7.29 
(s, 2H, NH2), 8.15 (s, 1H, H-8), 8.34 (s, 1H, H-2); 13C NMR (125 MHz, DMSO-d6) δ 
30.5 (COCH3), 31.3 (C-5’), 72.6, 72.7 (C-2’ and C-3’), 82.9 (C-4’), 87.6 (C-1’), 119.3 
(C-5), 140.0 (C-8), 149.5 (C-4), 152.7 (C-2), 156.2 (C-6), 194.8 (COCH3); HRMS for 
C12H16N5O4S ([M+H]+) calcd: 326.0917 found 326.0921. 
5’-deoxy-2’,3’-di-O-acetyl-N6,N6-diacetyl-5’-thioacetyl-adenosine (4.14) 
Acetic anhydride (556 µL, 5.88 mml) was added to an ice-cold solution of 4.13 (320 mg, 
0.98 mmol) and DMAP (10 mg, catalytic) in dry pyridine (5 mL). The reaction mixture 
was allowed to warm to room temperature and stirred for 24 h. Next, the reaction mixture 
was cooled to 0o C and quenched by addition of ethanol (0.5 mL). The solvent was 
evaporated to dryness and the residue was partitioned between ethyl acetate and saturated 
sodium bicarbonate. The organic layer was further washed with 1N HCl. The organic 
layer was collected, dried over anhydrous sodium sulphate, filtered and evaporated to 
dryness. The residue obtained was purified by silica gel chromatography. After 
purification, 120 mg (0.27 mmol, 27 %) of the N6-acetyl derivative and 200 mg (0.41 
mmol, 41%) of N6,N6-bisacetyl derivative (desired product) were obtained as a white 
solid. 
1H NMR (300 MHz, CDCl3) δ 2.10 (s, 3H, COCH3), 2.16 (s, 3H, COCH3), 2.38 (s, 9H, 
3xCOCH3), 3.35-3.52 (m, 2H, H-5’), 4.43 (q, 1H, J = 5.4 Hz, H-4’), 5.57 (t, 1H, J = 5.4 
Hz, H-3’), 6.01 (t, 1H, J = 5.1 Hz, H-2’), 6.20 (d, 1H, J = 5.1 Hz, H-1’), 8.31 (s, 1H, H-
8), 8.99 (s, 1H, H-2); 13C NMR (75 MHz, CDCl3) δ 19.5 (COCH3), 19.6 (COCH3), 25.4 
(2xCOCH3), 29.6 (COCH3), 29.9 (C-5’), 71.1 (C-3’), 72.1 (C-2’), 80.2 (C-4’), 86.0 (C-
1’), 130.0 (C-5), 143.8 (C-8), 150.2 (C-4), 152.0 (C-2), 152.2 (C-6), 168.4, 168.6, 170.9, 
193.5 (COCH3); HRMS for C20H24N5O8S ([M+H]+) calcd: 494.1340 found 494.1340. 
5’-chloro-5’-deoxyadenosine (4.16) 
Adenosine 4.6 (500 mg, 1.87 mmol) was suspended in a mixture of pyridine (0.5 mL) and 
acetonitrile (6.5 mL). This mixture was cooled to 0°C and thionylchloride (0.7 mL, 9.35 
mmol, 5 eq.) was added over a period of 5 min. This mixture was stirred for 4 h at 5°C, 
after which it was allowed to warm to room temperature and was stirred overnight during 
which a white precipitate formed. The precipitate was filtered and dried. The resulting 
powder was suspended in a 5:1 mixture of methanol and water (12 mL) and a 
concentrated solution of ammonia in water (0.94 mL) was added. The solvent was 
evaporated under reduced pressure, yielding the title compound 196 mg (0.69 mmol, 
37%) as a white solid. 
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1H NMR (300 MHz, DMSO-d6) δ 3.83-3.97 (m, 2H, H-5’),  4.06-4.11 (m, 1H, H-4’),  
4.19-4.24 (m, 1H, H-3’), 4.72-4.78 (m, 1H, H-2’), 5.43-5.59 (d, 2H, 2’-OH and 3’-OH), 
5.92 (d, 1H, J = 5.4 Hz, H-1’), 7.30 (bs, 2H, NH2), 8.15 (bs, 1H, H-8), 8.33 (bs, 1H, H-2);  
13C NMR (75MHz, DMSO-d6) δ 45.0 (C-5’), 71.4 (C-3’), 72.8 (C-2’),  83.8 (C-4’), 87.6 
(C-1’), 119.3 (C-5),  139.9 (C-8), 149.6 (C-4), 152.9 (C-2), 156.2 (C-6); HRMS for 
C10H13ClN5O3 ([M+H]+), calcd: 286.0701 found 286.0701. 
2’,3’-O-isopropylidene-5’-thiobenzyl-5’-deoxyadenosine (4.18) 
To an ice-cold solution of triphenylphosphine (940 mg, 3.6 mmol) in dry THF (5 mL), 
diethyl azodicarboxylate (0.57 mL, 3.6 mmol) was added over 5 min. After stirring for 30 
min, 4.11 (500 mg, 1.63 mmol) was added, and stirring was continued for 10 min. To the 
resulting yellow suspension a solution of benzylmercaptan (423 µL, 3.6 mmol) in dry 
THF (2 mL) was added drop wise and stirring was continued for another 1 h at 0°C. 
During this time the yellow suspension cleared, and an orange solution was obtained. At 
the end of the reaction the solvent was removed under reduced pressure, and the resulting 
yellowish residue was purified by flash chromatography on silica gel to yield 273 mg 
(0.66 mmol, 41%) of the title compound as a white solid. 
1H NMR (300 MHz, CDCl3) δ 1.39 (bs, 3H, CH3), 1.61 (bs, 3H, CH3), 2.63-2.81 (m, 2H, 
H-5’), 3.71 (bs, 2H, CH2-Ph), 4.33-4.38 (m, 1H, H-3’), 4.99 (dd, 1H, J = 3.3 Hz and J = 
6.3 Hz, H-4’), 5.46 (dd, 1H, J = 2.1 Hz and J = 6.3 Hz, H-2’), 5.54 (bs, 2H, NH2), 6.06 (d, 
1H, J = 2.4 Hz, H-1’), 7.19-7.26 (m, 5H, Ph), 7.91 (bs, 1H, H-8), 8.31 (bs, 1H, H-2); 13C 
NMR (75 MHz, CDCl3) d 25.6 (CH3), 27.4 (CH3), 33.5 (C-5’), 36.7 (CH2Ph), 84.1 (C-
3’), 84.2 (C-2’), 86.9 (C-4’), 91.0 (C-1’), 114.8 (quaternary C, acetonide), 127.4, 128.8, 
129.1 (C-5 and aromatic), 140.3 (C-8), 153.4 (C-2); HRMS for C20H24N5O3S ([M+H]+), 
calcd: 414.1594, found: 414.1593. 
5’-deoxy-2’,3’-O-isopropylidene-5’-mercapto-adenosine (4.20)[155]  
Compound 4.12 (8.4 g, 22.99 mmol) was dissolved in a mixture of methanolic ammonia: 
aqueous ammonia (1:1, 100 mL) and was stirred at 0o C for 1h. After 1 h, the ice-bath was 
removed and the reaction mixture was stirred at room temperature for 24 h while 
monitoring the reaction for completion. The solvent was evaporated under reduced 
pressure and the product was purified by column chromatography to yield 6.9 g (21.34 
mmol, 93 %) of the title compound as a foam. 
1H NMR (300 MHz, DMSO-d6) δ 1.32 (s, 3H, CH3), 1.52 (s, 3H, CH3), 2.96 (dd, 1H, J = 
7.0 Hz and 13.5 Hz, H-5’a), 3.04 (dd, 1H, J = 7.5 Hz and 14.0 Hz, H-5’b), 4.33 (dt, 1H, J 
= 2.5 Hz and 4.5 Hz, H-4’), 5.01 (dd, 1H, J = 2.5 Hz and 6.0 Hz, H-3’), 5.50 (dd, 1H, J = 
2.0 Hz and 6.0 Hz, H-2’), 5.75 (bs, 1H, SH), 6.17 (d, 1H, J = 2.0 Hz, H-1’), 7.34 (bs, 2H, 
6-NH2), 8.17 (s, 1H, H-8), 8.30 (s, 1H, H-2); 13C NMR (75 MHz, DMSO-d6) δ 25.2 
(CH3), 26.9 (CH3), 55.0 (C-5’), 83.26 (C-3’), 83.32 (C-2’), 84.8 (C-4’), 89.4 (C-1’), 113.4  
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(C(CH3)3), 119.3 (C-5), 140.2 (C-8), 148.8 (C-4), 152.8 (C-2), 156.2 (C-6); HRMS for 
C26H33N10O6S2(disulfide) ([M+H]+) calcd: 645.2020 found 645.2023. 
5’-(sulfonamido)-2’,3’-O-isopropylidene-5’-deoxyadenosine (4.19) 
To an ice-cold solution of 4.20 (6.9 g, 21.34 mmol) in a mixture of CH3CN-HOAc-H2O 
(104.0 mL-4.0 mL– 2.7 mL) was added 1,3-dichloro-5,5-dimethylhydantoin (6.31 g, 
32.01 mmol) in two portions over 5 min. The cooling bath was removed and the reaction 
mixture was allowed to warm to 20o C and was further stirred for 1 h. Next, the reaction 
mixture was added drop wise to an ice-cold aqueous ammonia solution over a period of 
30 min and was stirred at 0o C for an additional hour. The ice-bath was removed and the 
reaction mixture was stirred at room temperature overnight. The next day, the solvent was 
evaporated to dryness and the residue was subjected to column chromatography to afford 
2.53 g (6.84 mmol, 32%) of the title compound as a pale yellow solid. 
1H NMR (500 MHz, DMSO-d6) δ 1.33 (s, 3H, CH3), 1.54 (s, 3H, CH3), 3.21 (dd, 1H, J = 
6.5 Hz and 14.0 Hz, H-5’a), 3.58 (dd, 1H, J = 6.5 Hz and 14.0 Hz, H-5’b), 4.58 (dt, 1H, J 
= 2.5 Hz and 6.0 Hz, H-4’), 5.17 (dd, 1H, J = 3.0 Hz and 6.5 Hz, H-3’), 5.50 (dd, 1H, J = 
2.0 Hz and 6.0 Hz, H-2’), 6.21 (d, 1H, J = 2.0 Hz, H-1’), 6.92 (s, 2H, SO2NH2), 7.36 (s, 
2H, 6-NH2), 8.18 (s, 1H, H-8), 8.33 (s, 1H, H-2); 13C NMR (125 MHz, DMSO-d6) δ 25.2 
(CH3), 26.9 (CH3), 57.4 (C-5’), 81.9 (C-3’), 83.3 (C-2’), 84.1 (C-4’), 89.6 (C-1’), 113.2 
(C(CH3)3), 119.3 (C-5), 140.3 (C-8), 148.7 (C-4), 152.8 (C-2), 156.2 (C-6); HRMS for 
C13H17N6O5S ([M-H]-) calcd: 369.0987 found 369.0985. 
5’-(N-L-isoleucyl-sulfonamido)-5’-deoxyadenosine (4.21) 
To a solution of sulfonamide 4.19 (100 mg, 0.27 mmol) in dry DMF (2 mL) were added 
DBU (102 µL, 0.68 mmol) and Boc-Ile-OSu (177 mg, 0.54 mmol). The reaction mixture 
was stirred at room temperature for 8 h during which the reaction was monitored by TLC. 
Next, the solvent was evaporated and the product was purified by silica gel column 
chromatography (0-60% MeOH:DCM). The fractions containing desired product were 
evaporated yielding the coupled intermediate which was dissolved in a mixture of 
TFA/water (5:2 v/v, 3.5 mL) at 0o C and the mixture was stirred at room temperature for 2 
h. The volatiles were evaporated under reduced pressure followed by co-evaporation with 
toluene (2x) and ethanol (2x). The yellow residue obtained was purified by column 
chromatography and finally with RP HPLC using PLRP-S column to afford 24 mg (0.06 
mmol, 20%) of the title compound 4.21 as a white solid. 
1H NMR (500 MHz, D2O) δ 0.75 (t, 3H, J = 7.5 Hz, Ile-δ-CH3), 0.82 (d, 3H, J = 7.0 Hz, 
Ile-γ-CH3), 1.01-1.11 (m, 1H, Ile-γ-CH2 Ha), 1.32-1.41 (m, 1H, Ile-γ-CH2 Hb), 1.79-1.88 
(m, 1H, Ile-β-CH), 3.57 (d, 1H, J = 4.5 Hz, Ile-α-CH), 3.73 (dd, 1H, J = 3.0 Hz and 15.0 
Hz, H-5’a), 3.84-3.91 (m, 1H, H-5’b), 4.44 (t, 1H, J = 5.0 Hz, H-4’), 4.49-4.53 (m, 1H, 
H-3’), 6.07 (d, 1H, J = 4.5 Hz, H-1’), 8.23 (s, 1H, H-8), 8.30 (s, 1H, H-2); 13C NMR (125 
MHz, D2O) δ 10.8 (Ile-δ-CH3), 14.3 (Ile-γ-CH3), 24.1 (Ile-γ-CH2), 36.3 (Ile-β-CH), 54.6 
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(Ile-α-CH), 60.2 (C-5’), 72.9 (C-3’), 73.0 (C-2’), 79.3 (C-4’), 88.2 (C-1’), 118.9 (C-5), 
140.4 (C-8), 148.9 (C-4), 152.9 (C-2), 156.6 (C-6), 175.3 (C=O); HRMS for 
C16H24N7O6S ([M-H]-) calcd: 442.1514 found 442.1518. 
5’-(N-L-leucyl-sulfonamido)-5’-deoxyadenosine (4.22) 
This compound was synthesized analogously to 4.21. Yield: 48% 
1H NMR (600 MHz, D2O) δ 0.61 (d, 3H, J = 6.6 Hz, Ile-δ-CH3), 0.75 (d, 3H, J = 6.6 Hz, 
Ile-δ-CH3), 1.03-1.10 (m, 1H, Ile-γ-CH), 1.36-1.42 (m, 1H, Ile-β-CH2 Ha), 1.46-1.54 (m, 
1H, Ile-β-CH2 Hb), 3.51 (dd, 1H, J = 4.2 Hz and 9.0 Hz, Ile-α-CH), 3.65 (dd, 1H, J = 2.4 
Hz and 15.0 Hz, H-5’a), 3.94 (dd, 1H, J = 9.6 Hz and 15.0 Hz, H-5’b), 4.40 (t, 1H, J = 4.8 
Hz, H-4’), 4.48-4.50 (m, 1H, H-3’), 4.74 (t, 1H, J = 4.8 Hz, H-2’), 6.08 (d, 1H, J = 4.8 
Hz, H-1’), 8.24 (s, 1H, H-8), 8.29 (s, 1H, H-2); 13C NMR (150 MHz, D2O) δ 20.0 (Ile-δ-
CH3), 21.5 (Ile-δ-CH3), 23.4 (Ile-γ-CH), 39.9 (Ile-β-CH2), 53.7 (C-5’), 53.9 (Ile-α-CH), 
72.6 (C-3’), 72.7 (C-2’), 78.9 (C-4’), 87.6 (C-1’), 118.4 (C-5), 139.9 (C-8), 148.4 (C-4), 
152.6 (C-2), 155.3 (C-6), 177.4 (C=O); HRMS for C16H24N7O6S ([M-H]-) calcd: 
442.1514 found 442.1510. 
5’-(N-L-tyrosyl-sulfonamido)-5’-deoxyadenosine (4.23) 
To a solution of 4.19 (200 mg, 0.54 mmol) in dry DMF (3 mL) were added DBU (164 
µL, 1.08 mmol) and Boc-Tyr(Bzl)-OSu (379 mg, 0.81 mmol). The reaction mixture was 
stirred at room temperature for 6 h during which the reaction was monitored by TLC. 
Next, the solvent was evaporated and the product was purified by silica gel column 
chromatography using MeOH:DCM as eluents. Fractions containing the desired product 
were evaporated to afford the intermediate which was dissolved in a mixture of 
TFA/water (5:2 v/v, 3.5 mL) at 0o C and was stirred at room temperature for 2 h. The 
volatiles were evaporated under reduced pressure followed by coevaporation with toluene 
(3x) and ethanol (3x). The yellow residue obtained was purified by column 
chromatography. The fractions containing the desired product were evaporated to yield an 
intermediate which was dissolved in a mixture of methanol-water (4:1 v/v, 5 mL) 
containing glacial acetic acid (0.5 mL). To this solution Pd/C (10%w/w, 70 mg) was 
added and the mixture was stirred under H2 atmosphere at room temperature for 
overnight. Next, the catalyst was filtered off and washed with a mixture of methanol: 
water (1:1 v/v, 10 mL). The solvent was evaporated under reduced pressure followed by 
coevaporation with toluene (3x) and ethanol (3x) to remove traces of acetic acid and 
water. The crude product was purified by column chromatography and finally by RP-
HPLC to yield 81 mg (0.17 mmol, 31%) of the title compound 4.23 as a white solid. 
1H NMR (500 MHz, D2O) δ 1.88 (dd, 1H, J = 10.0 Hz and 14.5 Hz, Tyr-β-CH2 Ha), 2.67 
(dd, 1H, J = 3.5 Hz, 14.5 Hz, Tyr-β-CH2 Hb), 3.57 (dd, 1H, J = 2.0 Hz and 15.0 Hz, Tyr-
α-CH), 3.65 (dd, 1H, J = 4.0 Hz and 10.0 Hz, H-5’a), 3.80-3.90 (m, 1H, H-5’b), 4.35 (t, 
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1H, J = 6.0 Hz, H-4’), 4.40-4.45 (m, 1H, H-3’), 5.99 (d, 1H, J = 4.0 Hz, H-1’), 7.95 (s, 
1H, H-8), 8.29 (s, 1H, H-2); 13C NMR (150 MHz, D2O) δ 35.5 (Tyr-β-CH2), 53.4 (Tyr-α-
CH), 57.0 (C-5’), 72.1 (C-3’), 72.5 (C-2’), 78.4 (C-4’), 87.1 (C-1’), 115.4 (Tyr-ortho-C), 
118.2 (C-5), 125.7 (Tyr-ipso-C), 130.0 (Tyr-meta-C), 139.6 (C-8), 148.4 (C-4), 152.5 (C-
2), 154.5 (Tyr-para-C), 155.0 (C-6), 175.3 (C=O); HRMS for C19H23N7O7S ([M-H]-) 
calcd: 492.1307 found 492.1310. 
5’-(N-L-glycyl-sulfonamido)-5’-deoxyadenosine (4.24) 
This compound was synthesized analogously to 4.21. Yield: 16% 
1H NMR (300 MHz, D2O) δ 3.59 (s, 2H, Gly-α-CH2), 3.76-3.82 (m, 2H, H-5’a and H-
5’b), 4.42 (t, 1H, J = 5.1 Hz, H-4’), 4.51 (q, 1H, J = 5.4 Hz, H-3’), 6.06 (d, 1H, J = 4.8 
Hz, H-1’), 8.18 (s, 1H, H-8), 8.26 (s, 1H, H-2); 13C NMR (125 MHz, D2O) δ 42.5 (Gly-α-
CH2), 54.0 (C-5’), 72.55 (C-3’), 72.63 (C-2’), 78.8 (C-4’), 87.9 (C-1’), 118.4 (C-5), 139.8 
(C-8), 148.3 (C-4), 152.4 (C-2), 155.1 (C-6), 172.7 (C=O); HRMS for C12H16N7O6S ([M-
H]-) calcd: 386.0888 found 386.0894. 
5’-(N-L-seryl-sulfonamido)-5’-deoxyadenosine (4.25) 
This compound was synthesized similar to 4.23. Yield: 9% 
1H NMR (500 MHz, D2O) δ 3.58-3.64 (m, 2H, H-5’a and H-5’b), 3.69-3.84 (m, 4H, Ser-
α-CH, Ser-β-CH2 and H-4’), 4.41 (q, 1H, J = 5.4 Hz, H-3’), 4.46-4.52 (m, 1H, H-2’), 
6.06 (d, 1H, J = 2.4 Hz, H-1’), 8.22 (s, 1H, H-8), 8.28 (s, 1H, H-2); 13C NMR (150 MHz, 
D2O) δ 54.0 (Ser-α-CH), 57.3 (C-5’), 61.3 (Ser-β-CH2), 72.7 (C-2’ and C-3’), 79.0 (C-
4’), 87.9 (C-1’), 118.7 (C-5), 140.1 (C-8), 148.7 (C-4), 152.7 (C-2), 155.4 (C-6), 175.8 
(C=O); HRMS for C13H18N7O7S ([M-H]-) calcd: 416.0994 found 416.0998. 
5’-(N-L-aspartyl-sulfonamido)-5’-deoxyadenosine (4.26) 
This compound was synthesized similar to 4.23. Yield: 9% 
1H NMR (600 MHz, D2O) δ 2.53 (dd, 1H, J = 9.0 Hz and 17.4 Hz, Asp-β-CH2 Ha), 2.77 
(dd, 1H, J = 3.6 Hz and 17.4 Hz, Asp-β-CH2 Hb), 3.72-3.82 (m, 2H, H-5’a and H-5’b), 
3.89 (dd, 1H, J = 3.6 Hz and 8,4 Hz, Asp-α-CH), 4.43 (t, 1H, J = 5.4 Hz, H-3’), 4.53 
(quin, 1H, J = 4.2 Hz, H-4’), 6.10 (d, 1H, J = 4.8 Hz, H-1’), 8.27 (s, 1H, H-8), 8.33 (s, 
1H, H-2); 13C NMR (150 MHz, D2O) δ 35.9 (Asp-β-CH2), 52.6 (Asp-α-CH), 53.7 (C-5’), 
72.55 (C-3’), 72.58 (C-2’), 79.0 (C-4’), 87.9 (C-1’), 118.6 (C-5), 140.3 (C-8), 148.3 (C-
4), 151.3 (C-2), 154.4 (C-6), 174.7 (C=O), 176.3 (β-COOH); HRMS for C14H18N7O8S 
([M-H]-) calcd: 444.0943 found 444.0940. 
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5’-(sulfonamido)-5’-deoxyadenosine (4.27) 
Compound 4.19 (70 mg, 0.19 mmol) was dissolved in a mixture of TFA and water (5:2 
v/v, 1 mL) at 0o C and stirred at room temperature for 2.5 h. Next, the reaction mixture 
was co-evaporated with toluene (3 times) and further co-evaporated with ethanol (3 
times). The residue was dissolved in ethanol, neutralized with TEA (0.5 mL) and co-
evaporated with toluene (2 times). The yellow residue obtained was purified by column 
chromatography and finally with RP HPLC using a PLRP-S column to yield 24.5 mg 
(0.07 mmol, 40%) of the title compound as a white solid. 
1H NMR (300 MHz, D2O) δ 3.75-3.91 (m, 2H, H-5’a and H-5’b), 4.46 (t, 1H, J = 5.4 Hz, 
H-4’), 4.53-4.61 (m, 1H, H-3’), 6.07 (d, 1H, J = 4.5 Hz, H-1’), 8.17 (s, 1H, H-8), 8.25 (s, 
1H, H-2), H-2’ merged in D2O signal; 13C NMR (75 MHz, D2O) δ 56.4 (C-5’), 72.3 (C-
3’), 72.4 (C-2’), 78.5 (C-4’), 80.1 (C-1’), 139.9 (C-8), 148.3 (C-4), 152.4 (C-2), 155.1 (C-
6), C-5 not detected; HRMS for C10H15N6O5S ([M+H]+) calcd: 331.0819 found 331.0822. 
5’-O-sulfamoyl-adenosine (4.29) 
To a solution of 4.28 (500 mg, 0.87 mmol) in dry THF was added triethylamine 
trihydrofluoride (1 mL) and the solution was stirred at room temperature for 24 h. Next, 
the solvent was evaporated and the residue was purified by column chromatography to 
yield 678 mg of a pale yellow foam. The residue was further purified by HPLC using a 
PLRP-S column to yield 201 mg (0.58 mmol, 67%) of the title compound as a white 
solid. 
1H NMR (600 MHz, CD3OD) δ 4.30-4.33 (m, 1H, H-4’), 4.33-4.36 (dd, 1H, J = 4.2 Hz 
and 10.8 Hz, H-5’a), 4.39 (t, 1H, J = 4.8 Hz, H-3’), 4.41-4.44 (dd, J = 3.0 Hz and 10.8 
Hz, H-5’b), 4.66 (t, 1H, J = 4.8 Hz, H-2’), 6.07 (d, 1H, J = 4.8 Hz, H-1’), 8.21 (s, 1H, H-
8), 8.29 (2, 1H, H-2); 13C NMR (150 MHz, CD3OD) δ 69.7 (C-5’), 71.9 (C-3’), 75.6 (C-
2’), 83.7 (C-4’), 89.9 (C-1’), 120.4 (C-5), 140.9 (C-8), 150.7 (C-4), 154.0 (C-2), 157.4 
(C-6); HRMS for C10H15N6O6S ([M+H]+) calcd: 347.0768 found 347.0767. 
4.7.2  Model Building and analysis 
Pdb entry 1c0a with the E coli Asp-tRNA synthetase was used as template. The aspartyl-
adenosine-5'-monophosphate was remodeled into a sulfonamide with AspSoA 4.26 by 
substituting the phosphate group for a sulfonamide group as found in csd entry BIVTAB 
(without O5'). The Ade base and sugar are in the same position as in the original 1C0A 
structure. The Asp-sulfonamide is positioned by rotation of dihedral angles, so that the 
overlap with the original substrate in the X-ray structure is optimized (no clashes with the 
surrounding residues as verified by Chimera). Although the sulfonamide linker is shorter 
due to the missing O5', many of the original hydrogen bonds of the aspartyl-adenosine-5'-
monophosphate with the enzyme are preserved upon substituting with the inhibitor in the 
active site. 
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4.7.3 Biological evaluation 
4.7.3.1  Whole-cell activity determination 
The respective bacteria were grown overnight in LB medium and cultured again the 
following day in fresh LB medium. Compounds were titrated in a 96-well plate using LB-
medium to dilute the compounds. To each well, 85 µL LB-medium was added to a total 
volume of 90 µL. Next, 10 µL of bacterial cell culture grown to a OD600 of 0.1 was added. 
The cultures were next placed into a Tecan Infinite M200® incubator and shaken at 37°C, 
subsequently the OD600 was determined after 18 h. The broth dilution tests were 
performed in triplicates. 
Bacterial strains used for the evaluations: E. coli K-12 BW28357, S. aureus (ATCC 
6538), S. lutea (ATCC9341) and C. albicans CO11. The antibacterial activities of all 
compounds were determined by monitoring the optical density of suspensions of cell-
cultures. All experiments have been performed in triplicate. 
LB medium was prepared as follows: 10 g tryptone (Becton-Dickinson, cat. no. 211705), 
5 g yeast extract (Becton-Dickinson, cat. no. 288620) and 10 g NaCl were dissolved in 
800 mL of water. The pH was adjusted to 7.0 by 5N NaOH. The volume was adjusted to 
1 L and the solution was sterilised. 
4.7.3.2  Aminoacylation experiments:  
These are as described previously in chapter 2, section 2.5.2.3. 
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5 General discussion 
5.1  Background 
In recent years, aaRSs have emerged as valuable and clinically validated targets 
for the development of anti-infective agents.[8] Among the several non-hydrolysable 
mimics of aa-AMP, aaSA analogues proved to be the strongest inhibitors of the 
corresponding aaRSs in vitro. However, these analogues can not be used as anti-infective 
agents due to their lack of selectivity and poor in vivo efficacy.[16] Efforts have been 
invested to improve the in vivo efficacy and selectivity of these analogues. For instance, 
in 1998, Cubist Pharmaceuticals reported a series of aaRS inhibitors where, although still 
based on aaSA analogues, the adenine base was replaced with an aryl-tetrazole moiety 
which was linked to the sugar through a two carbon linker. Although being strong and 
specific inhibitors of the corresponding aaRSs, these analogues could not be pursued 
further due to high serum albumin binding and poor cell penetration.[8, 61]  
Previously, in our efforts to improve the in vivo efficacy of aaSA analogues by a 
Trojan-horse mechanism, aaSA analogues were coupled to the McC signal peptide and 
evaluated for their antibacterial activity. It has been found that these analogues also act as 
Trojan-horse inhibitors and their growth inhibitory properties were comparable to the 
parent McC. It has been shown that by replacing the C-terminal amino acid in McC 
analogues (the one which remains attached to the nucleoside moiety following 
metabolisation), different aaRSs could be targeted.[81] Different peptide variants of McC 
containing aaSAs as active moieties were synthesized and evaluated for their antibacterial 
activity. It has been likewise found that most of the alteration in the amino acid sequence 
had little effect on the uptake potential of these compounds whereas the N-formyl 
methionine at first position and the arginine at the second position are clearly essential for 
recognition by the YejABEF transporter.[82] In addition, the minimum peptide chain 
length of five amino acids is required for efficient uptake by the same transporter.[77] 
However, when aryl-tetrazole containing sulfamates were coupled to the McC signal 
peptide, these constructs failed to cross the cell membrane.[83] We therefore concluded 
that the YejABEF transporter may be selective for peptide-adenylates or very closely 
related derivatives (research work done by my colleague, Dr. G. Vondenhoff). 
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5.2 Siderophore-drug conjugates: an attempt to improve the in vivo 
efficacy  
As our attempts to improve the in vivo efficacy of the aryl-terazole containing 
sulfamates by coupling them with the McC signal peptide were unsuccessful,[83] we 
looked for other transport systems such as an iron channel. Iron being an essential 
micronutrient required for all living organisms, it is a suitable candidate for a Trojan-
horse strategy. Being selective inhibitors of the corresponding aaRSs, we opted for the 
aryl-tetrazole containing sulfamates instead of non-selective aaSA analogues. Out of 
several compounds reported by Cubist Pharmaceuticals, the compounds CB432 (2.2) and 
CB168 (2.3, chapter 2) were selected for their broad-spectrum of activity and high 
selectivity, respectively. We hypothesized that when a SDC-Fe(III) complex would be 
presented to bacteria, it will be internalized actively via their iron channel. Once inside 
the cell, the iron will be released by iron reductase and the SDC would be metabolized by 
broad-specificity peptidases to release the active moiety which will exert its antibacterial 
effect (analogous to McC). However, no antibacterial activity was observed for the 
trihydroxamate-based SDCs (2.26 and 2.27) although these SDCs did show nice in vitro 
activity in cell extracts (except ∆ABN cell extracts which lack peptidase activity). Thus, 
the results indicate that these SDCs are efficiently metabolized by cellular peptidases and 
thus release the active moiety which exerts it inhibitory activity whereas intact SDC does 
not have an inhibitory effect on the amino acid incorporation. Hence, failure of uptake is 
the main reason for the inactivity of the SDCs. Therefore we concluded that analogous to 
the YejABEF transporter, the iron-channel may be selective for a peptide-adenylate 
construct or very closely related derivatives. However, the iron channel is a very complex 
system and comprised of FhuABCD proteins and an energy dependent TonB-ExbB-ExbD 
complex. Thus, at which stage the loss of the recognition resulted in impairment of the 
transport across the cell membrane remains to be determined. Along the same lines, we 
attempted to synthesize SDCs containing an aaSA as the active moiety. However, due to 
their chemical instability (concomitant formation of cycloadenosine) our efforts to 
synthesize the desired conjugates were unsuccessful (Scheme 2-4).  
As the delivery mediated by trihydroxamate-based siderophores failed, we also 
looked for an unnatural and relatively simple siderophore such as the biscatecholate 
(2.33). This unnatural siderophore is known to promote the growth of several bacteria 
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indicating it can transport iron across the cell membrane.[115] Moreover, β-lactam 
antibiotics coupled to biscatecholate siderophores have shown before to enhance the 
antibacterial activity as of active transport via the iron channel.[110a] As catecholate 
siderophores use a different iron acquisition system, we assumed that iron acquisition 
may not be specific for peptide-adenylates. However, it was found that the biscatecholate-
based SDC failed to release the active moiety. Recently, while studying intracellular 
processing of McC, it was uncovered that cellular peptidases could not metabolize the 
McC peptide if the N-terminal is protected or blocked with a formyl group. Moreover, 
these peptidases also lack endopeptidase activity. In other words, the intracellular 
peptidases metabolize the peptide sequentially from the N-terminal to the C-terminal and 
metabolisation is hampered if the N-terminal is protected.[122] In our SDC, the α-amine 
moiety of the ornithine is protected as a catecholamide which might be the limiting factor 
to release the active moiety. However, whether or not this SDC is recognized by the iron 
channel is less important as an in vitro experiment already showed lack of activity. In 
addition, our attempts to synthesize a linear enterobactin analogue were unsuccessful. 
Overall, the choice of siderophore, linker and drug all seem to be very crucial for 
successful drug delivery. For successful siderophore mediated drug delivery, the SDC 
should be recognized by the iron channel and should undergo metabolism upon 
internalization to release the active moiety. While very few successful examples of SDCs 
have been reported in the literature, most of the SDCs having cytoplasmic targets showed 
lower activity compared to the free drugs. It appears that most often conjugation of the 
drug with a siderophore either perturbs its transport across the cell membrane or fails to 
release the drug.[105] As demonstrated by albomycin and salmycin, nature seems to have 
addressed these issues more cleverly. However, in case of salmycins, despite of good 
antibacterial activities in the in vitro assays, low in vivo activity was observed mainly due 
to chemical instability owing to its ester function connecting the siderophore and the 
active moiety.[99]   
5.3  Base substituted 5’-O-(N-isoleucyl)sulfamoyl nucleoside analogues 
as potential antibacterial agents 
When our attempts to improve the in vivo efficacy of aryl-tetrazole containing 
sulfamates were unsuccessful, we analyzed the structures of albomycin and 
trihydroxamate-based SDCs. This shows that albomycin carries a modified pyrimidine 
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attached to a thioxylofuranose, whereas our SDC has an aryl-tetrazole moiety connected 
to a ribose through a two carbon linker. Interestingly, both these analogues differ from 
aaSA analogues in having either a modified pyrimidine base or a heterocyclic base while 
still acting as potent and selective aaRS inhibitors. These observations prompted us to re-
investigate the pharmacophoric importance of the adenine base in aaSA. Towards this 
end, we synthesized and evaluated several nucleoside sulfamate analogues containing 
natural and unnatural heterocyclic bases substituting for the adenine base. IleRS being an 
extensively studied enzyme before (e.g. mupirocin and the compounds reported by Cubist 
Pharmaceuticals all target IleRS) was chosen to study the effect of different bases 
substituting for adenine.  
Several isoleucyl-sulfamoyl nucleosides hereto were synthesized and evaluated 
for their antibacterial activity. The remarkable order of inhibitory activity for the different 
base substituents found in the in vitro assays was U >I>A=C>4-ABI>4-NBI>G. 
Interestingly, U and C derivatives proved to be either more or equally active respectively, 
as compared to the original aaSA analogue. Although, the hypoxanthine derivative is well 
tolerated, additional substitution with a C-2 amino group as in the G analogue resulted in 
significant loss of the activity possibly due to steric clashes. Therefore we concluded that 
the adenine base is not a prerequisite for aaRS inhibition. However, no growth inhibitory 
activity was observed for different analogues up to 5 mM by the disc diffusion method. 
This lack of antibacterial activity was rather expected and can be contributed to poor cell 
penetration as found for the IleSA analogue. Therefore, with the McC strategy in mind, 
these analogues were coupled to the McC signal peptide in an effort to improve the 
uptake of these analogues via a Trojan-horse strategy. Unfortunately, only transient 
antibacterial activity was noticed for purine derivatives carrying the bases A, I or 4-ABI 
(1,3-dideazaadenine) following incubation with the Ara-Yej inducer strain. This 
observation again supports our previous assumption that the YejABEF transporter is 
selective for peptidyl-adenylate analogues or closely related derivatives. Apparently, even 
a conjugate carrying an unnatural base such as 1,3-dideazaadenine (4-ABI) can be 
transported via this YejABEF transporter. In addition, the lack of inhibitory activity found 
for G and 4-NBI conjugates can be explained from the marginal in vitro activity as seen 
for the guanosine derivative. Moreover, despite of excellent in vitro activities for the U 
and C derivatives, no growth inhibitory activity was observed for their hexapeptidyl 
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conjugates in a whole-cell assay. This lack of inhibitory activity can only be attributed to 
a lack of recognition at the transporter. 
5.4  5’-(N-aminoacyl)-sulfonamido-5-deoxyadenosines: potentially 
stable alternative to aaSA analogues 
As mentioned above, aaSA analogues could not be pursued as potential antibiotics 
due to their lack of selectivity and poor in vivo efficacy. Moreover, synthesis of aaSA 
analogues remained problematic due to the formation of cyacloadenosine as a side 
product. It has been reported in the literature that aaSA analogues are prone to form a 
cyclic degradation product (as shown in Scheme 2-4) resulting in low yields for coupling 
of an amino acid to the  core and difficult purification.[114] Similarly, in our synthetic 
efforts to improve the in vivo efficacy of aaSA analogues by conjugation with a peptidic 
carrier (either siderophore or McC signal peptide), we consistently observed 
cycloadenosine as a side product. We failed to synthesize the desired siderophore 
conjugate of aaSA whereas synthesis of hexapeptidyl conjugates was low yielding with 
tedious purification.  
In an effort to reduce this side reaction, we proposed 5’-(N-aminoacyl)-
sulfonamido-5’-deoxyadenosine (aaSoA) as a potentially stable alternative to aaSA 
analogues. We hypothesized that deletion of the 5’-oxygen in aaSA analogues renders the 
C-5’ less electrophilic which in turn should improve the stability of these analogues, 
while hopefully preserving equal potency as compared to aaSA analogues. We therefore 
synthesized several nucleoside sulfonamides and evaluated them for their inhibitory 
activity in in vitro and in whole-cell assays. It was shown however that these analogues 
(except for AspSoA) are not able to inhibit the corresponding aaRS. Only the AspSoA 
derivative displayed some growth inhibitory activity against E. coli wt whereas the 
intermediate sulfamate (SA analogue without any attached amino acid) showed a broad-
spectrum of activity. As Asp-SoA also showed AspRS inhibition in the in vitro test, we 
assumed that this growth inhibitory effect against E. coli wt is mediated via AspRS 
inhibition. However, the mode of action of the SA intermediate remains to be determined. 
There are several possible reasons for the loss of activity of these aaSoA 
derivatives as compared to their respective aaSA analogues. Most obvious reason could 
be the shortened overall length of the inhibitor which might impair H-bonding of the α-
amino group of the inhibitor with the peptidic backbone of aaRS. Recently, we 
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established that the α-amino group is an important recognition point at the active site of 
aaRS. Alteration of the α-amino group may lead to complete loss of activity.[160] 
Alternatively, aaSoA analogues might fail to mimic the stereoelectronic properties of 
sulfamate. It has been observed previously that the distance between the sugar and the 
amino acid is important for tight binding. Alteration in the distance between the amino 
acid and the sugar resulted in significant loss of activity.[39c] However, whether it is the 
overall length or the charge around the sulfonamide linkage which contributes to the 
significant loss of affinity remains to be determined. Whether in the end these analogues 
are more stable as compared to the respective aaSA is less important now as the in vitro 
assays showed lack of activity against the respective aaRSs. 
5.5  Future perspective 
Although we have achieved limited success in promoting the in vivo efficacy of 
the aminoacyl-sulfamates, the results from this work can form a foundation on to which 
further development can be accomplished. As noted in the literature, release of the active 
moiety is always the main bottleneck in siderophore mediated drug delivery, which is 
attributed to stability of the linkage between the siderophore and the active moiety. Ester 
linkages are too labile, whereas some other linkages are too stable to release the active 
moiety. PepN contributes about 1% to the total intracellular protein concentration and is a 
major aminopeptidase. Chandu et al. demonstrated that pepN has endopeptidase activity 
and preferentially cleaves the peptide bond between the amino acids having either basic 
(Arg, Lys) or small (Gly, Ala) side chain.[162] Therefore, it is recommended that a 
dipeptide containing either combination of these four amino acids as a spacer could be 
inserted between the siderophore and the drug, so that selective endopeptidase activity by 
pepN can be exploited for releasing the active moiety (analogous to albomycin). 
Alternatively, one can use a danoxamine like siderophore where the SDC does not depend 
on any enzyme to release its active moiety. Here, upon iron removal, one of the N-
hydroxyl groups act as a nucleophile to release the active moiety (Figure 1-11).  
Therefore, it would be desirable to couple aryl-terazole containing sulfamates with 
different siderophores to find an ideal SDC which would fulfil all criteria as stated above. 
It was claimed that a mixed ligand siderophore containing SDC is able to use multiple 
iron-transport systems to deliver the active moiety.[108b] These mixed ligand siderophores 
(e.g. a combination of hydroxamate and catecholate component) were shown to be 
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promising candidates to obtain SDCs which would have a broad-spectrum of activity, 
being recognized by multiple iron-transport systems, but this research has not been 
followed up.  
Moreover, the clinical use of albomycin is frequently advocated provided a 
sufficient quantity of albomycin can be isolated from producing strains or can be 
chemically synthesized. Benz et al. have synthesized an albomycin δ1 analogue 
substituting xylose for thioxylose but the compound was found to be inactive.[101] 
Synthetic efforts therefore need to achieve synthetic albomycin itself in sufficient 
quantities. Recently, albomycin biosynthetic genes have been identified that may pave the 
way to improve the production of albomycin itself or some biosynthetic intermediates by 
genetic engineering. The biosynthetic intermediates can be used to yield semisynthetic 
albomycin.[103] Synthesis of a modified serine having 4-thioxylofuranose substituents at 
the β-position is the rate limiting step in obtaining synthetic albomycin. 
As different heterocyclic base substitutions for the adenine base are well tolerated, 
it would be interesting to evaluate such analogues for human IleRS inhibition. Being 
structurally different from the adenine base, some of these analogues have been shown to 
be selective for bacterial aaRSs over their human orthologs. Therefore, different 
heterocyclic modifications in aaSA analogues should be further explored to uncover aaRS 
inhibitors with excellent in vivo efficacy, high selectivity and better stability. In addition, 
different base substituted sulfamoyl nucleoside analogues could be coupled to a 
siderophore to improve their in vivo efficacy. These SDCs may yield some information 
about the structural requirement of the iron channel. As found for aaSoA analogues, 
eliminating the 5’-oxygen resulted in complete loss of activity (except for the AspSoA). 
Therefore, it would be interesting to synthesize and evaluate all remaining aminoacylated 
aaSoA analogues. Indeed, in analogy to AspSoA, deletion of the 5’-oxygen in aaSA 
derivatives may be well tolerated in other aaRS enzymes. Further detailed studies are 
needed to establish the SAR for these aaRS inhibitors. Along the same lines, to address 
the question whether it is the overall length or the charge around the sulfonamide linkage 
which is the main culprit for the loss binding affinity, it is desirable to synthesize and 
evaluate homoadenosine analogues replacing the 5’-oxygen with a methylene in aaSA. 
These analogues may rescue aaRS inhibitory activity owing to the same overall length as 
compared to aaSAs. 
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Nature has demonstrated that that a diverse set of chemicals can be used as aaRS 
inhibitors. Therefore, besides nucleoside antibiotics (like albomycin, McC, ascamycins) 
efforts should be invested to explore other natural compounds as a platform/lead for 
further optimization of structures, to yield aaRS inhibitors which could lead to clinically 
useful antibiotics. For example, indolmycin has a narrow spectrum of activity due to its 
hydrophobic nature.[42] More efforts could be invested to enhance the hydrophilicity of 
indolmycin and thus broaden the spectrum of activity. Recently, Anacor Pharmaceuticals 
elaborating on its boron-based compound platform reported substituted benzoxaborole 
derivatives (e.g. AN2690) for treatment of fungal infections. Unlike other aaRS 
inhibitors, AN2690 acts by inhibiting an editing site of LeuRS. This compound is in 
phase III clinical trials for treatment of onychomycosis.[9a] This confirms the editing site 
of aaRS could also be explored as a potential target. Therefore in general, random 
screening of heterocyclic compound libraries may yield aaRS inhibitors or lead 
compounds which could be further optimized to finally yield clinically useful antibiotics. 
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